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ABSTRACT 
 
Daptomycin is a lipopeptide antibiotic that is clinically used to treat severe infections caused by 
Gram-positive bacteria. It is highly potent against resistant strains of bacteria such as methicillin-
resistant Staphylococcus aureus. However, in cases of community-acquired pneumonia (a leading 
cause of death worldwide), daptomycin is somehow inhibited by lung surfactant and therefore 
unable to exert its bactericidal activity against Streptococcus pneumoniae, the primary cause of this 
disease. This thesis presents the successful development of lipid model systems to mimic the 
lipid composition of S. pneumoniae bacterial membranes, human cell membranes, and both 
synthetic and natural lung surfactant. Experiments were performed that help to elucidate the 
basis for daptomycin’s inhibition by lung surfactant, culminating in a new, detailed model of 
daptomycin sequestration that summarizes the findings from these studies.  
Daptomycin is believed to be sequestered by lung surfactant and has been shown to insert into 
this surfactant. Fluorescence spectroscopy experiments were used to test the interaction of 
daptomycin with different lipid model membranes in the presence of calcium. It was discovered 
that at physiologically relevant calcium concentrations, daptomycin induced larger changes in 
fluorescence intensity with lung surfactant than in the bacterial membrane and human 
membrane models. This suggests that daptomycin has a greater affinity for lung surfactant at 
lower calcium concentrations, which may account for its inhibition in these conditions. 
Using Langmuir-Blodgett monolayer techniques, studies were performed on how daptomycin 
affects monolayer properties. Compression isotherms provided data on monolayer 
compressibility, and it was found that daptomycin and calcium reduce the compressibility of 
lung surfactant monolayers, possibly improving its function. Constant-area insertion assays 
provided additional data that verified daptomycin’s avid binding to lung surfactant at low calcium 
concentrations. 
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Scanning probe microscopy techniques were employed to obtain atomic force microscopy and 
Kelvin probe force microscopy images for monolayers in air. In the presence of daptomycin and 
calcium, the lung surfactant monolayers exhibited multilayer formation and increased electrical 
surface potential. Atomic force microscopy images taken of model lipid bilayers in liquid show 
multi-bilayer formation for the lung surfactant bilayers in the presence of daptomycin and 
calcium. This provides further evidence that daptomycin and calcium induce multilayer 
formation in lung surfactant. 
These findings allowed for the development of a novel model of daptomycin inhibition by lung 
surfactant. In the presence of physiological levels of calcium, daptomycin binds to lung 
surfactant and is sequestered. This binding causes a decrease in lung surfactant compressibility, 
allowing it to easily form multilayers that effectively reinforce the sequestration of daptomycin. 
The lipid models, methods, and experimental protocols developed in this thesis will help foster 
future studies in the field of membrane biophysics. 
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CHAPTER 1 
1 INTRODUCTION 
 
We live in a world of innovation and adaptation on every scale imaginable, from nanoscopic to 
macroscopic. As we increase our knowledge in the scientific community, we continuously fuel 
our desire for advancement and innovation. When new discoveries come to light, a period of 
adaptation occurs where everything is encouraged to adjust and conform to those changes placed 
upon them. The relationship between pathogens and drugs is no different. As we discover new 
antibiotics, their associated target bacteria can adapt, mutate, and evolve to thrive in new 
conditions. Unfortunately for us, we have to go back to the drawing board and come up with 
alternative ways to tackle these resistant strains of pathogenic microorganisms.  
There has always been a never-ending struggle for humans to overcome the illnesses they 
contract from pathogenic strains of bacteria. Before the invention of drugs and antibiotics, a 
failure to improve one’s condition would have almost certainly meant death. Although herbal 
medicine goes back thousands of years, pharmaceutical drug research has only been in existence 
for just over a century [1]. During this century of research, technological advances have allowed 
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for better and stronger drugs to be made to overcome both the symptoms and the root of the 
illness itself. But as time progressed, pathogenic bacteria caught up with our progress and 
eventually self-adapted to resist the drugs we created to target them specifically. 
Antibiotics such as tetracycline, streptomycin, and penicillin are not as effective as they once 
were. An example is methicillin-resistant Staphylococcus aureus (MRSA), a superbug that is resistant 
not only to methicillin, but also penicillin, tetracycline, erythromycin and more [2]. For a while, 
the only antibiotic that could still exert antimicrobial activity against MRSA was vancomycin, but 
by 2002, strains of vancomycin-resistant Staphylococcus aureus (VRSA) had already appeared across 
the globe [3]. This gave us no choice but to adapt and continue researching new ways to treat 
MRSA and many other illnesses that have become resistant to popular antibiotics. 
Daptomycin is an antimicrobial peptide that was in development for approximately two decades 
before receiving FDA approval in 2003 to treat infections caused by Gram-positive 
microorganisms [4-8]. It has a distinct mechanism of action that allows it to target bacteria that 
are resistant to numerous antibiotics, but the details of this mechanism are still unclear [4, 8, 9]. 
Even more peculiar is its inhibition by pulmonary surfactant when used to treat community-
acquired pneumonia (CAP) caused by Streptococcus pneumoniae [10]. Due to its broad spectrum of 
bactericidal activity and unique, organ-specific inhibition, it is therefore imperative that we 
pursue further research into elucidating daptomycin’s mechanism of action to benefit future 
antibiotic discovery, development and optimization.  
This chapter will provide a thorough introduction to the different antibiotic compounds 
presented in this thesis as well as the necessary background information on antimicrobial 
peptides, cell membranes and lung surfactant. This chapter will also help give a brief overview 
of what the scientific community has discovered so far to elucidate daptomycin’s mechanism of 
action and inhibition by lung surfactant. Subsequent chapters will detail the development of lipid 
membrane models, the methods and techniques used for the experiments in this thesis, and 
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present my experimental work on elucidating daptomycin’s organ-specific inhibition and 
mechanism of action. 
 
1.1 Antimicrobial Peptides 
Antimicrobial peptides (AMPs) are small proteins made up of approximately 15-50 amino acids 
and are naturally derived from living organisms to confer host defense [11]. These molecules 
have evolved throughout the years in the so-called “arms race for survival” between living 
organisms, but they share similar features such as size and electrostatic properties [12]. There are 
many classes of AMPs, but their antimicrobial activity and specificity can be defined by their 
individual characteristics such as size, peptide sequence, charge and hydrophobicity [12-14].  
Although each antimicrobial peptide may have its own specific mechanism of action, certain 
steps need to occur in order to induce bacterial cell death [13]. First, the AMP must be attracted 
to the bacterial surface. One of the most obvious mechanisms for such an attraction is the 
electrostatic bonding between peptides and bacterial surface structures [13, 15]. Since the 
majority of AMPs are cationic peptides with amphiphilic properties, they have a tendency to 
attack and permeabilize the negatively-charged bacterial cell membranes, where the net negative 
charge is brought upon by the lipopolysaccharides (LPS) in Gram-negative bacteria and teichoic 
acids in Gram-positive bacteria [13, 15, 16].  
Once these AMPs have approached bacterial cell surfaces, they must be able to attach to and 
traverse the capsular polysaccharides found in both Gram-negative and Gram-positive bacteria 
[13, 17]. Afterwards, the AMPs must get through a layer of LPS in order to reach the outer 
membrane of Gram-negative bacteria and a layer of teichoic and lipoteichoic acids before they 
can interact with the cytoplasmic membrane of Gram-positive bacteria [13, 17].  
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Figure 1.1 AMPs can kill bacteria via transmembrane pores. There are various proposed 
models in which antimicrobial peptides can target and subsequently kill bacteria through the 
formation of transmembrane pores in the bacterial cell membrane. (A) In the barrel-stave model, 
the attached peptides aggregate and insert into the bacterial cell membrane to form a pore. (B) 
In the toroidal-pore model, the attached peptides aggregate and cause each bilayer leaflet to bend 
around the pore. (C) In the carpet model, AMPs are oriented parallel to the surface of the 
membrane to disrupt its integrity, causing localized areas of the membrane to form micelles 
(Adapted from [13]). 
 
As soon as the antimicrobial peptide has worked its way to the bacterial membrane, it starts to 
interact with the membrane. Although the mechanisms by which some AMPs inhibit pathogen 
infections are not yet fully known, studies have shown that AMPs can use various methods to 
mediate cell killing, three of which pertain to the formation of transmembrane pores as seen in 
Figure 1.1 [13, 15]. In the barrel-stave model, barrels made of peptide helices aggregate and 
insert into the membrane, parallel to the direction of phospholipid chains, to form pores with 
diameters between 2 to 4 nm [18-22]. This configuration has been found with the AMP 
alamethicin through studies in oriented circular dichroism, neutron scattering, and synchrotron-
based X-ray scattering [20, 21, 23]. In the toroidal-pore model, the AMP helices insert 
perpendicularly into the bilayer and induce a local membrane curvature so that the inner and 
outer leaflets are connected together [22, 24, 25]. Studies have shown that magainins, protegrins 
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and melittin use the toroidal-pore method of forming pores [21, 24, 26]. Meanwhile, the carpet 
model explains how AMPs such as ovispirin orientate themselves parallel to the bacterial 
membrane surface and cover it in a carpet-like manner until such a high AMP concentration is 
reached that the bilayer is disrupted and forced to form micelles [27-32]. However, these are not 
the only ways of destroying bacterial cells. 
 
 
Figure 1.2 AMPs can kill bacteria via intracellular targets. Antimicrobial peptides can also 
induce cell death through intracellular modes of action. In this figure, an example bacterial target 
is presented with a cell wall and cytoplasmic membrane. Depending on the AMP, different 
methods can be used to disrupt crucial cell processes within the bacterial cell. Some of these 
processes are highlighted in the image: inhibition of cell wall synthesis, inhibition of nucleic acid 
and protein synthesis (affecting DNA replication and transcription as well as mRNA translation), 
inhibition of enzymatic activity, and alteration of the cytoplasmic membrane [13]. 
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Over the past few years, there has been increasing evidence which indicates that AMPs can not 
only form pores, but can also target intracellular molecules to disrupt crucial cell processes such 
as DNA and protein synthesis (Figure 1.2) [13]. For example, an autolysin in the bacterial cell 
wall can be activated by the introduction of an AMP Pep5, which causes the cell to lyse [33].  
With over 2000 AMPs known [11, 15, 34], there are many opportunities to gain further insight 
into the mechanisms of actions that pertain to the AMPs we are interested in studying. 
Technological advances in methodology can help us learn more about these AMPs and their 
mechanisms, but no single technique can provide us with all the information we need. Current 
research has focused on microscopy, X-ray crystallography, NMR spectroscopy, fluorescence 
spectroscopy, black lipid membranes, circular dichroism and neutron diffraction, but a 
combination of these techniques along with other methodologies will be required to fully 
understand each antibiotic’s mechanism of action [13]. 
 
1.2 Bacterial Resistance 
Unfortunately, when a new and highly effective antimicrobial peptide is discovered, experience 
tells us that the bacteria it was meant to target will eventually grow resistant to its attacks. Over 
the past few years, an increasing number of Gram-positive pathogens such as staphylococci, 
streptococci and enterococci have become resistant to common antibiotics [5]. Specifically, 
serious infections caused by multi-drug resistant strains of methicillin-resistant Staphyloccocus 
aureus (MRSA), vancomyin-resistant enterococci (VRE) and penicillin-resistant or drug-resistant 
Streptococcus pneumoniae (PRSP or DRSP) are on the rise and the need to develop new and effective 
agents to treat these diseases is an ongoing mission [35-39].  
Although vancomycin, which inhibits cell wall synthesis, has been widely used for treatment 
against serious Gram-positive infections [40], its increasing ineffectiveness against infections 
with Gram-positive pathogens has sparked concern in the healthcare system [37, 39, 41]. As the 
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future of this antibiotic is questionable, novel antimicrobial agents have been developed to 
somewhat replace vancomycin by carrying out its bactericidal actions against the same bacteria, 
but in different ways. 
 
Table 1.1 Various antibiotics used to treat MRSA and their mechanisms of action. The 
name, mechanisms of actions, and known issues are presented for select antibiotics that are 
commonly used to treat methicillin-resistant Staphylococcus aureus (Adapted from [42-44]).  
Antibiotic Mechanism of Action Comments 
Clindamycin Inhibits protein synthesis by binding to 50S 
ribosome 
Treatment failures reported 
Daptomycina Membrane depolarization Cannot be used for MRSA-based 
pneumonia; treatment failures reported for 
patients previously treated with vancomycin 
Doxycycline Inhibits protein synthesis by binding to 30S 
ribosome 
Clinical experience in treating MRSA is 
limited 
Linezolid Prevents formation of 70S initiation complex 
by binding to 23S rRNA of 50S ribosomal 
subunit 
Prolonged therapy may cause 
myelosuppression 
Minocycline Inhibits protein synthesis by binding to 30S 
ribosome 
Clinical experience in treating MRSA is 
limited 
Quinupristin-
dalfopristin 
Inhibits protein synthesis Poor tolerability has restricted its use 
Telavancina Inhibits cell wall synthesis May cause potential fetal risk 
Tigecycline Inhibits protein synthesis by binding to 30S 
ribosome 
Should not be routinely used for bacteremia  
Trimethoprim-
sulfamethoxazole 
Inhibits biosynthesis of folic acids Caution for sulfa allergies 
Vancomycina Inhibits cell wall synthesis Treatment failures reported; may cause 
infusion-related reactions 
a Dose should be adjusted for renal function  
 
 
Recently introduced agents (see Table 1.1) that are bactericidal against Gram-positive organisms 
include linezolid, telavancin, tigecycline, and daptomycin [5, 36, 37, 45, 46]. Of these four, 
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daptomycin is the only drug from the cyclic lipopeptide class of antimicrobial peptides. It has 
strong bactericidal activity against MRSA and other resistant strains of bacteria, and it only 
requires one dose per day [38, 46]. Its unique proposed mechanism of action, which involves 
the calcium-dependent depolarization of the bacterial cell membrane (causing cell death), means 
that there is a low chance of cross-resistance between daptomycin and other antimicrobial agents 
[39, 47]. Simply put, daptomycin is a young player in the field of antibiotics, and further research 
will need to be done to elucidate its mechanism of action. 
 
1.3 Daptomycin 
 
Figure 1.3 Chemical structure of daptomycin. Daptomycin is a cyclic lipopeptide antibiotic 
with 13 amino acids and a decanoyl side chain. It has two nonproteinogenic amino acids: L-3-
methylglutamic acid (3MeGlu) in the 12th position as well as the unusual and unique L-kynurenine 
(Kyn) residue in the 13th position. 
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Daptomycin (Figure 1.3) is a 13-member cyclic antimicrobial lipopeptide that is produced by 
the actinobacterium Streptomyces roseosporus through fermentation, and supplementing decanoic 
acid to its growth medium allows for increased daptomycin yield [5, 8]. This process gives it its 
decanoyl side chain linked to the N-terminal tryptophan of the cyclic amino acid peptide. 
However, its large molecular weight of around 1620 g/mol restricts it from being absorbed from 
the gastrointestinal tract and hence its distribution into tissues [5, 35, 48, 49].  
Daptomycin has proven to exert bactericidal activity against every clinically important Gram-
positive pathogen in vitro, including those which are highly resistant and leave us with limited 
therapeutic options such as MRSA, VRE and DRSP [49-53]. Currently, daptomycin is only 
available as an intravenous injection to target Gram-positive organisms [5]. 
 
1.3.1 History and Development 
Daptomycin (developed under the name LY 146032) was discovered by Eli Lilly and Company 
(Indianapolis, Indiana, USA) in the early 1980s through the screening of bacterial fermentation 
extracts for antimicrobial activity [6, 7, 49]. Specifically, Eli Lilly isolated Streptomyces roseosporus 
from a soil sample that came from Mount Ararat in Turkey [54]. Throughout the 1980s and 
1990s, almost twenty Phase I and Phase II clinical studies with around 400 subjects were 
conducted with daptomycin, presenting highly encouraging results against bacteremia and skin 
and soft tissue infections [49]. The results for the treatment of endocarditis suggested a higher 
dosage of daptomycin would be required, but upon testing this increased dosage (at 4 mg/kg 
every 12 hours), Eli Lilly observed cases of reversible skeletal muscle toxicity and ceased its 
development of daptomycin in 1991 [5, 49, 55, 56]. Unfortunately, at this point in time, the rise 
of bacterial resistance to common drugs continued, which prompted Cubist Pharmaceuticals 
Inc. (Lexington, Massachusetts, USA) to step in.  
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In 1997, Cubist took over daptomycin research and development by licensing worldwide rights 
from Eli Lilly [6, 7, 57]. Cubist believed that the first step was to find the optimal dosing regimen 
of daptomycin, which is exactly what they did. In order to determine what kind of dosing 
regimen would have the least effect on skeletal muscle, two separate studies were conducted 
with dogs to compare repeated intravenous daptomycin administration once-daily (intervals of 
24 hours) versus twice-daily (intervals of 8 hours) for a total period of 20 days [58]. Parameters 
such as dosing interval, drug concentration in the plasma and concentration-time curve areas 
were examined, but the results showed that the strongest correlation was between skeletal muscle 
toxicity and dosing intervals [58]. From their data, Cubist determined that a once-daily dosing 
regimen appeared to minimize skeletal muscle toxicity, and further licensing studies and clinical 
usage confirmed their findings, since skeletal muscle toxicity only arose in rare cases [6, 58].  
 
 
 
 
Figure 1.4 Vials of Cubicin® and Cubicin® RF. Daptomycin is available under the 
trademarked name Cubicin®, once-a-day daptomycin for injection. Although these two different 
formulations have different methods of reconstitution and storage requirements, both have the 
same indications, limitations of use, and general performance. 
 
Moving on to Phase III clinical trials, Cubist decided to test the safety and efficacy of daptomycin 
in the treatment of complicated skin and skin structure infections (cSSSIs) caused by Gram-
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positive pathogens [49, 57, 59]. The drug would be tested against those of current standards of 
widely used drugs, such as vancomycin, that targeted the same types of cSSSIs. Two randomized, 
international trials were performed with 1092 patients who had contracted cSSSIs. Before 
randomization, the investigator assigned one of two comparator drugs (either a penicillinase-
resistant penicillin (PRP) or vancomycin) to each treatment group to be compared with 
daptomycin [59]. Once randomized, patients in each group would receive daptomycin (through 
a 30-minute intravenous infusion at 4 mg/kg) or, depending on which group, either PRP (4-12 
g daily in equally-divided intravenous doses) or vancomycin (1 g twice-daily 60-minute 
intravenous infusions) [59]. At the end of the clinical trials, it was determined that among the 
902 clinically evaluable patients, the success rate for daptomycin was 83.4% compared to the 
comparator-treated groups of 84.2% [6, 59, 60]. However, 63% of those patients successfully 
treated by daptomycin only required less than a week of therapy, whereas only 33% of those 
who took the comparator drugs had recovered within that time frame [6, 59]. This meant that 
daptomycin was just as good as the other drugs already in use, being safe and efficient for 
treatment with cSSSIs [59]. 
Around the time that these Phase III clinical trials were performed, daptomycin (marketed as 
Cubicin® by Cubist, see Figure 1.4) gained Food and Drug Administration (FDA) approval 
from the United States of America in September 2003 [5, 10, 47]. Additional approval by the 
European Medicines Agency (EMEA) was granted in January 2006 for the use of daptomycin 
in treating cSSSIs caused by Gram-positive pathogens with a once-daily dosage of 4 mg/kg [5, 
6]. In March 2006, further FDA approval was granted for the use of daptomycin at a once-daily 
dosage of 6 mg/kg to treat bacteremia and right-sided endocarditis caused by Staphylococcus aureus 
[5, 6]. Currently, studies are still underway to further elucidate daptomycin’s mechanism of 
action.  
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1.3.2 Mechanism of Action 
Daptomycin is the a clinically-approved drug from a class of antimicrobial peptides called the 
cyclic lipopeptides [47]. Its distinctive structure (13-member amino acid cyclic head and decanoyl 
side-chain lipophilic tail) allows daptomycin to have a novel mechanism of action [6, 61]. Its 
acidic nature and negative charge at neutral pH allow it to be highly soluble in aqueous solutions, 
while its lipid tail and hydrophobic amino acids give it its amphipathic properties [4]. Although 
its precise mechanism of action is still unclear, it is distinct from other antimicrobial peptides as 
it does not kill bacteria by penetrating the cytoplasm, but rather by disrupting multiple aspects 
of the bacterial plasma membrane [5, 36, 49]. 
For the past couple of decades, there have been various studies that have tried to determine 
daptomycin’s precise mechanism of action. One of the first studies reported that daptomycin 
caused bacterial cell death by inhibiting the formation of precursor molecules required in 
peptidoglycan biosynthesis [62]. Later, studies suggested that daptomycin targeted the 
lipoteichoic acids on the surface of Gram-positive organisms [63-65]. These latter models were 
refuted when further studies showed that bactericidal activity against various bacterial isolates 
was still present in the absence of peptidoglycan and lipoteichoic acid synthesis [61, 66]. 
In the late 1980s, a new proposed mechanism of action for daptomycin was suggested (see 
Figure 1.5), one that was more complex than its predecessors and is now a primary focus of 
much research in determining the specifics of daptomycin’s mechanism of action [62]. This 
proposed multi-step mechanism of action involves the calcium-dependent binding of its tail and 
subsequent insertion into the cell membrane of Gram-positive bacteria [61]. An oligomerization 
event occurs where daptomycin oligomerizes to form ion channels, pores or aggregated 
structures that trigger a depolarization event [4, 61]. This disrupts the membrane’s functional 
integrity, which in turn causes an arrest of DNA, RNA and protein synthesis and ultimately 
bacterial cell death [56, 61, 65, 67]. This oligomerization event was recently demonstrated, where 
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membrane lesions were shown to be caused by daptomycin oligomers on model membrane 
vesicles [68].  
 
 
Figure 1.5 Proposed model of daptomycin’s mechanism of action. Daptomycin has a 
proposed distinct mechanism of action which physically changes the bacterial membrane and 
causes rapid depolarization. The steps shown in the figure represent a general overview of the 
different stages of this mechanism: (1) daptomycin inserts into the bacterial membrane upon 
binding to calcium, (2) daptomycin oligomerizes on the surface to (3) form an ion channel that 
disrupts the functional integrity of the cytoplasmic membrane by (4) triggering a release of 
intracellular potassium (K+), which causes rapid cell death (Adapted from [61]).  
 
It is clear that daptomycin’s mechanism of action is calcium-dependent, since its bactericidal 
activity is at its highest at a calcium concentration of around 50 mg/L, a level comparable to the 
free Ca2+ concentration in human serum [50, 69-71]. It is also clear that daptomycin has rapid 
bactericidal effects as it is capable of killing over 99.9% of MRSA bacteria within the span of an 
hour [61, 67, 72, 73]. But several questions still need to be answered to help elucidate 
daptomycin’s mechanism of action, such as its possible interference with cell activity and its 
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structure-activity relationships. Of particular interest is the unique inhibition of daptomycin 
when it is used treat community-acquired pneumonia caused by Streptococcus pneumoniae.   
 
1.3.3 Organ-Specific Inhibition of Daptomycin within the Lungs 
As an FDA-approved member of the lipopeptide antibiotic family, daptomycin has a unique 
mechanism of action that is powerful against Gram-positive bacteria, even those that are 
resistant to common therapeutic drugs such as vancomycin and methicillin [10]. Streptococcus 
pneumoniae, or Pneumococcus, is one of these Gram-positive bacteria that is susceptible to 
daptomycin. In fact, the minimum inhibitory concentration to kill 90% of the S. pneumoniae 
isolates tested in vitro was 0.06 µg/mL [74]. Accordingly, one would expect daptomycin to be 
very potent in treating community-acquired pneumonia, whose main causative agent is S. 
pneumoniae [75]. However, this is not the case. 
During Phase III clinical trials, studies were conducted for patients with community-acquired 
pneumonia, but daptomycin failed to meet the noninferiority criteria against its comparator 
ceftriaxone [10]. But how could daptomycin be efficient against S. pneumoniae in vitro but not in 
vivo? Daptomycin’s low efficacy against this disease has been attributed to its inhibition by 
pulmonary (lung) surfactant, a crucial component of the lung’s alveolar air-liquid interface [10]. 
This lung surfactant (see Figure 1.6) is a phospholipoprotein complex, whose primary 
constituent is dipalmitoylphosphatidylcholine (DPPC), along with other surfactant proteins and 
neutral lipids [76-78]. It is synthesized by type II alveolar cells and forms a monolayer lipid film 
that coats the air-liquid interface of the lung’s alveoli [79]. Apart from increasing pulmonary 
compliance by reducing alveolar surface tension to facilitate lung inflation and deflation during 
respiration, lung surfactant also plays a role in pulmonary innate immunity, which is an important 
function since the lung is constantly exposed to air that is contaminated with microbes [80]. But 
how exactly does daptomycin get inhibited by the thin film surfactant inside our lungs? 
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Figure 1.6 Lung surfactant lines the alveolar air-liquid interface. (A) When we breath, the 
air we inhale and exhale travels through a respiratory tree of different structures: trachea, 
bronchus, bronchiole, alveolar duct, to the alveoli within the alveolar sac. Each alveolus is hollow 
and is a basic unit of respiration, since it is located at the end of the respiratory tree. (B) At each 
alveolus gas exchange occurs at the alveolar membrane, which has direct access to capillary beds. 
This allows for the rapid diffusion of carbon dioxide and oxygen molecules. While alveolar Type 
I cells form the structure of the alveoli, Type II cells secrete lung surfactant, which covers the 
surface of the alveolus to reduce surface tension and enhance lung compliance. 
 
The answer lies in the composition and vast amount of lung surfactant lining our alveolar 
surfaces. Lung surfactant is made up of primarily phosphatidylcholine (PC) and approximately 
10% phosphatidylglycerol (PG), amongst low levels of other lipids and molecules [76-78]. Not 
only is PG found in Gram-positive bacterial cell membranes, but daptomycin is known to 
interact with lipid vesicles of pure PC at high levels of calcium, with the presence of PG 
enhancing daptomycin insertion into the membrane [10, 81]. With there being hundreds of 
millions of alveoli inside the human lung, the vast amount of pulmonary surfactant covering the 
alveolar surface area greatly exceeds the surface area of any bacterial cells [10]. If daptomycin 
cannot differentiate between lung surfactant and the bacterial cell surface, then the huge amount 
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of lung surfactant with some PG content will certainly sequester the daptomycin, preventing it 
from attaching to the bacteria and effectively inhibiting its bactericidal activity [9, 10, 82]. This 
is now presumed to be the first case of organ-specific inhibition of an antibiotic [10], which 
means that further research will need to be performed to better understand daptomycin’s precise 
mechanism of action and prevent its sequestering by lung surfactant.  
 
 
1.3.4 Brief Overview of Recent Studies 
Many studies have been done on daptomycin in recent years to shed light on daptomycin’s 
structure, mechanism of action, and bactericidal activity. The following subsections will review 
different categories of recent advances in daptomycin research. 
 
1.3.4.1 Structural Studies 
Daptomycin was discovered in the early 1980s as a fermentation product of Streptomyces roseosporus 
[7]. Since then, there has been an ongoing quest to elucidate its three-dimensional structure and 
its mechanism of action [83]. 
Daptomycin is a cyclic lipopeptide that is the only one of its class to be approved for clinical 
use. It has 13 amino acid residues (see Figure 1.3): tryptophan (Trp-1), ᴅ-asparagine-2 (Asn-2), 
aspartic acid-3 (Asp-3), threonine-4 (Thr-4), glycine-5 (Gly-5), ornithine-6 (Orn-6), aspartic acid-
7 (Asp-7), ᴅ-alanine-8 (Ala-8), aspartic acid-9 (Asp-9), glycine-10 (Gly-10), ᴅ-serine-11 (Ser-11), 
(2S,3R)-3-methylglutamic acid-12 (mGlu-12), and kynurenine-13 (Kyn-13) [81, 84-86]. 
Daptomycin’s 10-membered ring is formed by amino acids Thr-4 to Kyn-13, where an ester 
bond between the hydroxyl group of Thr-4 and the C-terminal carboxyl group of Kyn-13 links 
the amino acids into the shape of a ring [81, 84, 86]. Meanwhile, the decanoyl side chain branches 
off at the N-terminal residue, Trp-1 [84, 86]. It is also important to note that with one basic 
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amino acid residue (Orn-6) and four acidic residues (Asp-3, Asp-7, Asp-9, mGlu-12), 
daptomycin possesses an overall molecular charge of -3 at neutral pH level [81, 86]. 
Numerous studies have been performed that focus on the structure of daptomycin, whether it 
be the properties of its amino acids or its three-dimensional structure and orientation through 
aggregation. In its native state without calcium, daptomycin is known as apo-daptomycin and 
detailed nuclear magnetic resonance (NMR) spectroscopic studies have been performed to 
elucidate its three-dimensional structure. NMR spectroscopy is especially useful in determining 
the composition of organic compounds, since it is capable of determining the entire structure of 
one molecule using just one set of analytical tests [87-89]. Using an isotope with a nuclear spin 
of l = ½, such as hydrogen-1 (1H) or carbon-13 (13C), we can see whether it is at a lower or 
higher energy state depending on whether it aligns itself with or against the magnetic field it has 
been placed in, respectively [88]. Should a nucleus in a lower energy state be present, 
electromagnetic radiation can be applied whose energy is absorbed, allowing that particular 
nucleus to jump to a higher energy state. This means that we can either observe the absorption 
of energy that the nucleus receives, or the subsequent release of energy when the electromagnetic 
radiation has been emitted (the relaxation stage where the nucleus returns from a higher energy 
state to a lower energy state) [88]. 
In real molecules, the magnetic field experienced by each nucleus includes not only the applied 
magnetic field, but also the magnetic effect of nearby nuclei and electrons [88]. Therefore, it is 
common practice to reference the resonant frequencies against a zero standard, usually 
tetramethylsilane (TMS) for 1H NMR spectra [90]. In NMR spectroscopy, a series of peaks (the 
NMR spectrum) is obtained and plotted as absorbance versus frequency. The difference between 
the TMS zero standard point and each peak frequency is known as the chemical shift in parts 
per million (ppm), and these can be compared to characteristic chemical shifts of known atoms 
and functional groups [87, 88, 90]. As a result, the structure of a particular molecule can be easily 
determined. 
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Figure 1.7 3D structure of apo-daptomycin. This three-dimensional structure of apo-
daptomycin (in its native state without calcium bound to it) was obtained using the lowest energy 
results from NOESY spectra in 2D NMR spectroscopy (Adapted from [84]). 
 
In a study from 2004, apo-daptomycin was shown not to have a well-defined conformational 
structure in aqueous solution [81]. In a later study, this structure was determined through 2D 
NMR spectroscopy, in which two frequency axes were used as opposed to the one in 1D NMR 
[84]. For 1D experiments, NMR spectra were measured with a 0.8 mM concentration of 
daptomycin and both 1H and 13C chemical shifts (ppm) were reported for each amino acid 
residue of the molecule [84]. Subsequently, 2D NOESY (Nuclear Overhauser effect 
spectroscopy) spectra were obtained to gain insight into protein structure since it uses the dipolar 
interaction of spins to correlate protons depending on their distance from one another [88]. 
Through the NOESY spectra obtained, 20 structures with low energy were ultimately 
determined, but with further conformational analysis, Ball et al. were able to determine its best-
quality structure, illustrated in Figure 1.7 [84]. This structure showed that apo-daptomycin has 
an extended conformation, with the majority of the side chains in the cyclic head protruding out 
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and away from the cyclic core [84]. It was also shown that the decanoyl chain has a high degree 
of conformation freedom [84]. 
To further test daptomycin’s structure, Ball et al. also obtained NMR spectra for daptomycin in 
the presence of calcium at different molar equivalents. Although the resonances of daptomycin 
were broadened, a close analysis of the data obtained indicated that the addition of calcium ions 
did not cause any discernable changes to the chemical shifts at each resonance [84]. In particular, 
at one molar equivalent of calcium, increasing the temperature from 293 K to 313 K narrowed 
the broadened spectra of daptomycin, indicating less binding to calcium, but when the 
temperature was brought back to 293 K, the original broad spectra was obtained, indicating the 
reversible effect of calcium binding to daptomycin [84]. 2D NMR spectra were also obtained 
and showed that daptomycin did not go through any conformational changes upon binding to 
calcium and that the stoichiometry of Ca2+ binding to daptomycin is 1:1 [84]. 
A similar study was done in 2005, where another best-quality structure of apo-daptomycin was 
suggested [91]. Though overall this structure was similar to the one presented by Ball et al., this 
group suggested that clustering was existent between amino acid residues Trp-1 and Kyn-13. 
More thorough analysis and investigation from this group resulted in a higher quality and 
informative structure of apo-daptomycin that is comparable to the one shown in Figure 1.7. As 
seen with the previous study, this structure shows that the backbone amide groups seem to be 
shielded from solvent, which is likely to play a role in enhancing the lipophilicity of daptomycin 
and thus its penetration into a cell membrane’s hydrophobic environment [91].  
After the three-dimensional structure had been determined, more focus was placed on the effect 
of calcium on the structure of daptomycin. Previous studies had shown that calcium led to line 
broadening in NMR spectra which indicated daptomycin aggregation [84, 91], but a study by Ho 
et al. in 2008 focused on the effect of divalent cations (calcium and magnesium) on daptomycin’s 
structure and aggregation state. Through NMR techniques, the 1:1 stoichiometric ratio for 
calcium binding to daptomycin was confirmed and it was determined that a 5 Mg2+ : 2 DAP 
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stoichiometric ratio for magnesium ions was required for daptomycin aggregation [92]. 
Minimum inhibitory concentrations (MICs) for daptomycin were also determined using a 
microtitre broth dilution method for different divalent cations. The results show that the MIC 
increased by at least 32-fold when a divalent cation other than calcium was used, signifying much 
weaker interactions between those cations versus calcium with daptomycin [92]. However, there 
were also similarities when substituting calcium with other divalent cations. When comparing 
the structural changes between calcium or magnesium ions binding to daptomycin, there was 
very little change between those spectra and that of apo-daptomycin [92]. Also, when either of 
the divalent cations were added to daptomycin, the formation of micelles was observed in both 
cases, which makes sense due to daptomycin’s amphiphilic properties [92, 93].  
Various other studies have also been done to further elucidate daptomycin’s structure and its 
conformation in different scenarios through the use of different techniques [83, 84, 86, 91-94]. 
One study involved the determination of pKa values for ionizable amino acids residues in 
daptomycin [86]. Another recent study used various methods to evaluate daptomycin’s 
aggregation in the presence of calcium [94]. Fluorescence spectroscopy analyzes the fluorescence 
of a sample through the emission of light after excitation [95]. In this study by Qiu et al., they 
exploited the fluorescence resonance energy transfer (FRET) between the two fluorophores, 
Trp-1 (donor) and Kyn-13 (acceptor), to determine the critical aggregation concentration of 
daptomycin at various pH levels, which were confirmed by NMR spectroscopy and dynamic 
light scattering. Of significance is their data obtained at physiological conditions of pH with 
varying calcium and daptomycin concentrations. Their results showed that daptomycin 
aggregated when concentrations of 0.06 mM daptomycin and 1.0 mM calcium ions were used at 
a pH of 7.4 [94]. This means that daptomycin does aggregate under normal physiological 
conditions and may be a part of its mechanism of action.  
Although it is important to understand the structure of daptomycin, it is of even more 
importance that we understand how that structure is connected to its activity or mechanism of 
action. With us beginning to understand the three-dimensional structure of daptomycin, more 
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questions arise as to how it actually aggregates and how these structures interact with the bacterial 
membrane to carry out their bactericidal role. 
 
1.3.4.2 Membrane Interaction Studies 
Since daptomycin’s development, there has always been one puzzling question that has plagued 
researchers studying this novel antimicrobial peptide: how exactly does daptomycin work? In 
2003, Silverman et al. proposed a multistep model for daptomycin’s mechanism of action after 
studying the correlation between daptomycin’s bactericidal activity and the dissipation of 
membrane potential on bacterial membranes. With their interest triggered by a previous study 
about how daptomycin could reduce the membrane potential of Staphylococcus aureus [96], 
Silverman’s group decided to re-evaluate daptomycin’s effect on membrane potential through 
the use of fluorimetry and flow cytometry techniques. In the former, a fluorescent probe DiSC3 
was used as it is sensitive to membrane potentials, being attracted to the surface of polarized 
cells. A depolarized environment would not allow the dye to partition to the surface of the 
membrane, releasing it into the medium and increasing the fluorescence signal [97]. Accordingly, 
membrane depolarization will be observed as an increase in fluorescence intensity. This was 
exactly the case with daptomycin when 5 µg/mL of daptomycin were incubated for 0, 15, 30 
and 60 minutes; DiSC3 fluorescence intensity at 670 nm increased very strongly [61]. Flow 
cytometry and cell viability testing were also performed to confirm the results of the fluorimetric 
assay. All three tests showed that daptomycin indeed dissipates the membrane potential in 
Staphylococcus aureus cells, with full membrane depolarization being observed between 30 to 60 
minutes [61]. Further testing by this group involved determining what would cause membrane 
depolarization. It must have been some kind of ion movement across the cytoplasmic 
membrane, so they added a potassium-sensitive fluorescent probe PBFI to a suspension of S. 
aureus cells to test potassium efflux due to daptomycin [61]. Both a signal increase and cell 
viability decrease were observed upon addition of daptomycin to the bacterial cells, suggesting 
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that potassium efflux plays a role in daptomycin’s mechanism of action [61]. However, this does 
not mean that the membrane pores are K+-selective.  
A new study has shown that sodium influx is the primary cause of depolarization under typical 
in vivo conditions, complementing the potassium efflux upon daptomycin insertion [98]. This 
group used fluorescence spectroscopy to study the permeability of liposomes for different 
cations and anions, in which they found that daptomycin permeabilized the liposome 
membranes in a cation-selective fashion and that the pores could discriminate between different 
cations according to size.  
Recently, there have been various studies focusing on the interaction of daptomycin with model 
membranes. In one study, fluorescence spectroscopy was used to examine daptomycin’s 
insertion into membranes [81]. Since daptomycin contains two aromatic residues that are 
intrinsically fluorescent (Trp-1 and Kyn-13), these properties can be exploited in fluorescence 
experiments. It is also important to note that upon the insertion of these residues into a less 
polar environment (such as that of a phospholipid membrane), an increased intensity has been 
observed from previous experiments [99, 100]. As a result, when determining whether 
daptomycin inserts into a model membrane, an increase in fluorescence for either Trp-1 or Kyn-
13 would indicate insertion due to its association with a less polar environment. In the 2004 
study by Jung et al., an emission wavelength of 465 nm was used and the fluorescence intensity 
was observed for daptomycin in the presence or absence of calcium. They discovered that in an 
aqueous solution, daptomycin with and without calcium exhibited low fluorescence intensities, 
but when exposed to neutral phosphatidylcholine (PC) liposomes, a 5-fold increase in 
fluorescence intensity was observed for daptomycin in the presence of calcium. When they used 
a 1:1 PC and PG (phosphatidylglycerol) liposome combination, a 9-fold increase was observed 
[81]. Not only do these results show that daptomycin does insert into the membrane of lipid 
models, but also that daptomycin exhibits different membrane interactions with membranes 
composed of PC/PG and just PC [81]. The group postulated that daptomycin inserted more 
deeply into the mixed PC/PG liposomes than the PC liposomes. 
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In the same study, the researchers determined that daptomycin, in the presence of calcium, was 
able to induce a significant amount of lipid flip-flop in both types of lipid models [81]. This lipid 
flip-flop occurs when the polar head group of a lipid traverses the hydrophobic core of the 
membrane, essentially flipping over to the other leaflet of the bilayer membrane [101, 102]. The 
maximum extent of flip-flop was in correlation with the MIC for daptomycin, between 0.5 to 
2.0 µg/mL [81]. With evidence of lipid flip-flop as well as insertion into model lipid membranes, 
the group decided to test daptomycin’s induction of membrane leakage as well, using the 
liposome-encapsulated dye called calcein to see if it would be released upon the interaction of 
daptomycin with the membrane. Indeed, calcein leakage was observed at high percentages with 
the PC/PG liposome, but only at 10% for the PC liposomes [81]. Additional findings brought 
forth some modifications to the initial multi-step model for daptomycin’s mechanism of action 
by Silverman et al. [61]. It was proposed that when calcium binds to daptomycin, a 
conformational change is induced which increases the complex’s amphipathicity while 
decreasing its charge, allowing it to interact with neutral or acidic membranes [81]. It was 
proposed that once daptomycin has inserted into these membranes, an additional 
conformational change occurs, where calcium acts as a bridge between daptomycin and the 
acidic phospholipids on the lipid membrane to promote deeper insertion [81]. 
In a subsequent study by the same group, the interaction of daptomycin with neutral and acidic 
membranes in the presence of calcium ions was examined [103]. Apart from confirming their 
previous results about daptomycin insertion into the membrane through fluorescence 
spectroscopy, the phase transitions that phospholipids undergo when the structural organization 
and dynamics of lipids are changed was studied by differential scanning calorimetry (DSC) [103]. 
From the endotherms obtained, different transition peak temperatures could be attributed to 
changes in surrounding electrostatics in the lipid bilayer [103]. In these experiments, the group 
showed that a combination of electrostatic and hydrophobic interactions occurred when 
daptomycin was bound to neutral bilayers. Bilayers with acidic lipids primarily involved 
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electrostatic interactions but led to the formation of non-lamellar lipid phases and membrane 
fusion [103]. 
Another group has studied the oligomerization of daptomycin in detail. In 2011, Palmer’s group 
used FRET between native daptomycin and a fluorescently-labelled NBD (7-nitro-2,1,3-
benzoxadiazol) daptomycin derivative to prove that membrane-associated oligomers form as 
part of daptomycin’s mechanism of action [68]. Their experiment involved measuring FRET at 
different ratios of daptomycin (donor) to NBD-daptomycin (acceptor), where the concentration 
of the latter would be kept constant. FRET efficiency was measured through a decrease in donor 
emission. With the PC-only lipid membranes, there was no change in FRET between donor-
acceptor ratios of 16:1 and 1:1, which meant that no oligomerization occurred. Meanwhile, on 
the PC/PG membranes, a fourfold reduction in the Kyn-13 lifetime indicated the presence of 
oligomerization [68]. FRET experiments were also performed in the presence and absence of 
calcium, with results indicating that FRET only occurred in its presence and therefore is required 
for membrane binding [68]. 
To further characterize these membrane oligomerization events, Palmer’s group used perylene 
excimer fluorescence, where a perylene-butanoic acid replaced daptomycin’s N-terminal side 
chain [104]. Although possessing only one-third of the original daptomycin’s bactericidal activity, 
the perylene daptomycin was capable of forming excimers (short-lived molecule between two 
species) to show that neighbouring oligomeric subunits were in direct contact with one another. 
They showed that daptomycin oligomerizes on live bacterial cells and that there was a high extent 
of oligomerization on model membranes that signifies these events play a large role in 
daptomycin’s bactericidal effect. Apart from this, their results suggests that neighbouring 
subunits of the daptomycin oligomer are aligned parallel or at acute angles from one another 
and that this oligomerization event is mediated by phosphatidylglycerol [104]. 
In another study by the same group, daptomycin was used together with a semisynthetic 
derivative of A54145 (CB-182,462), which shares 5 identical and 4 similar amino acid residues 
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with daptomycin. Through fluorescence spectroscopy and antibacterial activity testing, they 
determined that the two antibiotics formed hybrid oligomers; however, the antimicrobial activity 
of these hybrids was reduced. This confirmed that oligomerization is required, but not sufficient 
for antibacterial activity [105]. 
Using similar techniques as before, the group also showed that lipid membranes with cardiolipin 
prevented membrane translocation and permeabilization by daptomycin [106]. Through FRET, 
it was observed that even with cardiolipin, daptomycin oligomers continued to form, but in 
groups of four subunits as indicated before with FRET experiments [107], which is half of what 
was observed on membranes without cardiolipin. They believe that cardiolipin prevents 
daptomycin from translocating to the inner leaflet of the lipid membrane, thus being unable to 
form the tetramer (the other half of the subunit) on the other side [106]. Their findings led them 
to suggest an updated model of daptomycin’s mechanism of action (see Figure 1.8) where 
daptomycin aggregates in tetramers on the outer leaflet of the lipid membrane and then (through 
lipid flip-flop) translocates to the inner leaflet until such time that an outer tetramer combines 
with the inner one to form an octameric pore [106]. 
Expanding from this proposed mechanism where bacterial membrane permeabilization involves 
the formation of transmembrane pores that are made of six to eight daptomycin subunits, Taylor 
et al. discovered that each daptomycin molecule sequentially binds two calcium ions, which they 
believe is required for antibacterial activity [108]. It was suggested that the first calcium ion 
encourages daptomycin to bind to the membrane, and the second calcium ion allows for deeper 
insertion and incorporation of daptomycin into the bacterial membrane, where it confers its 
bactericidal activity [108]. 
26 
 
 
 
Figure 1.8 Updated model of daptomycin pore formation. This figure presents an updated 
model of daptomycin’s mechanism of membrane insertion, pore formation and structure. (1) 
Daptomycin binds to calcium and inserts into the membrane as in Figure 1.5, oligomerizing on 
the surface. (2) Daptomycin forms a tetramer on the outer leaflet of the bacterial cell membrane. 
(3) This daptomycin tetramer inserts itself into the membrane. (4) The absence of cardiolipin 
allows for deeper penetration of daptomycin into the membrane, which means that the head 
group of the daptomycin tetramer may very well cause a localized cave-in of the outer leaflet of 
the bacterial membrane. (5) Once this tetramer is situated in the membrane, it combines with 
another tetramer on the other side of the membrane to form an octameric pore which causes 
potassium ion leakage and subsequent cell death. In order to get a daptomycin tetramer on the 
other side of the membrane, it is posited that lipid flip-flop may occur, where the tetramer 
translocates to the inner leaflet. In this figure, lipid flip-flop has occurred for one daptomycin 
tetramer, represented by the orange arrows [106]. 
 
Another group studied daptomycin’s effect on the membrane through cell biological assays 
[109]. They showed that daptomycin induces the formation of randomly-positioned membrane 
patches that are colocalized with a fluorescent daptomycin derivative. This means that they are 
a direct result of daptomycin’s insertion into the membrane. In addition, evidence is given to 
show that daptomycin severely alters the shape and peptidoglycan biogenesis of the bacterial cell 
wall [109]. Another recent study has shown that daptomycin causes a lipid extracting effect when 
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interacting with giant unilamellar vesicles in the presence of calcium, but no clear conclusions 
could be made [110]. The group claims that this lipid extraction leads to ion permeation, but 
further experiments will need to be performed [110]. Transmission electron microscopy has also 
been used to qualitatively determine that daptomycin does not cause lysis of bacterial cell 
membranes [111]. Although numerous membrane interaction studies have been completed, 
there is a lack of these types of studies in relation to complex lipid model membrane systems. 
Apart from membrane interaction studies, susceptibility testing also plays a large role in 
daptomycin research, especially with many questions still to be answered about its organ-specific 
inhibition in the lungs. 
 
 
1.3.4.3 Antimicrobial Susceptibility Testing 
Although the action mechanism of daptomycin has not been clearly established, there are some 
certainties to this mystery. First of all, daptomycin’s dependency on calcium to carry out its 
bactericidal activity has been proven in many cases [4-9, 49, 61, 67, 103, 105]. In particular, 
studies have shown that daptomycin’s minimal inhibitory concentration (MIC) increases 
significantly when calcium is not present [6, 103]. This indicates that calcium is required in order 
for daptomycin to carry out its bactericidal action. But exactly how much bactericidal action does 
daptomycin confer? That’s where antimicrobial susceptibility testing comes in. 
Before FDA approval, a study compared the MIC and minimal bactericidal concentration (MBC) 
of daptomycin with other pharmaceutical alternatives such as vancomycin and gentamicin [112]. 
In vitro susceptibility tests were performed using microdilution techniques, and it was determined 
that daptomycin’s MIC and MBC for MRSA-67 (methicillin-resistant Staphylococcus aureus, strain 
67) were 0.125 μg/mL and 0.5 μg/mL respectively [112]. In comparison with the other drugs, 
daptomycin’s MIC was half of theirs while the MBC remained the same [112]. These results were 
confirmed once again in another study that tested for the MIC and MBC for various drugs, 
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including linezolid and quinupristin-dalfopristin [72]. Out of all these drugs, daptomycin was the 
most bactericidal against the highest number of strains, meaning it had a broad range of 
antibacterial activity as well as efficient bactericidal qualities [72]. Many of the previous drugs 
had already experienced increasing resistance from the bacteria they were supposed to target. 
 
Table 1.2 MIC values of daptomycin and comparator drugs against PRSP. Select 
antibiotics have been evaluated for their bactericidal activity against penicillin-resistant 
Streptococcus pneumoniae worldwide. MIC50 and MIC90 minimal inhibitory concentration values are 
presented for each antibiotic, as well as susceptibility and resistance of bacterial strains against 
each antibiotic. Daptomycin has the best combined values with low MIC90 and 100% 
susceptibility (Adapted from [113]). 
Antibiotic MIC50 (µg/mL) MIC90 (µg/mL) Susceptibilitya (%) Resistanceb (%) 
Amoxicillin-Clavulanate ≤2 8 79.2 11.9 
Ceftriaxone ≤1 1 91.6 4.0 
Clindamycin ≤0.06 8 64.0 34.0 
Daptomycin ≤0.12 0.25 100.0 0.0 
Erythromycin 4 32 25.6 72.9 
Levofloxacin 1 1 98.5 1.5 
Linezolid 1 1 100.0 --- 
Quinupristin-Dalfopristin 0.25 0.5 100.0 0.0 
Vancomycin 0.25 0.5 100.0 --- 
a Refers to the percentage of strains susceptible to the antibiotic 
b Refers to the percentage of strains resistant to the antibiotic 
* Values of susceptibility and resistance may not add up to 100% due to a subset of strains that are categorized as 
neither susceptible or resistant to the antibiotic, but rather intermediate (susceptible/resistant only under certain 
conditions) 
 
In testing daptomycin against various strains of multi-drug resistant Gram-positive strains of 
bacteria, it was shown that daptomycin had high activity against vancomycin-resistant 
enterococci (VRE) as well as various resistant strains of staphylococci [111, 113, 114]. The MIC90 
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(MIC required to kill 90% of bacterial strains) was determined to be 0.25, 1, and 4 μg/mL for 
Streptococcus pneumoniae, Enterococcus faecium, and Enterococcus faecalis respectively [113]. Daptomycin 
was recorded to be the most potent compound against S. pneumoniae with the lowest MIC90 value 
(see Table 1.2), but an in vitro study showed that there was no bactericidal activity against this 
bacterium in cases of community-acquired pneumonia [10, 113]. It was discovered through 
microdilution techniques and fluorescence spectroscopy that daptomycin interacts with and is 
sequestered by the pulmonary surfactant found within the alveoli of the lungs, thus marking a 
unique example of organ-specific inhibition of an antibiotic [10]. More studies still have to be 
performed to elucidate this interesting case of daptomycin inhibition inside the lungs. 
Nevertheless, daptomycin is still effective against many other Gram-positive infections such as 
complicated skin and skin structure infections, bacteremia, endocarditis, osteomyelitis, and more 
[115]. In the first few years of its use, daptomycin has gained much popularity due to its 
favourable safety and tolerability despite various treatment durations [115]. In fact, apart from 
its usual dosage of 4 mg/kg/day for most Gram-positive infections, doses between 8 to 12 
mg/kg/day have been used for acute cases of infections [116]. Even with these high dosages, 
no adverse events were reported, indicating its strong efficacy and safety for clinical use [117-
120]. 
Daptomycin has indeed shown a significant potency and activity against many Gram-positive 
bacteria, including those that are multi-drug resistant. It is no doubt a great alternative to the 
drugs afflicted by the emergence of resistant bacteria, and has been useful in treating many 
patients with Gram-positive infections. In fact, daptomycin was found to be active against all 
833 isolates of MRSA tested in a recent study to encourage the use of daptomycin in Japan [121]. 
A worldwide study of daptomycin’s activity against 164,457 bacterial isolates from hospitalized 
patients has also shown its potency against an impressive amount of Gram-positive pathogens 
[122]. 
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However, with daptomycin increasingly replacing these drugs that are no longer as effective on 
their bacterial targets, what will happen should daptomycin fall into the same category and 
resistance starts to rise against it? Unfortunately, the bacterial world adapts quickly to change, 
and several cases have already reported daptomycin-resistant strains of bacteria. 
 
1.3.4.4 Rising Resistance to Daptomycin 
As pathogens receive more exposure to antibiotics, they build stronger resistance towards these 
drugs, creating barriers to prevent their own demise. MRSA (methicillin-resistant Staphylococcus 
aureus) infections are becoming more frequent, but due to an increase in resistance, it has become 
increasingly difficult to treat patients who are afflicted by these illnesses [123]. Vancomycin has 
been used against Gram-positive infections for quite some time, and decreased susceptibility has 
been reported in various staphylococcal strains, sparking widespread interest to create a 
“replacement” drug that can be just as efficient as vancomycin, but with zero or minimal 
resistance. Enter daptomycin, a rapidly bactericidal AMP that is approved for various Gram-
positive infections at daily dosages of 4 to 6 mg/kg depending on the type of infection [123]. 
Although only having been on the market since its FDA approval in 2003, various reports have 
shown that clinical S. aureus strains had increased daptomycin MICs or a loss of its susceptibility 
[124-127]. Another study had shown that daptomycin resistance has emerged in enterococci as 
well, specifically Enterococcus faecium [128]. With daptomycin’s mechanism not well understood, 
its mechanism of resistance is even less understood. A study by Jones et al. in 2008 used 
fluorescence techniques to compare various membrane parameters between the parental and 
resistant strains. They showed that the resistant isolates had enhanced membrane fluidity, 
increased translocation of lysyl-PG from the inner to the outer membrane leaflet, increased net 
positive surface charge, reduced susceptibility to daptomycin-induced permeabilization and 
depolarization, decreased surface binding of daptomycin, and increased cross-resistance to other 
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cationic AMPs [129]. But a precise understanding of daptomycin’s non-susceptibility (where the 
MIC is greater than 1 μg/mL) has yet to be revealed. 
Throughout the past decade or so, various studies have focused on the genetics of non-
susceptible daptomycin strains [129-135]. Mutations in certain genes, namely: mprF (lysyl-PG 
synthetase), yycG (histidine kinase also known as WalK), and rpoB and rpoC (subunits of RNA 
polymerase) have been correlated with daptomycin non-susceptibility [130]; mprF mutations 
seemed to favour the repulsion of a functional, calcium-bound daptomycin complex [134]. This 
reduced drug binding has been attributed to changes in the expression or function of genes 
associated with cell surface charges, such as dltA, which mediates the ᴅ-alanylation of the 
teichoic acids of the bacterial cell wall [131, 136]. Various other studies have shown that 
modifications to the cytoplasmic membrane’s fluidity and cell wall thickness play a role in non-
susceptibility [129, 134]. In a study by Patel et al., it was concluded that multiple genetic changes 
are associated with daptomycin resistance in Gram-positive pathogens [135]. Cell viability and 
gene sequencing techniques were used in a couple of experiments to show that substitution 
mutations in mprF and yycG induced cell wall thickening on a frequent basis [132, 135]. Such 
thickening was confirmed by transmission electron microscopy in other studies, which showed 
that the daptomycin-resistant bacterial isolates produced more cell wall, by weight, than the 
parental strains [131, 137]. Further studies have confirmed that strains acquire resistance in 
multiple steps, which include strain-dependent phenotypes, adaptations in metabolic functions 
and modification of lipid and protein contents of the cell wall and membrane [138]. Some 
proposed resistance mechanisms include repulsion, where the membrane surface charge and 
phospholipid content block daptomycin from binding and oligomerizing, and diversion, where 
cardiolipin clusters or microdomains help to trap daptomycin away from areas prone to pore 
formation [54]. 
Apart from genetic mutations, there has also been much discussion about how daptomycin could 
be inactivated as a mechanism of resistance from any class of bacteria. The first comprehensive 
analysis of such a mechanism was presented in a study by D’Costa et al. in 2011, which discovered 
32 
 
that various types of hydrolases were capable of cleaving the ester linkage of daptomycin’s ring 
structure. Although S. aureus has yet to exhibit resistance to daptomycin through enzymatic 
hydrolysis, this group said that it is highly possible that S. aureus could synthesize and secrete 
extracellular proteases that could hydrolyze daptomycin in the future [139]. 
A different study focusing on the genetic, genomic and phenotypic analyses of daptomycin-
resistant bacterial isolates of Bacillus subtilis has suggested that reduced levels of PG in the 
membrane would decrease the net negative charge of the membrane. As a result, this would 
weaken the bacterium’s interaction with a positively-charged calcium-bound daptomycin 
complex and increase the chance of its cell survival [140]. Recently, one group proposed an 
additional model for daptomycin resistance amongst bacteria, specifically that of Enterococcus 
faecalis [141]. Their evidence suggested that vancomycin-resistant enterococci (VRE) use a novel 
strategy to avoid daptomycin killing by diverting the antibiotic molecules to distinct membrane 
regions and trapping them there. Fluorescence techniques and TEM were used to elucidate these 
cell membrane sites, which were discovered to be deficient in PG and rich in other negatively-
charged phospholipids [141]. These studies on different methods of daptomycin resistance have 
led researchers to think about the consequences of this non-susceptibility and whether other 
drugs and antibiotics can be affected by bacterial evolution as well. 
The notion of cross-resistance has also been touched on by several studies. It is unfortunate that 
when certain antibiotics share similar mechanisms of action, any resistance built up towards one 
type of antibiotic in that category might cross over to other antibiotics of that type. Although 
daptomycin has a unique mechanism of action, it still has properties of a cationic AMP once 
bound to calcium, and even though it may take more time to build a resistance towards 
daptomycin, it makes sense that this resistance could potentially carry over to cationic AMPs. 
This is exactly what was reported in a recent study, where it was shown that for MRSA isolates 
developing reduced susceptibilities to daptomycin, reduced in vitro susceptibilities to two other 
cationic AMPs were observed [132, 133]. Due to the mounting evidence of antibiotic resistance 
mechanisms, it is clear that future studies will need to involve more precise evaluations of how 
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such drug-resistance patterns can occur [142]. But in the meantime, there is another alternative 
to improving daptomycin’s bactericidal activity should some resistant bacteria come its way. 
 
1.3.4.5 Combination Treatments 
To counter the trend toward increasing resistance to it, daptomycin has more recently been used 
in combination with various other antibiotics. The synergistic effects of daptomycin with various 
types of antibiotics have been tested against multi-drug resistant strains of Staphylococcus aureus 
and other Gram-positive bacteria. For example, a study in 2007 tested the activity of daptomycin 
in combination with gentamicin, another antibiotic used in the treatment of MRSA [143]. Using 
in vitro time-kill studies (a measure of bactericidal activity and killing speed for each individual 
bacteria or in combination), this group combined daptomycin with gentamicin at sub-MIC levels 
and observed synergy in 68% of the strains tested. In fact, for these successful results, a marked 
change in the slope of the killing curve indicated that the combination treatment of daptomycin 
and gentamicin was more rapidly bactericidal than either antibiotic by itself [143]. Rifampin, 
ceftriaxone, and some β-lactams have also been tested with daptomycin, yielding favourable 
results against VRE and other resistant bacteria [112, 143-157]. 
These results have proven useful, as rifampin has been used as an addition to daptomycin in the 
successful treatment of daptomycin-resistant MRSA infections such as meningitis and 
bacteremia [158-161]. Linezolid and gentamicin, each combined with daptomycin, have also 
been used to successfully treat vancomycin-intermediate Staphylococcus haemolyticus and VRE 
infections [162, 163]. Other studies have proven the efficacy of daptomycin combined with 
fosfomycin for the treatment of MRSA osteomyelitis and ceftaroline for the treatment of MRSA 
infections [164, 165]. A recent study incorporated high-dose daptomycin regimens with 
rifampicin to treat Gram-positive osteoarticular infections [166]. Although the clinical uses of 
these combination therapies have been successful, questions arise as to how and why daptomycin 
either enhances or is enhanced by the activity of its partnered drug. 
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In a study by Berti et al. in 2013, several β-lactams such as ampicillin and nafcillin were used in 
combination with daptomycin to test its relative enhancement of bactericidal activity against 
MRSA. Since there is high variability in the profiles of penicillin-binding proteins (PBPs) 
between different β-lactam antibiotics, the goal of this study was to determine whether a specific 
profile was associated with enhanced daptomycin activity. Using time-kill assays, this group 
showed that β-lactams indeed possess different potencies in enhancing daptomycin’s bactericidal 
activity against MRSA. Their results indicated that the β-lactams exhibiting PBP1 binding 
enhanced daptomycin activity more than those with minimal PBP1 binding [167]. 
 
 
 
Figure 1.9 Silver nanoclusters packed with daptomycin act as antimicrobial bombs. To 
improve the efficacy of antimicrobial agents, integrating two bactericides into one entity could 
be an option for future development. This figure represents the work done by one group in 
designing an antimicrobial hybrid made of silver nanoclusters (AgNCs) conjugated with 
daptomycin. These antimicrobial cluster bombs (depicted as D-AgNC in the figure) allow for 
greater bacterial membrane damage through the (A) creation of larger pores due to its larger size, 
while (B) localized high reactive oxygen species (ROS) concentrations, shown in red, 
continuously generate within the bacteria and causes severe DNA damage (Adapted from [168]). 
 
There is also a growing interest in incorporating daptomycin into antimicrobial “cluster bombs”, 
which involve a hybrid of silver nanoclusters with daptomycin (see Figure 1.9) [168]. Since silver 
(Ag) is known to exert a wide spectrum of bactericidal activity through a multitude of killing 
mechanisms [169], its combination with the antimicrobial activity of daptomycin should not only 
allow for enhanced antimicrobial activity but also be less prone to bacterial resistance. The results 
from this group showed that their novel antimicrobial hybrid obtained through silver nanocluster 
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and daptomycin conjugation was able to enhance the killing effect for S. aureus, suggesting that 
a synergistic killing mechanism is taking place: localized daptomycin damages the bacterial 
membrane in its usual way while localized silver nanoclusters can generate reactive oxygen 
species to oxidize the lipids of the bacterial membrane and help intensify membrane damage 
[168]. 
All of these studies reveal that daptomycin’s synergistic effects are particular to each drug it is 
paired up with. Every antibiotic has its own mechanism of action, and the consequences of those 
interactions may directly promote or reduce daptomycin’s bactericidal activity. On the flip side, 
daptomycin’s mechanism of action could do the same for the antibiotic it is partnered with as 
well. This leads us to believe that the most common type of enhancing interaction between 
daptomycin and its partnered drugs would involve some kind of coupled or additive response 
[170]. However, further studies will certainly be required to elucidate each combination’s effect 
on daptomycin’s mechanism of action. 
 
1.3.4.6 Daptomycin Derivatives 
Various derivatives of daptomycin have been produced by Cubist Pharmaceuticals. After FDA 
approval of daptomycin in 2003, novel antibiotics related to daptomycin were produced for 
further antimicrobial screening and drug development [171]. These derivatives are important not 
only for determining new antibiotics that can be of clinical use, but also in determining 
daptomycin’s mechanism of action and its inhibition by pulmonary surfactant. In one study, 
daptomycin derivatives were tested along with hybrid molecules of a structurally related 
lipopeptide called A54145, which is produced by Streptomyces fradiae instead of S. roseosporus [172]. 
These hybrids were obtained by swapping the coding sequences of some modules between the 
daptomycin and A54145 NRPS systems. Subsequently, MIC tests for bactericidal activity against 
Staphylococcus aureus were performed in the absence and presence of 1% bovine pulmonary 
surfactant [173]. From this study, it was discovered that, although some derivatives could exhibit 
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antibacterial activity in the presence of pulmonary surfactant, they were less efficient and resulted 
in higher MIC values. These derivative compounds were CB-182,561, CB-182,575 and A54145D 
with MIC values of 2, 4, and 4 μg/mL, respectively [173]. When we compare these derivative 
MICs to the original daptomycin compound with an MIC of 64 μg/mL in the presence of 
surfactant, this is a great improvement. However, in the case of an environment without 
surfactant, the MIC increases by 2- or 8-fold as compared to the original, indicating a decrease 
in bactericidal activity [173]. Experiments have yet to be performed to elucidate the difference 
in interactions, either action mechanisms or affinity, between daptomycin and these derivatives 
in the presence of pulmonary surfactant. Such information would provide further insight into 
daptomycin’s usual mechanism of action as well as guidance for future research and development 
of antimicrobial drugs. In fact, a lot more research still needs to be done in order to answer the 
many questions we have about daptomycin and how it works. 
 
 
1.3.4.7 A54145 and CB-182,462 
Due to increasing bacterial resistance to daptomycin and lack of bactericidal activity in the 
presence of lung surfactant, there was an increasing effort to develop various daptomycin 
derivatives to overcome these obstacles. One study focused on the development of different 
hybrids between daptomycin and A54145, a calcium-dependent antibiotic that comes from the 
same A21978C complex as daptomycin [82, 173]. Although homologous to daptomycin, A54145 
is known to be toxic [105, 174]. However, numerous hybrids and derivatives of A54145 have 
proven to exhibit bactericidal activity within the presence of lung surfactant [173]. 
One such A54145 derivative is CB-182,462 (see Figure 1.10), which was found by Cubist 
Pharmaceuticals to be potent against S. pneumoniae in the presence of lung surfactant; in fact, 
more potent than most of the naturally-occurring molecules of A54145 (J. Silverman, personal 
communication). Unfortunately, CB-182,462 caused toxicity in experiments with mice, which 
developed kidney phospholipidosis when exposed to the drug; accordingly, the development of 
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462 was stopped (J. Silverman, personal communication). Nevertheless, testing this antibiotic 
and comparing its mechanism of action with that of daptomycin may help to shed further light 
into the issue of daptomycin’s inhibition by lung surfactant. 
 
 
 
Figure 1.10 Chemical structure of CB-182,462. The compound CB-182,462 is a semisynthetic 
derivative of the natural compound A54145, which has the same architecture as daptomycin. As 
a result, CB-182,462 has a 13 amino acid chemical structure. 
 
The structure of CB-182,462 is very similar to that of A54145, but with a substituted alkyl-
carbamyl residue replacing the naturally-occurring fatty acyl residue at the N-terminus [105]. As 
it is a semisynthetic derivative of A54145, CB-182,462 will also share a number of structural 
features with this complex, which in turn will be comparable to daptomycin. This means that 
CB-182,462 has a 10-member ring, has Asp residues at positions 7 and 9 to form a calcium-
binding motif, has achiral amino acids at positions 5 and 10, has ᴅ-amino acids at positions 2, 8 
and 11, and has the rare amino acid 3mGlu, all structures that are shared with daptomycin. 
However, this also means that CB-182,462 has different amino acids than daptomycin: ᴅ-Asn is 
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replaced by D-Glu in position 2, L-Asp by L-HO-Asn in position 3, Gly by Sar in position 5, L-
Orn by L-Ala in position 6, D-Ala by D-Lys in position 8, L-Asp by L-MeOAsp in position 9, D-
Ser by D-Asn in position 11, 3-L-MeGlu by L-Glu in position 12, and finally L-Kyn by L-Ile in 
position 13.  
Only one study has been published regarding CB-182,462, related to its use in forming a hybrid 
oligomer with daptomycin to test whether daptomycin’s antimicrobial activity came from 
oligomer formation alone or additional steps to confer proper antibacterial activity [105]. There 
are currently no published studies on just CB-182,462 and its interaction with model membrane 
systems or in comparison to daptomycin.  
 
39 
 
CHAPTER 2 
2 OVERVIEW OF THESIS 
 
2.1 Research Goals 
The primary objective of the research outlined in this thesis is to use advanced biological 
nanotechnology tools to investigate daptomycin’s molecular mechanism of action and gain 
further insight into its inhibition by pulmonary surfactant when used to treat Gram-positive 
Streptococcus pneumoniae infections within the lung. We are interested in elucidating the interactions 
of daptomycin with model lipid monolayers and membranes that mimic bacterial membranes (S. 
pneumoniae), human membranes (erythrocytes), and lung surfactant.  
Until now, daptomycin’s general mechanism of action has been modeled as ion channel 
formation within the bacterial membrane, which causes membrane depolarization and 
subsequent cell death. Daptomycin is an extremely potent antimicrobial peptide that acts against 
all Gram-positive microorganisms, but somehow loses its bactericidal activity when inside the 
lungs, in the presence of lung surfactant. 
Although additional details regarding daptomycin oligomerization and pore formation have been 
obtained, there is little research done to elucidate daptomycin’s inhibition by lung surfactant and 
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why this would happen. There is a hypothesis that ascribes daptomycin’s inhibition to a much 
greater abundance of lung surfactant than daptomycin, therefore dampening its activity or 
binding to lung surfactant and preventing it from attacking bacterial cell membranes. 
Nevertheless, daptomycin’s inhibition in the presence of lung surfactant is highly unique as it is 
the first ever reported case of organ-specific inhibition of an antibiotic within the lungs, and it 
is still a problem that needs to be solved. 
The specific objectives of this thesis are as follows: 
1. Can we mimic different natural lipid membranes? In order to study daptomycin’s 
interaction with different membranes, we must first develop these membrane systems. 
The first objective is to develop model lipid membrane systems that mimic the lipid 
membrane composition of S. pneumoniae, erythrocytes, and lung surfactant. Bovine lipid 
extract surfactant (BLES®) will be used as a readily-available tool to validate the lung 
surfactant lipid model. The development of these lipid models is the focus of Chapter 
3.  
 
2. Is there strong binding of daptomycin to lung surfactant? There is evidence that 
daptomycin can insert into surfactant, and the widely accepted theory is that there is such 
a vast abundance of surfactant within the lungs (greater surface area) that daptomycin is 
incapable of distinguishing between lung surfactant and bacterial pathogens (with a 
smaller surface area) [10]. However, there is no study that compares the binding of 
daptomycin to different model lipid systems, specifically those of lung surfactant and 
bacterial membrane. Experiments that provide additional insight into this area are 
presented in Chapter 5. 
 
3. Can we quantify the changes that daptomycin insertion incurs on different 
monolayer models? Monolayers are useful models for membrane interactions. Since 
daptomycin can insert into lung surfactant as well as bacterial membranes, what changes 
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in monolayer properties does daptomycin insertion incur in each monolayer model? 
Even if we determine whether it has strong binding or not, the question remains as to 
how daptomycin affects the properties of lung surfactant after it has incorporated itself 
within this thin film. Thin film compression and insertion assay experiments using the 
Langmuir-Blodgett trough help elucidate these changes and are presented in Chapter 6.  
 
4. Can we visualize the changes that daptomycin insertion incurs on different 
monolayer models? Various scanning probe microscopy methods are excellent 
nanotechnology tools that allow for high-resolution imaging of nanoscale structures. The 
goal is to apply atomic force microscopy, phase imaging and Kelvin probe force 
microscopy techniques to obtain high-resolution topographical, phase and surface 
potential images of monolayers with and without daptomycin and/or calcium. These 
experiments will provide novel insight into the qualitative effects of daptomycin on 
different lipid models and are covered in Chapter 7.  
 
5. Can these visualizations be seen using membrane models instead? No model 
system can mimic all the properties of a natural membrane. Although lipid monolayer 
models are good representatives of lipid bilayers and membranes, we want to take that 
extra step and use liquid AFM imaging to further visualize daptomycin’s interaction with 
model bacterial membranes and lung surfactant bilayers. This question is examined in 
Chapter 7 as well. 
 
6. How does CB-182,462 differ from daptomycin? Since daptomycin exhibits organ-
specific inhibition in the lungs, it is a natural response for pharmaceutical companies to 
modify and create additional analogues of daptomycin and derivatives for testing. Cubist 
Pharmaceuticals, Inc. (a subsidiary of Merck & Co. since 2015) developed multiple 
genetically engineered lipopeptide antibiotics related to A54145, a naturally-existing 
lipopeptide in Streptomyces fradiae that has a similar structure to daptomycin [173]. A 
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compound that was obtained through chemical modifications, labeled CB-182,462, was 
shown to have potent bactericidal action against S. pneumoniae in the presence of lung 
surfactant (J. Silverman, personal communication). However, there was evidence of 
kidney toxicity through phospholipidosis, so its development never went forward (J. 
Silverman, personal communication). Although the development of CB-182,462 has 
ceased, comparisons of this compound’s interactions versus daptomycin’s interactions 
can provide further insight into CB-182,462’s mechanism of action and toxicity. 
Experiments containing these comparisons are described in Chapters 5 to 7.  
The combined results of this thesis will help to elucidate the interaction of daptomycin and CB-
182,462 with each lipid model system, confirm its calcium-dependent mechanism of action, and 
provide further details on daptomycin’s inhibition by lung surfactant. This knowledge will 
provide a basis upon which other groups can expand to improve the use of daptomycin and its 
derivatives to treat community-acquired pneumonia more efficiently. The methods and 
techniques presented in this thesis can also be carried forth to future research in investigating 
the mechanisms of action of various different antibiotics and peptides. 
 
2.2 Organization of Thesis 
This thesis is organized into eight chapters. Chapter 1 presents background information related 
to different aspects of the thesis topic. Meanwhile, this Chapter 2 presents the overarching 
questions that subsequent thesis chapters seek to answer. 
Part of my thesis involved the novel design and development of lipid membrane model systems 
that mimic different types of membranes. Relevant background information, along with rationale 
behind the design of each model system, is presented in Chapter 3. Chapter 4 presents the 
different methods and techniques that were used in subsequent chapters to study these lipid 
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membrane model systems. Appendices are included at the end of this thesis that detail various 
experimental protocols that were developed for this thesis work. 
The thesis research projects are organized into three chapters, Chapters 5 to 7. Chapter 5 looks 
to provide evidence of daptomycin sequestration by lung surfactant and describes how 
daptomycin interacts with different membrane model systems. The monolayer studies 
performed in Chapter 6 aim to quantify the effect of daptomycin on different lipid model 
systems, specifically related to a monolayer’s compressibility and changes in pressure. Finally, 
Chapter 7 looks at the qualitative effect of daptomycin on the different lipid model systems by 
using AFM and KPFM to study topographical and electrical surface potential changes amongst 
different samples. Each of these research chapters is formatted as a distinct paper to be 
submitted for publication in a scientific journal.  
All of the thesis projects are summarized in Chapter 8, with generalized conclusions and 
possible avenues for future research. 
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CHAPTER 3 
3 DESIGN & DEVELOPMENT OF LIPID MODELS 
 
Cellular membranes and biological thin films are highly complex, containing not only the lipid 
molecules that make up the bulk of their fundamental structure, but also many proteins that 
confer additional functionality to the membrane. Due to their intricate structure and function, 
biological membranes have been widely studied in an attempt to gain further insight into their 
capabilities. Throughout time, biological membranes have been the inspiration behind many 
types of lipid model systems which allow researchers to tailor their size, structure, composition 
and organization. Common model membranes include vesicles, supported bilayers and bilayer 
islands wrapped by proteins [175]. Lipid monolayers are also excellent model systems that 
provide insight into the interactions taking place at model membrane surfaces [176]. 
All biological membranes are composed of lipids, proteins and carbohydrates, with the bulk of 
it being a bilayer of amphipathic lipids. According to the updated fluid mosaic model and lipid 
raft hypothesis, there are specialized, higher-order membrane domains that are enriched in 
certain lipids (mainly cholesterol and sphingolipids) and proteins that can move across a sea of 
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lower-order lipids (see Figure 3.1) [177, 178]. The theory behind the formation of these lipid 
rafts is constantly evolving, as more and more studies shed additional light into their structure 
and development. The current concept involves a reversible and dynamic process of lipid 
membrane nanodomains, which can form from the presence of hydrogen bonds, hydrophobic 
entropic forces, charge pairing, and van der Waals forces [178-184]. When these interactions are 
strong enough, the small structures created are called lipid rafts, which contain specific lipids or 
proteins that allow for compartmentalized functional platforms for various cellular functions 
[178, 185-189]. 
 
 
Figure 3.1 Overview of lipid raft organization. The plasma membrane of a cell has an outer 
leaflet and an inner leaflet. Certain areas of this bilayer are called lipid rafts, specialized membrane 
domains that tend to compartmentalize cellular processes. These lipid rafts are known to have 
high concentrations of cholesterol and sphingolipids, but every raft may not be identical due to 
the specific proteins or lipids contained within them. They are known to play a role in cell 
signalling and the regulation of membrane bioactivity [190].  
 
The complexity of biological membranes is too much to mimic accurately in lipid membrane 
models, and we can only hope to mimic the functions, properties, and compositions of isolated 
areas within these membranes that are related to what we are studying. For my thesis, the primary 
goal is to further elucidate daptomycin’s mechanism of action and inhibition by lung surfactant 
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in the context of an individual who has community-acquired pneumonia (CAP) caused by S. 
pneumoniae.  
Prior to beginning any experimental work on daptomycin’s mechanism of action, we must first 
develop lipid model systems to mimic different lipid membranes relevant to our study. In order 
to study daptomycin and CB-182,462’s interaction with different membranes, we need to 
determine which types of membranes these antibiotics would interact with in reality and try to 
mimic these as closely as possible. 
Streptococcus pneumoniae, commonly known as pneumococcus, is a leading cause of bacterial CAP 
[191]. Commonly residing in the upper respiratory tract of health individuals, S. pneumoniae can 
be easily spread to others via inhalation. Once it reaches the lungs (either through the 
bloodstream or via inhalation), S. pneumoniae interacts with alveolar surfaces and lung surfactant 
to activate inflammatory host responses [192]. Daptomycin and CB-182,462 are both antibiotics 
that show potent bactericidal activity against S. pneumoniae. However, the former is inhibited by 
lung surfactant and the latter is toxic to mammalian host membranes. In order to compare the 
effects and interactions that these antibiotics have on CAP patients, three lipid membrane model 
systems will need to be developed: (1) a bacterial membrane model system that mimics the lipid 
composition of S. pneumoniae, (2) a lung surfactant model system that mimics the lipid 
composition of human lung surfactant, and (3) a host human membrane model system that 
mimics the lipid composition of erythrocytes or regular tissues cells that these antimicrobial 
peptides may come into contact with. Since BLES® (Bovine Lipid Extract Surfactant) is readily 
available, our lung surfactant lipid model will be compared to our modified BLES® lipid model 
(the fourth model) to test the relevance of our surfactant model system.  
The following sections will cover the four different lipid model systems that will be used 
throughout the work in this thesis as well as the determination of lipid composition of these 
models.  
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3.1 Bacterial Membrane (BM) Lipid Model 
The process behind developing our bacterial membrane lipid model is multifold. First, we must 
understand the disease we wish to study, community-acquired pneumonia, and then look into 
the leading bacterial causes of this disease. Once that has been established, we can then delve 
into the properties of this bacterium, Streptococcus pneumoniae, and determine the lipid composition 
of its bacterial membrane. We can then choose relevant lipids and ratios to use for our simplified 
bacterial membrane model. 
 
3.1.1 Overview of Community-Acquired Pneumonia (CAP) 
Community-acquired pneumonia (CAP) is a severe infection of the lungs contracted by an 
individual that has had little to no contact with the healthcare system; it is the opposite of 
hospital-acquired pneumonia (HAP), which is contracted when patients spend extended 
amounts of time in healthcare facilities [193, 194]. CAP is the most common type of pneumonia, 
affecting people of all ages and walks of life. It causes the lung’s alveoli to fill up with fluid due 
to constant inflammation [195, 196].  
For the past two centuries, community-acquired pneumonia has secured its place as one of the 
leading causes of death due to infectious disease. In the pre-antibiotic era, Streptococcus pneumoniae 
was the culprit behind at least 95% of these cases, with mortality rates ranging from 20 to 40% 
[191]. In 1995, the United States of America reported over 4 million cases per year, affecting 12 
per 1000 adults per year and causing annual costs of about US$23 billion [197]. After years of 
research and antimicrobial drug development, CAP remains a major cause of complications and 
death in our world. Specifically, the predominant causative pathogen has remained the same for 
all of these years. Although S. pneumoniae is detected from 5% to 35% of cases nowadays, it still 
remains the most commonly identified cause of CAP [193]. Other key pathogens associated with 
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CAP include Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and 
Chlamydophila pneumoniae [193, 197, 198].  
 
3.1.2 Overview of Streptococcus pneumoniae (Pneumococcus) 
Streptococcus pneumoniae, or pneumococcus, is a Gram-positive bacterium that is not only a leading 
cause of pneumonia, but can cause numerous diseases such as meningitis, bacteremia, sepsis, 
endocarditis, cellulitis and brain abscesses [199-201]. It was first isolated and named 
pneumococcus by Louis Pasteur, a renowned French chemist, as well as U.S. physician George 
Steinberg in 1881 [202, 203]. As time progressed, the organism was identified as Diplococcus 
pneumoniae from 1920 to 1974, when it was renamed as Streptococcus pneumoniae due to its 
similarities to typical streptococci [204] [205].  
In order for bacteria to colonize and spread throughout their hosts, they must first adhere to, 
multiply and invade a target tissue. As an extremely effective colonizer, S. pneumoniae performs 
these tasks with evolved mechanisms that allow it to not only adhere to respiratory epithelium 
and mucous, but also form pneumococcal biofilms by aggregating together and creating a 
protective extracellular matrix with dead cellular debris [206-208]. Although S. pneumoniae can 
exist harmlessly within the host’s nasopharynx , colonization can spread to more distant sites 
like the lung (causing pneumonia) or meninges (causing bacterial meningitis) [201, 209, 210]. Its 
transition from colonization to infection is not well understood, but studies have shown that the 
presence of phosphatidylcholine in the bacterial cell wall allows pneumococcal cells to internalize 
and translocate across epithelial and endothelial cells, and that the production of pneumolysin, 
a cholesterol-dependent toxin, leads to cell death and desquamation [201, 208, 210-212]. All of 
these steps give rise to the toxic effect of S. pneumoniae to host cells as well as its spread and 
colonization throughout the host organism. Individuals who are highly susceptible to S. 
pneumoniae invasion, colonization, and infection typically have impaired immune and 
inflammatory responses [209].  
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Figure 3.2 Gram-positive versus Gram-negative bacterial cell wall. Gram-positive bacteria 
have a thick peptidoglycan multilayer as well as teichoic acids that are anchored in the plasma 
membrane. Gram-negative bacteria have two membranes: the plasma membrane and an outer 
membrane, separated by a thin layer of peptidoglycan. Lipopolysaccharides occupy the outer 
envelope in abundance.  
 
Since it is a Gram-positive bacterium, S. pneumoniae has a thick peptidoglycan multilayer (versus 
the thin, single-layer that Gram-negative bacteria have) as well as teichoic acids that form a major 
constituent of its cell wall. These teichoic acids are cell wall polymers that include wall teichoic 
acids (WTAs) that are covalently attached to peptidoglycan and lipoteichoic acids (LTAs) that 
span the peptidoglycan layers and are anchored to the bacterial cell membrane [213-215]. Both 
types of teichoic acids protrude above the peptidoglycan layer and the phosphodiester groups in 
the regular repeating units of these polymer chains provides the Gram-positive cell wall with a 
net negative charge (one negative charge per repeating unit), which is of great significance for 
bacterial pathogenesis, immune response, and antibiotic attraction [215-221]. Unlike Gram-
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negative bacteria, Gram-positives do not have an outer membrane in addition to its inner 
cytoplasmic cell membrane (see Figure 3.2), which also carries a net negative charge due to its 
lipid composition [221, 222]. The negatively charged components of both Gram-negative and 
Gram-positive bacteria drive the electrostatic attraction of cationic AMPs onto the bacterial 
surface [17].  
 
3.1.3 Lipid Composition 
The membrane of S. pneumoniae is no doubt very complex, including many types of proteins, 
carbohydrates, and lipids. However, our primary interest lies in lipid-drug interactions, so we just 
want to focus on the lipid composition of the cellular membrane. Although membrane proteins 
are essential to the function of any bacterial cell membrane, they are difficult to incorporate into 
a lipid model system that will be used for both our monolayer and bilayer studies since a large 
portion of them require the use of solid supported substrates[223]. 
Trombe et al. showed that pneumococcal membranes contain a large amount of two glycolipids, 
monoglucosyldiacylglycerol (MGDG) and galactosylglucosyldiacylglycerol (DGDG), two acidic 
phospholipids: phosphatidylglycerol (PG) and cardiolipin (CL), and a neutral lipid, diacylglycerol 
(DAG) [224]. A few decades later, Pesakhov et al. determined the lipid composition of S. 
pneumoniae under aerobic and anaerobic growth conditions. Under aerobic conditions, it was 
discovered for various wild type strains of S. pneumoniae that there were approximately equal 
ratios of PG to CL (approximately 15-20% of the total lipid content), while the remainder was 
made up of neutral molecules including MGDG, DGDG and DAG [225].  
For our model, we wish to use only phospholipids and not incorporate the use of glycolipids in 
membrane models. As a result, we decided to substitute the group of neutral molecules (MGDG, 
DGDG, and DAG) with the neutral phospholipid phosphatidylethanolamine (PE), which is a 
principal phospholipid in most bacterial inner membranes, to better mimic the overall charge 
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density of the bacterial membrane lipid model [226-228]. We can then approximate the reported 
ratios as 20% phosphatidylglycerol, 20% cardiolipin, and 60% neutral lipids or 
phosphatidylethanolamine.  
 
 
 
Figure 3.3 Lipid composition of bacterial membrane model system. The bacterial 
membrane (BM) model is composed of 20% phosphatidylglycerol, 20% cardiolipin, and 60% 
phosphatidylethanolamine. The chemical structures of the exact lipids used in this thesis are 
shown: DOPG (1,2-dioleoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)]), TOCL (1,1’2,2’-
tetraoleoyl cardiolipin) and POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine). 
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When looking at this bacterial membrane model of 20:20:60 PG/CL/PE, we can look at each 
individual lipid to determine an overall net charge for the lipid model system. As seen in Figure 
3.3, PG has a negative charge on its phosphate group at neutral pH, making it an anionic lipid. 
Under the same conditions, cardiolipin can potentially carry two negative charges since it has 
four acyl groups and two phosphate groups [229]. Since PE is a neutral and zwitterionic lipid at 
neutral pH (due to its protonated amino group and presence of a phosphate group), the bacterial 
membrane model carries a net negative charge under physiological conditions. 
 
3.2 Lung Surfactant (LS) Lipid Model 
Lung surfactant, or pulmonary surfactant, is a widely studied component of the lung’s alveolar 
surface. Therefore, various models have already been created in previous studies to mimic the 
lipid composition of lung surfactant. Since daptomycin’s bactericidal activity is inhibited in the 
presence of lung surfactant, it is necessary to use a lung surfactant lipid model in comparison to 
the other models within this thesis. An overview of pulmonary surfactant will be given in the 
subsequent section, followed by an overview of the models that have been studied and which 
one this thesis will focus on. 
 
3.2.1 Pulmonary Surfactant 
The adult human breathes in approximately 10 L of air each minute, which contains around 107 
microorganisms [80]. Since the lung, the body’s gas exchange organ, is constantly exposed to air 
that is contaminated with an abundance of microbes, the presence of a pulmonary innate 
immunity is crucial to eliminating these pathogens and maintaining an inflammation-free 
environment [230]. This is especially true when it comes to the lung’s alveolar epithelium, where 
pulmonary surfactant exists at its air-liquid interface to protect it from such threats [231]. 
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Following its synthesis by type II alveolar cells, pulmonary surfactant is stored in lamellar bodies 
and secreted into the alveolar space to form tubular myelin, which eventually forms a monolayer 
lipid film that coats the single layer of alveolar epithelial cells [232]. This lung surfactant is a 
phospholipoprotein complex composed of approximately 10% surfactant proteins, 80% 
phospholipids (mainly dipalmitoylphosphatidylcholine or DPPC), and 10% neutral lipids [233]. 
Its components help to fight invading pathogens and stabilize the alveoli by reducing surface 
tension so that they can inflate and deflate more easily with respiration [234]. More specifically, 
the phospholipids and hydrophobic surfactant proteins SP-B and SP-C help to promote 
pulmonary compliance, regulate alveolar size, and prevent alveolar fluid accumulation, while the 
surfactant proteins SP-A and SP-D play a direct and crucial role in pulmonary host defense [235].  
There are four types of surfactant proteins that make up around 10% of lung surfactant: SP-A, 
SP-B, SP-C and SP-D. SP-A and SP-D are known as lung collectins that mediate innate immunity 
within the lung [236]. Each protein consists of subunits, each with a cysteine-containing N-
terminal and CRD (carbohydrate recognition domain) surrounding a collagenous domain [237]. 
Three of these subunits make a trimer, which recognizes carbohydrate and charge patterns on 
pathogens or nonself particles. Moreover, the trimeric CRD can interact with receptor molecules 
that are present on various immune cells [236]. These general functions and capabilities are 
carried over to the lung collectins, since SP-A is formed by 6 trimers, while SP-D contains 4 
trimers [237]. The key function of these lung collectins is the opsonisation of pathogens, where 
they bind to viruses, fungi, allergens, and both Gram-positive and Gram-negative bacteria after 
recognizing them through the binding motifs located on their CRDs [235]. This enhanced 
phagocytosis is crucial to host defence mechanisms within our lungs [235, 238-240]. 
SP-B and SP-C are hydrophobic spreading proteins that are essential for pulmonary compliance. 
SP-B plays a critical role in the reduction of alveolar surface tension to allow for easier inhalation 
and exhalation of the lungs [241]. Specifically, SP-B is capable of rearranging lipid molecules to 
reduce surface tension as well as interfere with the attractive forces between water molecules at 
the air-water interface [242, 243]. Without SP-B, lung conditions will develop, with the most 
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common being acute respiratory distress syndrome (ARDS), which is highly associated with 
surfactant dysfunction [244]. To help with pulmonary compliance, SP-C is a highly hydrophobic 
lipopeptide that inserts into phospholipids to alter their packing and facilitate a rapid spreading 
of surfactant lipids while imparting monolayer film stability [242, 245-247]. The particular 
method by which SP-C facilitates this rapid surfactant spreading is through its ability to reversibly 
transition a monolayer to surface-associated multilayers upon compression and expansion of the 
lungs [247, 248].  
 
3.2.2 Lipid Composition 
Lung surfactant has been widely studied using Langmuir monolayers as model surfactant systems 
[249]. These model systems tend to use dipalmitoylphosphatidylcholine (DPPC) to represent the 
saturated lipids and 1,2-dioleoylphosphatidylglycerol (DOPG) as the unsaturated lipids [249]. A 
general model for lung surfactant that has been widely used contains 70% to 80% 
phosphatidylcholines, 5% to 10% phosphatidylglycerols, 5% to 10% cholesterol, and additional 
surfactant-associated proteins [250-252]. It is important to note that, although the presence of 
cholesterol contributes to membrane fluidity and surfactant spreading, the presence of 
supraphysiological amounts of cholesterol will impair the self-assembly of lung surfactant into a 
functional film [252-256]. Studies with commercial surfactant BLES® (Bovine Lipid Extract 
Surfactant) have shown results comparable to model lipid systems of 80:20 DPPC/DOPG with 
5% cholesterol by weight [250, 256-258]. The work in this thesis will also be using this model 
(see Figure 3.4).  
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Figure 3.4 Lipid composition of lung surfactant lipid model. The synthetic lung surfactant 
model is composed of 80% PC and 20% PG with 5% cholesterol by mass. The exact lipids used 
in this thesis are shown in the figure: DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), 
DOPG (1,2-dioleoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)]), and cholesterol from sheep wool. 
 
3.3 BLES® (Bovine Lipid Extract Surfactant) 
Various synthetic lipid mixtures and extracts of mammalian lung surfactant have been developed 
to treat human patients with lung surfactant deficiencies. Natural surfactant preparations are 
derived from bovine or porcine lungs and contain the hydrophobic surfactant proteins SP-B and 
SP-C, which help with lung surfactant spreading [259]. One such natural surfactant is BLES®, 
Bovine Lipid Extract Surfactant, manufactured by BLES Biochemicals Inc. (London, Ontario, 
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Canada) and is commonly used for neonates affected by RDS [260]. Other modified natural 
surfactants are Curosurf® by Chiesi Farmaceutici S.p.A (Parma, Italy), Infasurf® by ONY Inc. 
(Amherst, New York, USA) and Survanta® by Abbott Laboratories Ltd. (Saint-Laurent, Quebec, 
Canada), just to name a few [261]. Compared to Survanta®, another natural bovine surfactant, 
BLES® was shown to achieve faster clinical responses for favourable RDS therapeutic outcomes 
[260]. As a result, BLES® surfactant systems were used in this thesis as a comparison to and test 
of validity for the purely synthetic lung surfactant lipid model presented in the previous section.  
 
3.3.1 History and Development 
BLES® is marketed as a leading treatment option for premature infants suffering from neonatal 
respiratory distress syndrome. It is unique because there is no generic form of this product and 
it is solely produced from BLES Biochemicals Inc., a Canadian-owned pharmaceutical company 
[262].  
BLES Biochemicals Inc. was incorporated in 1992 after decades of research at The University 
of Western Ontario by Dr. Fred Possmayer and colleagues [262]. After years of additional drug 
development, their streamlined product BLES® obtained Canadian drug approval in 2002. As of 
2015, they now have drug approval from India, New Zealand, South Africa (Liposurf as the 
brand name), Bolivia, Iran, Moldova, Ecuador and Saudi Arabia [262]. 
BLES® itself is bovine lipid extract surfactant, extracted from lung lavage fluid of slaughtered 
cows. Their unique manufacturing process involves the removal of hydrophilic proteins 
(specifically SP-A and SP-D), which allows for the selection of hydrophobic components such 
as phospholipids and surfactant proteins SP-B and SP-C, which play strong roles in surfactant 
spreading and fluidity [262]. 
When used to treat neonatal RDS in infants, BLES® is applied via intratracheal instillation at a 
recommended dosage of 5 mL/kg at 27 mg of phospholipids per mL [262].  
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3.3.2 Lipid Composition 
BLES® is prepared from lung lavage collected from adult cows being slaughtered [263]. This 
endotracheal lung fluid is subjected to an organic solvent extraction, resulting in a final lipid 
composition of approximately 97% phospholipid and 3% cholesterol [264]. The phospholipids 
within the 97% were phosphatidylcholine at 79%, phosphatidylglycerol at 11%, and smaller 
amounts of phosphatidylethanolamine, phosphatidylinositol, sphingomyelin, and lyso-bis-
phosphatidic acid [264]. Although a chloroform/methanol extraction was performed to remove 
proteins in the extracted lung lavage, the hydrophobic surfactant proteins were not affected by 
this extraction and approximately 10% (w/w) of the original protein content remains within the 
final BLES® solution [263].  
 
 
Figure 3.5 BLES® surfactant from BLES Biochemicals Inc. The work in this thesis used 
natural BLES® (bovine lipid extract surfactant) to create a natural lung surfactant model to 
compare with the synthetic lung surfactant model. The lipid composition of BLES® is fairly 
similar to the synthetic LS model. Additional lipid extraction and filtration techniques were 
applied to the natural BLES® solution to create this more complex model of lung surfactant. 
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For the experiments performed in this thesis, BLES® obtained from BLES Biochemicals Inc. 
was extracted using a chloroform/methanol mixture and centrifuged a significant number of 
times to allow for the formation of BLES® lipid vesicles in subsequent steps. As a result, the 
hydrophobic surfactant proteins SP-B and SP-C would be much less than the original BLES® 
solution, or be present in insignificant amounts. 
 
3.4 Human Membrane (HM) Lipid Model 
Daptomycin is now a popular antibiotic used in the treatment of drug-resistant Gram-positive 
microorganisms. However, it is inhibited by lung surfactant in the case of community-acquired 
pneumonia. CB-182,462 was developed by Cubist Pharmaceuticals (prior to their acquisition by 
Merck & Co.) as an alternative to daptomycin that could potentially work in the presence of lung 
surfactant, but it failed pre-IND testing due to animal toxicity and was abandoned. This toxicity 
problem presented itself as renal phospholipidosis, where kidney cells accumulated excessive 
membrane material within the cytoplasm (J. Silverman, personal communication). However, due 
to the ability of CB-182,462 to overcome inhibition by lung surfactant, it was interesting to study 
its mechanism of action as well. For this purpose, a human membrane lipid model was developed 
to mimic human tissue cells, or erythrocytes. This system will help compare the toxicities of 
daptomycin versus CB-182,462.  
 
3.4.1 Lipid Composition 
There are many different types of host cells, so it is important to choose a type of system to 
model our human membrane after. As a drug that is to be injected, daptomycin and CB-182,462 
will be in contact with red blood cells (erythrocytes) as well as tissue cells. 
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Figure 3.6 Lipid composition of human membrane lipid model. The human membrane 
(HM) model is comprised of five different components: 20% phosphatidylcholine, 20% 
phosphatidylethanolamine, 10% phosphatidylserine, 15% sphingomyelin, and 35% cholesterol. 
The specific lipids used in this thesis are: DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), 
POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine), DOPS (1,2-dioleoyl-sn-
glycero-3-[phospho-L-serine]), sphingomyelin (egg, chicken) and cholesterol (sheep wool). 
60 
 
The plasma membranes of human epithelial cells contain approximately 35% 
phosphatidylcholine (PC), 20% phosphatidylethanolamine (PE), 20% sphingomyelin (SM), and 
the remainder primarily consisting of cholesterol [265]. However, the presence of 
phosphatidylinositol (PI) and phosphatidylserine (PS) were suggested in a later study [266]. In 
1985, another study showed that rat erythrocyte lipid composition consisted of 21% 
phosphatidylethanolamine, 3% phosphatidylinositol, 3% phosphatidylserine, 32% 
phosphatidylcholine, 8% sphingomyelin, and 30% cholesterol, with trace amounts of 
diacylglycerols and lysophosphatidylcholine [267]. In 1998, the phospholipid composition of the 
human erythrocyte membrane was discovered to be approximately 29.3% PC, 25.5% SM, 14.9% 
PS, 0.6% PI, and 27.6% PE with traces amounts of other phospholipids [268]. Other studies 
have also shown similar ratios, but most contain a large amount of cholesterol [269-275]. 
From the lipid compositions presented in previous studies for mammalian erythrocytes, a 
simplified human membrane model (see Figure 3.6) was created for use in this thesis, consisting 
of 20% phosphatidylcholine, 20% phosphatidylethanolamine, 10% phosphatidylserine, 15% 
sphingomyelin, and 35% cholesterol. 
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CHAPTER 4 
4 METHODS & TECHNIQUES 
 
To study the effect of daptomycin and CB-182,462 on the different lipid membrane models 
presented in Chapter 3, various experimental methods were used to analyze the biological and 
physical properties of each system. Fluorescence spectroscopy was used to study the binding of 
these antibiotics to the different model membranes, while the Langmuir-Blodgett trough was 
used to study monolayer properties and antibiotic insertion. Difference atomic force microscopy 
methods in air and liquid were then performed to qualitatively observe any changes in physical 
properties of the monolayers and membranes, respectively.  
 
4.1 Fluorescence Spectroscopy 
A fluorophore is a chemical compound, most often aromatic, that absorbs and emits energy at 
two different wavelengths. When it absorbs an incident photon and is excited into a higher 
energy state, its emission (or return to a lower energy state) is called fluorescence of a photon 
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[276-278]. Such processes are usually illustrated through the use of a Jablonski diagram, which 
typically shows the single ground (S0), first (S1) and second (S2) electronic states of a fluorophore, 
with each state having possible existence in different vibrational energy levels [276]. Transitions 
between states are represented by vertical lines. 
 
 
Figure 4.1 Overview of the Jablonski diagram and fluorescence emission. The Jablonski 
diagram is a graphical depiction of a fluorophore’s electronic states and the transitions between 
those states. When a fluorophore is excited, it goes through a process of absorption and reaches 
a higher vibrational level (Sn) than its first electronic state. However, the excited fluorophore 
rapidly relaxes to the lowest vibrational level of its first electronic state (S1) through a process 
called internal conversion. From the lowest energy vibrational state of S1, fluorescence emission 
occurs as the fluorophore returns to its ground state (S0). Sometimes, fluorophores that exist in 
the S1 state can be converted into a first triplet state (T1) due to spin conversion, a process called 
intersystem crossing. When this happens, phosphorescence emission occurs instead of 
fluorescence emission, taking place at longer wavelengths and lifetimes. 
 
As can be seen in Figure 4.1, following light absorption, a fluorophore can be excited to a higher 
vibrational level than its first electronic state. Prior to fluorescence emission, the excited 
fluorophore rapidly relaxes to the lowest vibrational level of its first electronic state through a 
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process called internal conversion [276-278]. It is from this lowest energy vibrational state of S1 
that fluorescence emission occurs upon the fluorophore’s return to the ground state [276, 278]. 
Sometimes, molecules in the S1 state convert into a first triplet state (T1) due to spin conversion, 
called intersystem crossing [277]. This process results in phosphorescence (from triplet states) 
at longer wavelengths relative to fluorescence (from singlet states) [277].  
Fluorescence spectroscopy (FS) is a type of electromagnetic spectroscopy in which the 
fluorescence of a sample is measured after it has been excited by a photon source [277]. To 
observe such phenomena, a spectrofluorometer can be used to record emission spectra from a 
sample that has been excited at a certain wavelength [278]. Recently, fluorescence spectroscopy 
has been used to study daptomycin oligomerization and properties [68, 98, 104-108, 174].  
The use of fluorescence spectroscopy to study the binding of daptomycin and CB-182,462 to 
different lipid membrane models involves the preparation of lipid membrane liposomes. Full 
details on sample preparation and operation of the spectrofluorometer are available in 
Appendix B. 
 
4.2 Langmuir-Blodgett Trough Techniques 
Back in 1773, Benjamin Franklin (a Founding Father of the United States of America; 1706-
1790) dropped oil onto rough bodies of water and noticed a calming effect on the waves once 
the oil was added in [279, 280]. What he did not realize was that he had just formed a 
monomolecular layer of oil on top of the water’s surface, something that no one caught onto 
until Lord Rayleigh (1842-1919) entered the scene over a century later. In 1890, Rayleigh 
published his findings of the thickness of an olive oil monolayer after he spread it over the entire 
surface area of a bath to produce a repeatable calming effect on the surface of the water [281, 
282]. A self-taught scientist named Agnes Pockels (1862-1935) was fascinated by this discovery 
and invented a tin trough with small barriers that could measure surface tension through the use 
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of a small disk on the surface of the subphase [280]. This would later evolve into the Langmuir-
Blodgett trough that is now a core nanotechnology tool for membrane biophysicists across the 
globe. 
While working at the General Electric (GE) Research Laboratory in New York, Irving Langmuir 
(1881-1957) invented the Langmuir trough based on Pockels tin trough specifications, with the 
addition of a highly sensitive pressure-measuring device attached to a fixed arm, so that the 
surface tension of the Langmuir film could be measured [283-285]. Later on, Langmuir hired 
Katherine Blodgett as his assistant, and they both worked together to develop the Langmuir-
Blodgett film deposition process, where a preformed monolayer could be deposited onto a solid 
substrate multiple times to create multilayers of very accurate thickness [285, 286]. Langmuir’s 
work and contributions to surface chemistry garnered him a Nobel Prize in 1932 [282, 285].  
Today, Langmuir troughs are used for a wide variety of biophysical and nanotechnology 
applications to compress amphiphilic molecules into a monolayer and to directly measure surface 
phenomena resulting from this compression [287]. Although Langmuir troughs can be used to 
perform compression isotherms and insertion assays, a Langmuir-Blodgett trough is necessary 
for Langmuir-Blodgett film deposition due to the requirement for a dipping mechanism that a 
standard Langmuir trough does not have [287]. As the experiments presented in this thesis 
require the use of the Langmuir-Blodgett film deposition technique, only the Langmuir-Blodgett 
trough will be considered in subsequent discussions and descriptions. 
The typical setup of a Langmuir-Blodgett (LB) trough is presented in Figure 4.2. The frame of 
the apparatus holds a trough top that contains the liquid subphase where lipids will be deposited 
[288]. Software-controlled barriers are placed on top of the edges of the trough top, one on each 
side, which help compress the monolayer at a rate set by the user [288]. The trough top and 
barrier are usually made of the same hydrophobic material, such as Teflon, to help contain the 
liquid subphase [288]. 
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Figure 4.2 Diagram of Langmuir-Blodgett trough. A Langmuir-Blodgett (LB) trough is a 
trough that is capable of creating Langmuir films (compressed thin films) as well as Langmuir-
Blodgett films (thin films deposited on a solid substrate). The only difference between the two 
is the presence of a dipping mechanism that allows for the depositing of a thin film onto a 
substrate. Each trough will have a frame, a trough top, movable barriers to compress the thin 
film with, a surface pressure sensor to sense changes in pressure. The electronic components are 
controlled by an interface unit specific to the manufacturer.  
 
To measure the surface pressure of each monolayer system, a Wilhelmy plate or Langmuir 
balance is added to the LB trough apparatus, which consists of a partially-immersed plate that is 
connected to an electrobalance [289]. This Wilhelmy plate usually comes in the form of filter 
paper, which is wetted prior to and during any experiment to ensure constant mass. Once it has 
achieved equilibrium, the Wilhelmy plate detects the downwards force exerted by the meniscus 
formed by the liquid subphase and allows for the calculation of surface tension [289]. The 
reduction in surface tension between the ideal or absolute surface tension from Nanopure water 
(γ0) and the surface tension achieved after the monolayer sample has been added at the air-water 
interface (γ) is known as the surface pressure (Π) [289]: 
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Π = 𝛾𝛾0 − 𝛾𝛾 (Eq. 1) 
The ability of the Langmuir-Blodgett trough instrumentation to calculate the surface pressure of 
a system at different trough areas and time points allows for various types of experiments to be 
performed. The first of these are compression isotherms, where the trough barriers compress a 
monolayer either to the point of collapse, or until the trough barriers cannot close any further. 
This produces a pressure-area isotherm [289, 290]. The second type of experiment that can be 
performed is called an insertion assay, where a monolayer is created and sustained at a steady, 
constant pressure. After a set amount of time, peptides or other molecules can be injected 
underneath the monolayer to record any changes in surface pressure resulting from interactions 
with or insertion into the monolayer itself [291]. Finally, the dipper mechanism on the Langmuir-
Blodgett trough can be used to deposit a preformed monolayer onto a solid substrate, such as 
mica (muscovite), for further analysis using other tools such as atomic force microscopy [287, 
289].  
 
4.2.1 Monolayer Compression Isotherms 
Using the Langmuir-Blodgett trough, a Langmuir film can be compressed at a constant 
temperature to obtain a pressure vs. area plot, also known as a compression isotherm. When 
amphiphilic molecules, like phospholipids, are added on top of a liquid subphase, they orientate 
themselves in a predictable way, such that their hydrophilic (polar) heads face the liquid water 
subphase and their hydrophobic (non-polar) tails face away from the water at the air-water 
interface [288].  
During the measurement of a compression isotherm (Figure 4.3), the molecules within the 
monolayer organize themselves differently as the available surface area decreases due to the 
movement of the trough barriers [289]. A typical isotherm starts with the monolayer existing in 
a two-dimensional gas phase (G), where the molecules are disordered, spread far apart and do 
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not interact with each other. As the surface area of the trough decreases, the monolayer enters 
into a liquid phase (L), where the molecules are now more organized and closely packed together, 
therefore increasing the surface pressure [289]. When the monolayer is compressed far enough, 
it will enter into its solid phase (S), where the molecules are now tightly packed together into 
one cohesive structure, creating a spike in surface pressure readings [289]. If the trough barriers 
continue to compress a solid phase monolayer, a collapse pressure (πc) will be reached when 
monolayer packing can no longer be sustained and the molecules will not only become 
disordered once again, but collapse into three-dimensional structures as molecules are ejected 
out of the monolayer plane [289].  
 
Figure 4.3 Typical surface-area compression isotherm. This plot represents a typical surface 
pressure vs. molecular area isotherm obtained by compressing a lipid monolayer at an air-water 
interface. When the lipids are first deposited, they are in a gaseous phase, where they are 
disordered. As the lipids are compressed, they reach a more ordered, yet still expanded liquid 
phase, marked by a slight increase in pressure readings. When the lipids are further compressed 
into a tightly-packed monolayer, it enters a solid phase, and a sharp rise in pressure is recorded. 
However, too much pressure past a threshold will cause the monolayer to collapse.  
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Compression isotherms provide insight into a monolayer’s physical properties, specifically its 
packing behaviour and compressibility. Full sample preparation and experimental protocols can 
be found in Appendix C1-C3. 
 
4.2.2 Monolayer Insertion Assays 
A Langmuir insertion assay is a method for studying lipid-protein and lipid-peptide interactions 
by keeping the surface area of the trough or the surface pressure of a monolayer constant [292, 
293]. Once a target pressure has been determined that has physiological relevance to the model 
system being studied, the Langmuir monolayer is compressed until that pressure has been 
reached. Once that pressure is reached, one of two paths can be taken to continue with the 
experiment. First, the surface pressure can be kept constant using a feedback loop, and changes 
in surface area can be monitored to observe peptide interactions with the monolayer. If the 
peptide inserts into the monolayer, then the surface area should increase, whereas if the peptide 
causes the lipid monolayer to dissolve into the subphase, the surface area would decrease [291, 
293]. Second, the surface area can be kept constant by locking the trough barriers, and changes 
in surface pressure can be monitored to observe whether the peptide inserts into the monolayer 
and therefore increase the surface pressure [293]. A Hamilton syringe is used for injection of the 
peptide from underneath one of the trough barriers to avoid disturbing the lipid monolayer 
between the barriers [294].  
Multiple insertion assay studies have been performed with simple monolayers, where either a 
constant pressure or surface area is maintained and the change in surface area or surface pressure 
is measured upon peptide injection, respectively [291, 293, 294]. However, a recent study within 
our lab has shown that this technique is unreliable due to observed leakage of monolayer material 
in our trough [295].  
69 
 
Since previously published protocols for peptide insertion assays have not been successful or 
applicable to the scope of this thesis, a large portion of time was spent developing novel 
protocols for constant-area insertion assays for the interaction of daptomycin and CB-182,462 
with different, complex monolayer lipid models. These protocols have proven to be highly 
effective and reproducible, and are presented in Appendix C4. 
 
Figure 4.4 Schematic of constant-area monolayer insertion assays. The Langmuir-Blodgett 
trough can be used to perform insertion assays. These assays can be performed with constant 
pressure or constant area, the latter of which is depicted in this figure. In constant-area insertion 
assays, the following steps occur: (1) lipids are deposited onto the trough subphase and 
compressed to a target pressure, at which point the barriers are locked in place to ensure a 
constant area; (2) a specific peptide or protein (such as daptomycin or CB-182,462) can be 
injected using an L-shaped or bent Hamilton syringe that reaches underneath one of the barriers 
and releases its content underneath the monolayer; (3) pressure readings are recorded 
throughout these steps to monitor changes in pressure before, during, and after the injection.  
 
The work in this thesis is based on novel protocols for constant-area insertion assays (see Figure 
4.4), in which monolayers are compressed to a specific target pressure. Once the monolayer has 
reached that target pressure, the barriers of the trough are locked in place and the monolayer is 
“released” from a pressure stabilizer for a few minutes to ensure that the recorded target pressure 
remains the same without the help of automated controls. After that, a custom-bent L-shaped 
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Hamilton syringe is used to inject the antibiotic underneath one of the barriers at a consistent 
force and speed, and the change in surface pressure was monitored over a period of five minutes. 
A similar technique is applied when depositing a monolayer onto a solid substrate for imaging 
purposes. 
 
4.2.3 Monolayer Depositions on Mica Substrates 
 
 
Figure 4.5 Monolayer deposition on different types of substrates. Two types of lipid 
monolayer depositions can occur depending on the type of substrate being deposited on. If you 
have a hydrophilic substrate, such as mica, the hydrophilic heads of the lipids will orient 
themselves so that the heads are facing towards the mica surface. As a result, the substrate is 
pulled upwards using the Langmuir-Blodgett trough. If you have a hydrophobic substrate, the 
hydrophobic tails will orient themselves towards the surface of the substrate. This means that 
the substrate now has to be pulled downwards using the trough. 
 
Apart from compression isotherms and insertion assays, the Langmuir-Blodgett trough can also 
be used for Langmuir-Blodgett films, which can be deposited onto two types of solid substrates: 
hydrophobic and hydrophilic (see Figure 4.5). When depositing a monolayer onto a 
hydrophobic surface, the substrate must travel downwards across the air-water interface, so that 
the hydrophobic tails can attach to the substrate’s hydrophobic surface [289]. On the other hand, 
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when depositing a monolayer onto a hydrophilic surface, the substrate must already be 
submerged in the subphase and travel upwards across the air-water interface so that the 
hydrophilic heads can attach to the substrate’s hydrophilic surface [289]. Even if it is unknown 
whether a substrate’s surface is hydrophobic or hydrophilic, it is easy to distinguish by knowing 
whether the meniscus curves downwards (hydrophobic) or upwards (hydrophilic) when the 
substrate is partially immersed in the subphase [289]. 
One of the most common substrates used is muscovite, the most abundant mineral of the mica 
family [296-298]. Muscovite mica sheets not only cleaves perfectly into thin, flexible, elastic 
sheets, but it is also an excellent insulator that is chemically inert, dielectric, and hydrophilic [299-
302]. Since muscovite mica sheets are hydrophilic, that means that using a mica substrate would 
require it to be fully submerged and dragged upwards for a monolayer to adhere to its surface. 
A detailed overview of monolayer deposition on mica substrates is available in Appendix C5. 
 
4.3 Atomic Force Microscopy Techniques 
Atomic force microscopy (AFM) is a type of scanning probe microscopy that offers high-
resolution imaging of surface topography at nanometer and atomic scales [303-305]. As shown 
in Figure 4.6, a flexible cantilever acts like a spring as it is rastered across the sample’s surface. 
The cantilever’s movements alter the deflection of a laser beam reflecting off the cantilever tip 
and onto a quadrant photodiode. This signal is used to construct an image that reflects the type 
of interaction being measured by the probe in relation to the surface [303-305]. AFM is a highly 
versatile technique as it can be used for different life science applications, and imaging can be 
performed in different modes and environments [306]. 
AFM has been extensively used to image biological samples, such as bacteria and lipid 
monolayers and membranes, in the presence of antimicrobial peptides [307, 308]. As a result, 
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different variations of AFM techniques were used in this thesis to qualitatively observe the 
interaction of daptomycin and CB-182,462 with different model monolayers and membranes.  
 
 
 
Figure 4.6 Schematic of atomic force microscopy. In atomic force microscopy, a laser is 
reflected off a cantilever and onto a photodiode. As the cantilever tip scans across the surface 
of the sample, the forces it experiences will deflect the cantilever, therefore changing the 
placement of the reflected laser beam on the photodiode. These changes in deflection signals 
are then processed using AFM operating software into a viewable image of the sample’s 
topography. 
 
4.3.1 Topographical Imaging 
In AFM, a flexible cantilever acts like a spring to measure the interactions between the tip and 
the sample, whilst its deflections are electrically monitored by the reflection of a laser beam that 
bounces off the cantilever onto a quadrant photodiode. As the tip is rastered across the sample 
surface, an image is formed from the feedback signals. There are multiple imaging modes of 
atomic force microscopy that differ in the types of forces between the tip and the surface of the 
sample [305, 309, 310]. These types of attractive and repulsive forces can be represented by a 
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generic tip-sample force vs. distance curve as seen in Figure 4.7. As the tip approaches the 
sample surface from afar, it experiences attractive, long-range forces such as van der Waals and 
capillary forces [309, 311]. As the tip gets closer to the sample surface, this attraction gives way 
to a repulsive force governed by short-range interactions as their electron orbitals begin to 
overlap [305, 311]. 
The first and most basic imaging mode is contact mode, where a force value of tip repulsion is 
selected, and the feedback system adjusts the height of the tip to keep this repulsive force 
constant as the tip raster-scans the surface of the sample [305, 309, 311]. Accordingly, on the 
generic force curve, contact mode is a single point. In other words, the tip never leaves the 
surface of the sample when imaging. 
In intermittent contact mode, the tip is not always in contact with the surface, but rather 
oscillates between the attractive and repulsive parts of the force-distance curve [305, 311-313]. 
As a result, the lateral forces are much lower with this imaging mode, allowing for high-
resolution topographical images of soft samples to be obtained [309, 311]. Typically, the 
cantilever is driven close to the resonance of the system so that phase information can be 
obtained and a workable amplitude for the oscillation can be used to obtain topographical data 
from the sample [309, 311]. This makes phase imaging possible, which will be explained in the 
subsequent section. 
Although non-contact mode is another type of AFM imaging mode, it is rarely used because it 
is difficult to control and monitor the long-range interactions between the tip and sample [305, 
311].  
No matter which imaging mode is chosen, different cantilevers with different properties will 
affect its operation. Stiffer cantilevers will have a higher spring constant, which means that 
stronger forces are required to deflect the tip; these types of cantilevers are good for contact 
mode imaging [305, 311]. Softer cantilevers have a lower spring constant and therefore require 
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less force to deflect the tip, which means that they are more suitable for use with softer samples 
in intermittent contact mode, both in air and in liquid [305, 311-314].  
 
 
Figure 4.7 Different AFM imaging modes. In an atomic force microscope, as the tip 
approaches the sample surface, it experiences long-range attractive forces. As it gets closer to 
the sample surface, this attraction gets converted into a repulsive force and experiences short-
range interactions. Various operating modes of the AFM take advantage of these types of 
interactions. In contact mode, the tip touches the sample surface and experiences repulsive 
forces. In non-contact mode, the tip depends on short-range attractive forces to detect surface 
topography. Meanwhile, intermittent contact mode is where the tip is oscillated between 
repulsive and attractive interactions.  
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Experimental protocols for AFM imaging in air can be found in Appendix D while detailed 
sample preparation and techniques for AFM imaging in liquid can be found in Appendix E. 
 
4.3.2 Phase Imaging 
 
 
 
Figure 4.8 Schematic of AFM phase imaging. While an AFM is operating in intermittent 
contact mode, or tapping mode, the tip is oscillated vertically at its resonance frequency. Apart 
from tracking the height differences of the sample during a scan, the tip’s motion can also be 
characterized by its phase (solid lines) relative to the piezoelectric driver (dotted lines) of the 
system. When the tip encounters different phases (such as from material A to B in the figure), 
the phase signal shifts a certain amount, and different regions can be differentiated from these 
changes in phase shift. 
 
In intermittent contact mode, the cantilever is oscillated at a particular resonance frequency by 
the piezoelectric driver of the system [305, 311]. As the tip lightly taps the surface, the amplitude 
of the oscillation is reduced at that point, and these changes in amplitude provide information 
on surface topography [311]. Apart from this, the tip’s motion can be characterized by its phase 
in comparison to the piezoelectric driver of the system [311, 315, 316]. This means that phase 
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shifts can be monitored continuously as the tip scans the surface of the sample, as in Figure 4.8 
[311, 316]. These phase shifts are very sensitive to variations in composition, frictions, adhesion, 
viscoelasticity and surface stiffness, allowing for the detection of surface features and 
characteristics that may not be seen in a topographical image [311, 315, 316].  
 
4.3.3 Kelvin Probe Force Microscopy 
Invented in 1991, Kelvin probe force microscopy (KPFM) is a scanning probe microscopy 
method, similar to AFM. It involves the use of a conducting probe and conductive substrate to 
record nanoscale images which contain information on electrostatic interactions between the tip 
and the substrate [317]. KPFM is regularly used to study the work function differences in metals 
and electrical surface potential differences in other materials. KPFM can be performed 
simultaneously with AFM imaging, which allows for the direct comparison of topographical 
surface structures with electrical surface potential [318-320].  
When thin organic films like lipid monolayers, which are polar or charged molecules, are 
deposited on top of a conductive substrate, the differences in electrical surface potential can be 
recorded within the monolayer, provided the electrical surface potential of the conductive 
substrate below is uniform [317, 321]. The electrical surface potential of a lipid film has been 
defined by the molecular dipoles (µ) that are aligned perpendicular to the interface, the dielectric 
constant (ε), and the packing density (A) covered by each molecule [322]. When phospholipids 
are considered, a refined model is used, where the normal components of the dipole moments 
of the water molecules (µ1), lipid head groups (µ2), and lipid tail groups (µ3) are included [250, 
322]: 
Δ𝑉𝑉 = 𝜇𝜇⊥
𝜖𝜖0 ∙ 𝐴𝐴
= 1
𝐴𝐴 ∙ 𝜖𝜖0
�
𝜇𝜇1
𝜖𝜖1
+ 𝜇𝜇2
𝜖𝜖2
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𝜖𝜖3
�  (Eq.  2) 
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In KPFM, an AC bias (VAC) is applied between the tip and the sample while the cantilever is 
oscillated close to its resonance frequency. As the tip rasters across the sample surface, tip-
sample interactions induce changes in oscillation amplitude and electrical forces [323]. The 
KPFM feedback detects these changes and adjusts a DC bias (VDC) such that the induced 
changes are nullified, at which point the VDC is equal to the contact potential difference, or CPD 
(VCPD), between the tip and sample surface. We can then correlate local contact potential 
difference with surface features. Both voltages and the resonance frequency ω0 are related 
through the following equation for the electrostatic force Fω, where C(z) is the capacitance 
between the tip and sample surface and the ± sign depends on whether the bias VDC is applied 
to the tip (-) or sample (+) [324]: 
𝐹𝐹𝜔𝜔 = −𝜕𝜕𝜕𝜕(𝑧𝑧)𝜕𝜕𝑧𝑧 (𝑉𝑉𝐷𝐷𝐷𝐷 ± 𝑉𝑉𝐷𝐷𝐶𝐶𝐷𝐷)𝑉𝑉𝐴𝐴𝐷𝐷 sin(𝜔𝜔𝜔𝜔) (Eq.  3) 
As a result, a KPFM image of the electrostatic surface potential of the sample can be recorded 
from the nulling voltage VDC versus the tip’s positional coordinate, commonly outputted as (x, 
y, z, VDC) data points as opposed to the traditional (x, y, z) coordinates in AFM [325]. 
With KPFM, there are three main operation modes, which are AM (amplitude modulation) and 
FM (frequency modulation) KPFM that allow for high-resolution imaging, as well as lift mode 
[317, 324]. Both modes can be performed in a one-pass fashion, where the AFM imaging is done 
simultaneously with KPFM. It can also be done in a two-pass fashion, where AFM imaging is 
done in the first trace and KPFM is done in a retrace [326]. In this thesis, AFM images were 
collected using the latter technique, where AFM images were taken during the first trace and 
AM-KPFM in the retrace (see Figure 4.9). KPFM imaging can be done in air only. 
Due to its ability to measure a sample’s electrical surface potential and correlate them with their 
respective topographical structures, KPFM will be an important and useful method in elucidating 
electrostatic properties for biological samples. The KPFM experiments performed in this thesis 
are based on AM-KPFM, and detailed protocols can be found in Appendix D. 
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Figure 4.9 Simplified schematic of two-pass KPFM technique. KPFM requires both the 
sample and the tip to be conductive. In this figure, there is a gold-coated tip and a sample with 
regions of positive and negative charges. In amplitude-modulation Kelvin probe force 
microscopy, the imaging technique used in this thesis involves a two-pass method where (1) a 
conductive tip first takes a topographical AFM scan of the sample’s conductive surface, (2) lifts 
up a certain amount (10 nm setoff distance), and (3) performs a KPFM retrace of the height 
profile at that setoff distance.  
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CHAPTER 5 
5 FLUORESCENCE SPECTROSCOPY STUDIES: 
DAPTOMYCIN IS SEQUESTERED BY LUNG 
SURFACTANT AT PHYSIOLOGICAL CALCIUM 
CONCENTRATIONS 
 
 
5.1 Introduction 
The prevalence of resistance in Gram-positive pathogens has significantly risen over the past 
few decades, spurring a demand for novel antibiotics that are effective against multi-resistant 
bacterial strains [5, 327, 328]. Globally, pneumonia still presents as a serious public health 
concern and was rated as the eighth most common cause of mortality in the United States as of 
2014 [329]. In the same year, the World Health Organization reported Streptococcus pneumoniae,  
 
80 
 
 
Figure 5.1 Comparison of daptomycin and CB-182,462 chemical structures. Daptomycin 
and CB-182,462 have similar architecture. Daptomycin is derived from Streptomyces roseosporus, 
while CB-182,462 is derived from Streptomyces fradiae. Some core differences in CB-182,462 
include its alkyl-carbamyl residue (instead of daptomycin’s decanoyl tail) as well as the absence 
of kynurenine (replaced by isoleucine) and methyl-glutamate (replaced by glutamate). Both 
compounds are calcium-dependent in their mechanisms of action. The abbreviated names for 
non-standard amino acids are as follows: Orn for ornithine, MeGlu for methyl-glutamate, Kyn 
for kynurenine, Sar for sarcosine, and MeOAsp for methoxy-aspartate. 
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the main causative agent of community-acquired pneumonia (CAP), as one of the nine bacteria 
that should be of international concern due to its rise in antibiotic resistance [330, 331].  
Clinically, a novel lipopeptide antibiotic called daptomycin is used against Gram-positive 
bacterial infections caused by microorganisms such as Staphylococcus aureus, enterococci, and even 
their strains that are resistant to other drugs [49, 54]. As a fairly young drug, daptomycin has 
risen to become a widely-used antibiotic due to its role as a last-resort alternative to antibiotics 
that fail against serious infections [82]. Daptomycin’s antimicrobial activity depends on calcium, 
which promotes the initial insertion and subsequent oligomerization of daptomycin in the 
bacterial membrane, forming ion channels that disrupt its membrane potential and lead to cell 
death [61]. 
Although daptomycin is clinically effective against skin infections, bacteremia, and right-sided 
endocarditis caused by multi-resistant strains of Gram-positive bacteria, it is ineffective against 
CAP, which is most commonly caused by S. pneumoniae, another Gram-positive pathogen [4]. Its 
poor efficacy against CAP has been attributed to its inability to distinguish between the immense 
amount of lung surfactant present in the lungs versus the small surface area of the bacterial 
pathogens, rendering it sequestered by lung surfactant and therefore inactive against the bacteria 
[10]. It has been postulated that since lung surfactant contains a considerable fraction of 
negatively charged phosphatidylglycerol, which is also a main component of the bacterial plasma 
membrane, daptomycin’s insertion into lung surfactant is promoted [10]. In fact, a recent study 
has shown that the presence of phosphatidylglycerol allows for membrane-bound daptomycin 
to undergo a structural conformation and not only oligomerize, but insert deeper into the 
membrane itself [68]. Daptomycin sequestration has been shown through fluorescence studies 
before [10], but there is no study that compares the binding of daptomycin to lipid models of 
the relevant systems at hand. 
Due to daptomycin’s lack of bactericidal activity in the presence of lung surfactant, multiple 
derivatives and hybrids between daptomycin and A54145 were created in an attempt to find a 
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better alternative [171, 173]. Although numerous derivatives were proven to exert bactericidal 
activity within the presence of lung surfactant, all of them stemmed from A54145, which is 
known to be toxic [105, 174]. One such A54145 derivative is CB-182,462, with more potent 
bactericidal activity against S. pneumoniae than most of the other derivatives (J. Silverman, 
personal communication). However, CB-182,462 was discovered to be toxic with development 
of phospholipidosis in the kidneys, so its development was abandoned (J. Silverman, personal 
communication). As a semisynthetic derivative of A54145, CB-182,462 shares numerous 
structural features with this complex, which in turn is comparable to daptomycin’s structure 
(Figure 5.1). There have also been no studies performed that compare the interaction of CB-
182,462 with different lipid membrane models relevant to community-acquired pneumonia.  
To elucidate the inhibition of daptomycin by lung surfactant and further understand its 
mechanism of action, the studies performed in this chapter will compare the interaction of 
daptomycin versus CB-182,462 in different lipid membrane models that represent the lipid 
compositions of bacterial membranes, lung surfactant, and human cell membranes. The 
interaction of these antibiotics with these model liposomes will be compared using fluorescence 
spectroscopy, taking advantage of their intrinsic fluorescence. The emission intensity and 
spectral position of the kynurenine and tryptophan residues will be used to determine the 
insertion of daptomycin and CB-182,462 into each of the model liposomes, respectively. It has 
been shown that, when these residues transition from an aqueous to a hydrophobic environment 
such as the bilayer of the liposome, an increase in fluorescence will be observed, allowing their 
insertion to be determined from the emission spectra acquired [81].  
The results obtained from this experiment present novel insight into the inhibition of 
daptomycin by lung surfactant and provide strong evidence that daptomycin is sequestered by 
both synthetic and natural models of lung surfactant. Interestingly, it was observed that the 
binding of daptomycin into the bacterial membrane model increased accordingly with calcium 
concentration. At both 2 mM and 10 mM calcium concentrations, daptomycin exhibited minimal 
interaction with the human membrane model. However, CB-182,462 not only bound more 
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strongly to the human membrane model than it did the other models, but did not experience a 
blue spectral shift like the other models. CB-182,462 also did not bind strongly to the lung 
surfactant models, suggesting its function is unhindered by surfactant.  
These trends have several significant implications. It is shown here that daptomycin is 
sequestered by lung surfactant. Specifically, daptomycin has similar affinity for both lung 
surfactant and bacterial membrane, suggesting that these two membranes play a competitive role 
in the binding of daptomycin. Increased emission spectra for daptomycin and bacterial 
membranes at higher concentrations of calcium suggest that calcium may remove the inhibition 
that cardiolipin places on a late step of daptomycin pore formation. It is also shown that CB-
182,462 is not inhibited or sequestered by lung surfactant and exhibits strong binding to bacterial 
membranes, signifying potent bactericidal activity. However, it also binds strongly to the human 
membrane model. This suggests that CB-182,462 toxicity can be explained by its reduced 
selectivity for bacterial versus human cell membranes.  
 
 
5.2 Materials and Methods 
5.2.1 Lipid Models 
Four lipid models were used in this study: bacterial membrane lipid model, human endothelial 
membrane lipid model, synthetic lung surfactant lipid model, and lipid-extracted BLES® model. 
In molar percentages, the bacterial membrane (BM) lipid model consists of 20% 
phosphatidylglycerol, 20% cardiolipin, and 60% phosphatidylethanolamine; the human 
membrane (HM) lipid model consists of 20% phosphatidylcholine, 20% 
phosphatidylethanolamine, 10% phosphatidylserine, 15% sphingomyelin, and 35% cholesterol; 
the lung surfactant (LS) lipid model consists of 80% phosphatidylcholine and 20% 
phosphatidylglycerol, with 5% cholesterol; and the final model is a mixture of lipids extracted 
from bovine lipid extract surfactant (BLES®), which should have a similar lipid composition as 
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that of the LS lipid model. The derivation and reasoning behind each of these lipid models can 
be found in Chapter 3. 
 
5.2.2 Liposome Preparation 
Prior to preparing the liposomes for fluorescence spectroscopy, stock solutions of 1 mM 
daptomycin, 1 mM CB-182,462, and 100 mM calcium were made, along with a HEPES buffer 
(20 mM HEPES, 150 mM NaCl, pH 7.4) for liposome resuspension. See Appendix A for 
detailed procedures. 
The following lipids were purchased from Avanti Polar Lipids (Alabaster, Alabama, US) in 
powder form with >99% purity: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DOPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE), 1,2-dioleoyl-sn-glycero-3-[phospho-ʟ-serine] (DOPS), 1,1’2,2’-
tetraoleoyl cardiolipin (TOCL), and sphingomyelin (egg, chicken). Cholesterol was purchased 
from Sigma-Aldrich (St. Louis, Missouri, US), also with >99% purity.  
For fluorescence spectroscopy studies, a 5 mM solution of large unilamellar vesicles (LUVs) was 
prepared for each membrane lipid model according to their lipid compositions. For each lipid 
model, specific amounts of lipids were weighed into a round-bottom flask and dissolved in 
chloroform/methanol (4:1). The solvent mixture was evaporated with nitrogen gas until a thin 
film formed around the lower-half of the round-bottom flask, which was then further dried 
overnight under vacuum. The following day, HEPES buffer was added to the dried thin film to 
rehydrate and resuspend the vesicles within the buffer solution. The resulting solution was 
passed through a LIPEX™ Thermobarrel Extruder (from Transferra Nanosciences Inc., 
previously known as Northern Lipids, Burnaby, British Columbia, Canada) at least 15 times 
using 100 nm polycarbonate filters at a constant physiological temperature of 37°C. The process 
of extrusion allows the large multilamellar vesicles from the rehydration step to form smaller, 
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uniformly sized large unilamellar vesicles. Detailed experimental protocols are available in 
Appendix B1.  
Note that for preparing lipid mixtures with BLES®, novel protocols had to be designed to extract 
the lipids from the original surfactant suspension in order to successfully prepare BLES® LUVs. 
Prior to this, BLES® liposomes have only been prepared as giant unilamellar vesicles. To 
successfully form BLES® LUVs, specific aliquots of BLES® and chloroform/methanol (4:1) 
need to be thoroughly mixed together and centrifuged at least eighteen times, each spin lasting 
for 5 minutes at 2000 RPM. After each spin, a separation of phases can be seen; the bottom 
phase is saved to another tube for storage while the upper phase and supernatant are spun down 
again upon further additional of chloroform/methanol (4:1). Full details are available in 
Appendix B.1.1.2. 
All fluorescence experiments were repeated a total of three times, with at least 3 emission 
spectra obtained for each trial and scenario. Emission spectra specific to the daptomycin or 
CB-182,462 experiments were normalized separately so that the emission peaks of the controls 
shared a common scale within each group of data. One-way ANOVA (with Tukey’s post hoc 
test) was conducted using OriginPro 2016 (proprietary software owned by Origin®, Version 
b9.3.1.273) to determine statistical significance (α level set to 0.01) and compare the mean 
emission peaks observed for different lipid membrane models in the presence or absence of 
calcium ions for daptomycin and CB-182,462 data sets. 
 
5.2.3 Fluorescence Spectroscopy 
A Photon Technology International (PTI) QuantaMaster Spectrofluorometer was used to 
acquire fluorescence emission spectra. Both daptomycin and CB-182,462 (Cubist 
Pharmaceuticals Inc., Lexington, Massachusetts, USA) have intrinsic fluorescence due to their 
kynurenine and tryptophan residues, respectively. Accordingly, the samples with daptomycin 
were excited at 365 nm, with emission spectra recorded from 400 nm to 600 nm, while the 
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samples with CB-182,462 were excited at 280 nm with emission spectra recorded from 300 nm 
to 500 nm.  
Every lipid model studied had six separate scenarios: the lipid model by itself, in the presence of 
just calcium, just daptomycin, or just CB-182,462, and with both calcium and daptomycin or 
CB-182,462. Each 1 mL cuvette that was used for fluorescence measurements was incubated for 
3 minutes. The final concentration of daptomycin or CB-182,462 in the cuvette was 4 µM, while 
calcium was 2 mM or as indicated in the Results section, and liposomes were 250 µM total lipid. 
All solutions and measurements were taken at a temperature of 37°C. A total of three trials with 
fresh stock solutions and liposomes were performed, and the measurements for each scenario 
in each trial were taken at least three separate times on different days. Detailed instructions on 
fluorescence spectroscopy experimental protocols are available in Appendix B2.  
 
5.3 Results 
It has been previously shown that daptomycin only binds to bacterial membranes in the presence 
of calcium, and that the higher the calcium concentration, the stronger the binding [61, 81, 103]. 
A calcium titration was performed to determine the peak emission signal from a sample of 
daptomycin and bacterial membrane vesicles with increasing calcium concentrations from 0 mM 
to 50 mM (see Figure 5.2). A half-maximal increase was observed close to 0.5 mM Ca2+, and it 
was determined that the emission peaked at around 10 mM of calcium. As a result, initial 
experiments with fluorescence spectroscopy began at 10 mM of calcium concentration, well 
above that of physiological extracellular calcium concentration (which is under 2 mM). 
Subsequent experiments were done at 2 mM of calcium. 
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Figure 5.2 Determining emission plateau using calcium titration. A calcium titration of 
the bacterial membrane model with daptomycin was performed to determine the calcium 
concentration that provided a peak emission signal from the sample to begin experiments with. 
It was determined that the emission signal reached a plateau at approximately 10 mM Ca2+. 
 
 
5.3.1 Interaction of Daptomycin with Membrane Models 
5.3.1.1 Fluorescence Spectra of Daptomycin with Membrane Models at 10 mM Ca2+ 
Using a concentration of 10 mM Ca2+, emission spectra were obtained as preliminary data for 
each of the membrane lipid models, excluding the BLES® lipid model. In Figure 5.3, we can 
see a fluorescence vs. wavelength plot of the emission spectra obtained for daptomycin, with its 
kynurenine residue excited at 365 nm. The results show that there is minimal binding of 
daptomycin to the human membrane model (in green), which supports the notion that it is 
nontoxic and does not interact with human membranes. The plot also shows strong binding of 
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daptomycin to the lung surfactant lipid model (in red), providing preliminary evidence to support 
the hypothesis that daptomycin is sequestered by lung surfactant due to its lipid composition 
and presence of phosphatidylglycerol.  
 
Figure 5.3 Preliminary data obtained for BM, HM, LS models with daptomycin at 10 
mM Ca2+. These plots show the normalized emission spectra obtained for daptomycin in the 
presence of 10 mM Ca2+ for different model liposomes (bacterial  membrane, human membrane, 
lung surfactant lipid models). The kynurenine residue on daptomycin was excited at 365 nm, and 
the emission spectra were acquired from 400 - 600 nm. Each measurement was repeated at least 
3 times in each of the 3 trials. 
 
5.3.1.2 Fluorescence Spectra of Daptomycin with Membrane Models at 2 mM Ca2+ 
In order to better understand the inhibition of daptomycin by lung surfactant and elucidate 
daptomycin’s mechanism of action, experiments were performed close to a physiological calcium 
concentration of 2 mM to give our data more physiological relevance. This particular calcium  
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Figure 5.4 Emission spectra for 2 mM Ca2+ daptomycin experiments. The plots presented 
here represent the data obtained for all four lipid models in four different scenarios: the model 
itself as a control, the model with just calcium as another control, the model with just the 
antibiotic as a third control, and the model with both the antibiotic and calcium. (A) Emission 
spectra were obtained from 400 – 600 nm for a full set of experiments for daptomycin with 
excitation wavelength at 365 nm for kynurenine. Each membrane model is designated by a 
different set of hues: blue for the BM model, green for the HM model, red for the LS lipid 
model, and black for the BLES® lipid model. (B) Averaged emission spectra for different 
membrane models (BM, HM, LS, BLES®) in the presence of 2 mM Ca2+ and daptomycin. Both 
the LS and BLES® models have similar peaks and spectra, and it can be seen that daptomycin 
binds more strongly to the LS models than to the BM model. A HEPES buffer control is 
presented with no liposomes, daptomycin or calcium.  
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concentration has been widely used in various studies [332-336]. Each set of experiments 
involved studying daptomycin in four different scenarios for each of the membrane models: the 
membrane itself, the membrane with only calcium or daptomycin, and the membrane with both 
calcium and daptomycin included. Full sets of data are presented in Figure 5.4A, where the 
buffer, membrane, membrane with only calcium and membrane with only daptomycin (or CB-
182,462) samples acted as negative controls for the experiment. It can be seen that the controls 
(membrane with just calcium or daptomycin) have low readings for emission intensity, similar 
to the HM + Ca2+ + DAP spectra.  
Selected results are presented in Figure 5.4B for a clearer comparison between membrane 
models. As previously observed in Figure 5.4A, there is minimal interaction of daptomycin to 
the human membrane model (in green) as its emission spectra are comparable to the emission 
spectra obtained from the controls. However, the relative order of emission intensity for both 
the bacterial membrane (in blue) and lung surfactant lipid models (in red for synthetic; black for 
natural) at 2 mM Ca2+ have essentially become reversed from the trends seen at 10 mM Ca2+. 
Instead of higher emission peaks for bacterial membrane liposomes, daptomycin now induces 
higher emission peaks with the lung surfactant lipid models at 445 nm. When compared to the 
BLES® lipid model, even stronger emission intensities were observed. Both lung surfactant 
models had emission intensities almost twice as strong as that of the bacterial membrane model. 
One-way ANOVA and Tukey’s post hoc test were used to determine these averaged peak emission 
values as statistically significant (p < 0.0001). Note that the emission spectra obtained for both 
the LS and BLES® lipid models correlate well with each other. 
 
5.3.1.3 Effect of Increasing Calcium Concentration on Daptomycin’s Interaction with BM, LS, and BLES® 
Model Liposomes 
From the previous experiments performed, it seems that daptomycin interacts more strongly 
with lung surfactant than with bacterial membrane at low calcium concentrations, and then shifts 
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Figure 5.5 Comparison of daptomycin insertion into BM and LS models at different calcium concentrations. (A) A calcium 
titration from 0 – 50 mM Ca2+ was performed for daptomycin and three models (bacterial membrane, lung surfactant, and BLES®), 
with the LS® results shown here. (B) Averaged peaks of absorbance at 345 nm for emission spectra obtained at 0 – 50 mM Ca2+. Each 
point on a coloured line represents the average absorbance of at least 9 absorbance peaks (taken from at least 3 emission spectra of 3 
trials) for a singular model. (C) Zoomed-in plot of (B) from 0 – 14 mM Ca2+ to visualize the trends within this range of calcium 
concentrations. Daptomycin insertion into the two lung surfactant models reaches an initial plateau (PL1) just before 0.1 mM Ca2+ and 
a final plateau (PL2) at approximately 2 mM Ca2+; daptomycin insertion into the BM model reaches an initial plateau (PB1) at 0.1 mM 
Ca2+ and then a secondary plateau (PB2) at 10 mM Ca2+. The degree of daptomycin insertion into BM surpasses that of PL at 8 mM Ca2+. 
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at some higher calcium concentration to interact more strongly to bacterial membrane instead 
of lung surfactant. To further elucidate this odd behaviour, a full calcium titration experiment 
was performed to pinpoint what calcium concentrations these points of inflection are occurring 
at. 
Emission spectra were obtained for three models (bacterial membrane, lung surfactant and 
BLES®) in the presence of daptomycin and calcium ranging from 0 mM to 50 mM (Figure 
5.5A). At least three trials were performed, with three repeats or measurements each, and the 
emission peaks at 345 nm were averaged for each scenario and plotted onto a graph, as seen in 
Figures 5.5B and 5.5C. By looking at the full plot from 0 mM to 50 mM Ca2+, it can be seen 
that no significant changes occur past about 15 mM Ca2. For both the bacterial membrane and 
lung surfactant models, an initial plateau (PB1 and PL1) is reached at approximately 0.1 mM Ca2+. 
Daptomycin’s emission intensity increases immediately afterwards for the lung surfactant model 
until a secondary plateau (PL2) is reached at 2 mM Ca2+. Meanwhile, the intensity for the bacterial 
membrane model does not start to increase again until about 4 mM Ca2+, reaching a 50% increase 
at 6 mM Ca2+ until a final plateau (PB2) is reached at 10 mM Ca2+. 
The trends presented in this calcium titration provide information on why two different results 
were seen in the first two experiments with 2 mM and 10 mM Ca2+. With lung surfactant, the 
second plateau is reached much sooner than that of the bacterial membranes, so stronger 
intensities are observed for lung surfactant at lower calcium concentrations. However, when 
comparing final plateaus of intensity, bacterial membrane has a greater value of emission 
intensity, so when this plateau is reached at higher calcium concentrations, greater emission 
intensity will be observed for bacterial membrane models versus the lung surfactant models. 
These results also show the strong correlation between the two lung surfactant models. 
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5.3.2 Interaction of CB-182,462 with Membrane Models 
A second set of experiments were performed alongside those for daptomycin; these experiments 
focused on CB-182,462 instead. Similar to daptomycin, experiments were performed first at 10 
mM of calcium and then 2 mM of calcium.  
 
5.3.2.1 Fluorescence Spectra of CB-182,462 with Membrane Models at 10 mM Ca2+ 
In Figure 5.6, preliminary emission spectra were obtained for the tryptophan present in CB-
182,462 at a calcium concentration of 10 mM. Very low emission peaks were observed for the 
 
 
Figure 5.6 Preliminary data obtained for BM, HM, LS models with CB-182,462 at 10 mM 
Ca2+. These plots show the normalized emission spectra obtained for CB-182,462 in the 
presence of 10 mM Ca2+ for different model liposomes (bacterial membrane, human membrane, 
lung surfactant lipid models). The tryptophan residue on CB-182,462 was excited at 280 nm, and 
emission spectra were acquired from 300 - 400 nm. Each measurement was repeated at least 3 
times in each of the 3 trials. 
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interaction of CB-182,462 to the lung surfactant liposomes (in red), suggesting that this 
semisynthetic derivative may not interact much with or be inhibited by lung surfactant. 
Meanwhile, CB-182,462 induced greater emission intensities in the bacterial membrane model 
(in blue) and human membrane model (in green), suggesting it binds to and inserts with both 
types of membranes. Interestingly, for the human membrane model, a noticeable spectral shift 
in its emission spectrum was observed in the presence of calcium and CB-182,462, relative to 
the lung surfactant and bacterial membrane model emission spectra. This supports our 
hypothesis that CB-182,462 interacts with the human membrane model differently than other 
models, potentially causing toxic effects. To elucidate this spectral shift and determine whether 
any noticeable differences occurred at different calcium concentrations, further experiments and 
controls were performed at a 2 mM concentration of calcium to better mimic a physiological 
environment. 
 
5.3.2.2 Fluorescence Spectra of CB-182,462 with Membrane Models at 2 mM Ca2+ 
Emission spectra were obtained for CB-183,462 with different membrane models at 2 mM of 
calcium. If we look at Figure 5.7B, the trends for CB-182,462 are fairly similar to those we saw 
in the 10 mM Ca2+ set of experiments, so different calcium concentrations do not seem to play 
a role in the trends observed between models. 
The emission spectra for both the LS and BLES models are almost identical, showing great 
correlation with similar peak emission intensities at 333 nm, while the peak emission intensity 
for BM was at least twice this value. Interestingly, a blue-shift of 21 nm is observed in the 
emission spectra of the LS/BLES® and BM models, relative to their emission spectra in the 
absence of calcium (at 354 nm). For the HM model, the peak of the emission spectra is now 
wider than that of the BM model, and its peak emission intensity is slightly higher than that of 
the BM model and at a wavelength of 354 nm, which means that no blue shift is observed from 
the controls. These differences were statistically significant (p < α). 
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Figure 5.7 Emission spectra for 2 mM Ca2+ CB-182,462 experiments. (A) Emission spectra 
were obtained from 300 – 400 nm for a full set of experiments for CB-182,462 with excitation 
wavelength at 280 nm for tryptophan. Similar to the daptomycin set of experiments in Figure 
5.4, the same set of hues were used to designate each model. (B) Averaged emission spectra for 
each membrane models in the presence of calcium and CB-182,462, presented with a buffer 
control. There is less exhibited insertion of CB-182,462 in the LS/BLES® models as compared 
to the BM model, but there is strong insertion in the HM model. A blue shift relative to the 
liposome controls with CB-182,462, seen in (A), is observed for the LS/BLES® and BM models 
in the presence of 462 and Ca2+. For all experiments, three trials were performed with at least 3 
emission spectra obtained for each trial and scenario. 
96 
 
These results show that CB-182,462 does not interact with LS, which explains why LS does not 
inhibit its antibacterial activity. Moreover, they provide additional evidence that our synthetic LS 
liposomes are excellent models of natural BLES surfactant due to their similar findings. 
Moreover, although CB-182,462 can interact strongly with bacterial membranes, it is also toxic 
and not only interacts more into human membranes, but also does not experience the blue shift 
that other models do, which may signify other conformational or electrostatic changes are at 
play in its action mechanism. 
 
5.4 Discussion 
Model membranes have been used in a variety of studies to mimic biological structures and 
provide us with details on their interactions with different molecules, such as cationic peptides 
[337]. Liposome models for bacterial membranes, human cell membranes and both synthetic 
and natural lung surfactant were developed and used in this study. The bacterial membrane of a 
generic bacterium was modeled with a 20:20:60 ratio of DOPG/TOCL/POPE, while the 
human membrane was modeled with a 20:20:10:15:35 ratio of 
DPPC/POPE/DOPS/sphingomyelin/ cholesterol. Lung surfactant was represented by 
creating a liposome containing an 80:20 ratio of DPPC/DOPG with 5% cholesterol, a model 
which has been successfully used with previous studies [250, 258]. To test the validity of this 
synthetic lung surfactant lipid model, BLES® natural bovine surfactant was used to create a 
natural BLES® lung surfactant model following additional lipid extraction procedures. Large 
unilamellar vesicles of BLES® were successfully created and reported for the first time as 
previous studies have only been performed with giant unilamellar vesicles [338-340]. Lipid 
extraction had to be performed at least 18 times to be able to form working BLES® vesicles that 
could pass through an extruder and it is assumed that the original BLES® suspension contained 
too many large proteins (most likely surfactant proteins SP-B and SP-C that help in surfactant 
spreading) that hindered the formation of smaller lipid vesicles. However, it is important to note 
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that due to the large number of extractions performed, it is highly likely that the lipid 
composition of BLES® will be affected on top of the removal of these large proteins. As a result, 
our natural BLES® surfactant can only be considered a more complex lung surfactant model 
compared to our synthetic one. The results obtained for our synthetic lung surfactant lipid model 
and natural BLES® lipid model liposomes correlated extremely well with each other, which 
suggests that our lung surfactant lipid model with an 80:20 ratio of DPPC/DOPG with 5% 
cholesterol can act as a substitute for natural lung surfactant in modelling studies.  
 
5.4.1 Daptomycin Binds to Lung Surfactant and Bacterial Membranes with Similar 
Affinity 
In this study, fluorescence spectroscopy was used to evaluate the interaction of daptomycin with 
four model liposomes. In particular, the main goal of this study was to determine the interaction 
of daptomycin with bacterial membranes versus lung surfactant because direct experimental 
evidence of daptomycin’s sequestration by lung surfactant is lacking. 
The fluorescence spectroscopy data presented in Chapter 5.3.1 allow us to draw several 
conclusions when comparing daptomycin’s interaction with the different membrane models. In 
every experiment, the addition of daptomycin and calcium to the human membrane model did 
not result in a significant fluorescence increase compared to the controls, suggesting that 
daptomycin does not interact with the human membrane. Meanwhile, the addition of calcium 
and daptomycin to the bacterial membrane model induced a significant fluorescence increase. 
The high emission intensities observed for daptomycin’s interaction with bacterial membrane at 
2 mM Ca2+ indicate that the kynurenine residue is located within an environment with low 
polarity, which suggests a deeper insertion of kynurenine into the bacterial membrane. Although 
we can correlate emission intensity with the degree of interaction of daptomycin with the 
membrane, it is hard to pinpoint the type of interaction being experienced: daptomycin could 
be inserting more deeply into the membrane, there could be conformational changes brought 
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upon by varying membrane polarity, and it may be that daptomycin resides at the same depth of 
insertion in the same conformation while both membranes differ in polarity at that level. 
However, numerous studies have shown this increase in fluorescence, and there is a general 
consensus that the increase in emission intensity observed when daptomycin and calcium are 
added to bacterial membrane liposomes indicates the binding and insertion of daptomycin into 
the membrane [61, 68]. Our data provide additional evidence for daptomycin’s dependence on 
calcium as part of its mechanism of action.  
Interestingly, an increase in fluorescence was also observed when daptomycin and calcium were 
added to both the synthetic and natural lung surfactant models. This suggests that daptomycin 
does bind or insert into lung surfactant, and that this action is dependent on the presence of 
calcium. What is even more intriguing is that the initial binding of daptomycin to both the lung 
surfactant models and bacterial membrane occur very early on at approximately 0.1 mM Ca2+. 
This suggests daptomycin has a similar affinity to lung surfactant and bacterial membrane, and 
that, when both are present in the same compartment, lung surfactant will effectively compete 
with bacterial membranes for the binding of daptomycin. This scenario would apply to the lung 
tissue in community-acquired pneumonia and can readily explain why daptomycin is not 
therapeutically effective in this disease. 
Previous studies have shown that daptomycin’s bactericidal activity against S. pneumoniae is 
extremely potent in vitro (MIC90 at 0.06 µg/mL), but greatly diminished in vivo due to the presence 
of lung surfactant [10, 341]. This inhibition has also been confirmed by in vitro antibacterial 
assays, where daptomycin was shown to interact with bovine-derived lung surfactant extract 
aggregates and exhibit increased MIC (minimal inhibitory concentration) values in a calcium-
dependent manner [10]. It has been postulated that because lung surfactant and bacterial 
membranes share some of the same lipid composition, primarily phosphatidylglycerol (PG), 
daptomycin is capable of inserting into lung surfactant. It has also been shown that daptomycin 
requires the presence of PG in order to oligomerize and subsequently insert into the bacterial 
membrane to exert bactericidal activity [68, 104, 140, 342-344]. Although lung surfactant 
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contains somewhat less PG than bacterial membranes, the vast amount of surfactant outweighs 
the small, collective surface area of the exposed bacterial membranes, suggesting that 
daptomycin would be sequestered by lung surfactant. Our data not only confirm that the binding 
of daptomycin to lung surfactant is calcium-dependent, but provides evidence of the 
sequestration of daptomycin by lung surfactant due to possible competition between lung 
surfactant and bacteria to bind daptomycin. In fact, since it has been shown that daptomycin 
oligomerization occurs on membranes with PC and PG [68], we hypothesize that this 
sequestration of daptomycin may not just be driven by a strong binding affinity to lung 
surfactant, but also an oligomerization event which may lead to deeper membrane insertion. 
 
5.4.2 Higher Calcium Concentrations may Remove Inhibited Late Step of 
Daptomycin Pore Formation in Bacterial Membranes 
Apart from elucidating daptomycin’s interaction with lung surfactant, our fluorescence 
spectroscopy data also show that calcium concentration has a powerful effect on the emission 
intensity of daptomycin with bacterial membrane. As seen in Figure 5.5C, at lower calcium 
concentrations, daptomycin reaches an intensity plateau with bacterial membrane at about 0.1 
mM Ca2+. However, emission starts to rise again and reaches a second plateau at around 10 mM 
Ca2+. The calcium concentration that elicited an approximate 50% fluorescence increase from 
the initial plateau is 6 mM Ca2+, suggesting that the supplementation of additional calcium causes 
some sort of conformational change in either daptomycin or the bacterial membrane.  
A pronounced effect of high calcium concentrations has also been observed in a recent study by 
Lohani et al., where the MIC of daptomycin against B. subtilis (1046) was reduced from 0.75 
µg/mL at 5 mM CaCl2 to 0.5 µg/mL at 25 mM and 100 mM CaCl2 [345, 346]. However, their 
results only compared MIC values for three separate calcium concentrations. Our study expands 
on their findings by presenting a clear trend in increasing daptomycin insertion into bacterial 
membrane model liposomes with increasing calcium concentrations. Although the mechanism 
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by which this transition occurs needs to be elucidated in further studies, we know that the 
primary difference between our two models is their lipid composition.  
A previous study by Zhang et al. has shown that the presence of cardiolipin within the membrane 
can prevent a late step in daptomycin’s mechanism of pore formation [106]. Their suggested 
mechanism of action is presented in Figure 1.8, where (1) daptomycin binds to the outer leaflet 
of the target membrane, (2) four molecules of daptomycin form a tetramer in the outer leaflet, 
(3) this tetramer translocates to the inner leaflet of the membrane, and (4) two aligned tetramers 
from opposite leaflets form an octameric and functional pore. In their study, they showed that 
daptomycin bound to PG and CL more than PC in their lipid membrane models. This group 
also provided evidence that membranes containing both PG and CL can induce the 
oligomerization of daptomycin [106]. However, they hypothesized that the third step, the 
translocation of tetramers to the inner leaflet, is inhibited on membranes that contain cardiolipin 
at low calcium concentrations [106]. According to our results, we observe two intensity plateaus 
with bacterial membrane model. It may very well be that this translocation step correlates with 
the second plateau, and that a higher calcium concentration could overcome the inhibition 
placed upon it by cardiolipin. Further studies will need to be performed to elucidate this. 
Since there is evidence of two plateaus (PB1 and PB2 from Figure 5.5C) for the bacterial 
membrane model, with PB2 being much greater than the insertion plateau reached by daptomycin 
insertion into lung surfactant, we also speculate that the bactericidal activity of daptomycin 
against S. pneumoniae may increase with localized calcium supplementation in the presence of 
lung surfactant. Of course, it is harmful to increase the in vivo concentration of calcium to such 
high values, so additional avenues of research should be pursued to determine whether it is 
possible to localize such exposures to high calcium concentrations. 
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5.4.3 CB-182,462 Binds to Human and Bacterial Membrane Models 
Fluorescence spectroscopy studies were also performed to elucidate CB-182,462’s mechanism 
of action and the difference in interaction between different membrane models. In Chapter 
5.3.2, the trends in emission spectra for 2 mM and 10 mM Ca2+ did not change for CB-182,462 
and the four membrane models. It was shown that both the synthetic and natural lung surfactant 
models had the lowest emission intensity with calcium and CB-182,462, comparable to that of 
the membrane controls. This not only suggests that our LS model is a good substitute for BLES®, 
but that CB-182,462 may not interact much with surfactant, and is therefore uninhibited by it. 
However, a noticeable blue shift of 21 nm is observed between the membrane and CB-182,462 
controls and LS/BLES + Ca2+ + 462. Additional controls will need to be examined in further 
experiments to determine whether this blue shift is a result of just calcium binding to CB-
182,462, or whether it is due to a membrane interaction of some nature. Nevertheless, we 
hypothesize that because calcium induces daptomycin aggregation, that it may also induce CB-
182,462 aggregation, which would in turn produce a blue shift in the emission spectra.  
If we look at CB-182,462’s interaction with the bacterial membrane model in the presence of 
calcium, we see a similar blue shift as with the lung surfactant models with 462 and calcium, but 
much greater emission intensity. Red-shifts in tryptophan fluorescence have been reported in 
solutions with higher polarity [347-349]. In terms of bilayers, tryptophan residues buried deep 
into a bilayer have shown larger blue-shifts than those that are exposed to lipid and oligomerized 
at the surface of a bilayer leaflet [350-354]. The combination of a blue shift and increase in 
emission intensity suggest that multiple events are occurring, which may include the transition 
of CB-182,462 into a less polar environment as observed with previous studies on tryptophan, 
or some kind of membrane interaction. CB-182,462’s strong binding with the bacterial 
membrane model suggests that it can exhibit strong potency against bacteria in the presence of 
lung surfactant. This was already confirmed during pre-IND (Investigational New Drug) testing 
(J. Silverman, personal communication). 
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Interestingly, when CB-182,462 is added to the human membrane model with calcium, there is 
no longer a blue shift, but the emission intensity is even higher than that of the bacterial 
membrane. There are two possible explanations for this. First, the lack of a blue shift may 
indicate that the human membrane interaction of CB-182,462 may be incomplete or modified 
compared its interaction with bacterial membranes. Since this blue-shift was not observed for 
the human membrane model with calcium and 462, relative to its calcium-free counterpart, we 
believe that CB-182,462 does not insert more deeply into the human membrane model liposome, 
but rather localizes more onto the surface of the membrane; this may or may not be accompanied 
by the formation of oligomers. Second, CB-182,462 still binds to the human membrane and may 
trigger some form of perturbation that will ultimately result in tissue damage. The mechanism 
for this damage will need to be studied further, and future research should involve permeability 
studies to determine whether membrane permeabilization is required for toxicity, or whether 
this toxicity can be attributed to binding events.  
The oligomerization of CB-182,462 onto human membrane model liposomes and its strong 
insertion into bacterial membrane versus lung surfactant lipid models in the presence of calcium 
constitute the first of such evidence.  
 
5.5 Conclusion 
Direct experimental evidence of daptomycin sequestration by lung surfactant is currently lacking. 
It has been speculated that daptomycin is inhibited by lung surfactant due to the vast abundance 
of lung surfactant versus the small presence of bacterial cells, and therefore daptomycin would 
be trapped in this lung surfactant and not be free to exert its bactericidal effect on S. pneumoniae 
within the lungs. 
In this study, we have shown that fluorescence spectroscopy can be used to compare the extent 
of binding and insertion of an antimicrobial peptide into different lipid membrane models.  
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BLES® surfactant was also transformed into large unilamellar vesicles for the first time using 
novel protocols developed for this experiment. 
The results from this study provide strong evidence to support the theory that daptomycin is 
inhibited by lung surfactant not only because of the vast abundance of the surfactant, but also 
because it has a similar affinity to bind to lung surfactant as it does to bacterial membrane. This 
potential competition may exacerbate its inhibition by lung surfactant. Additional evidence was 
also obtained to verify daptomycin’s dependency on calcium to exert its mechanism of action. 
Our results also suggest that increasing the calcium concentration may help remove the 
inhibition that cardiolipin places upon a late step of daptomycin pore formation in bacterial 
membranes, which is related to its translocation to the inner membrane leaflet.  
Meanwhile, the semisynthetic antibiotic CB-182,462 was shown to exhibit strong binding to the 
human membrane model liposomes at all concentrations of calcium, providing a possible 
explanation for its toxicity where it binds to and causes some form of membrane damage.  
Overall, our studies present a good correlation of in vitro versus in vivo observations. Our lung 
surfactant models can be used for the rapid screening of novel daptomycin derivatives to test 
for surfactant-driven inhibition, while our human membrane models can be used to test for 
toxicity potential. 
Future studies that may help provide additional insight into daptomycin’s inhibition by lung 
surfactant in cases of pneumococcal infection could involve competitive binding assays that test 
daptomycin’s preference in binding between lung surfactant lipid models and bacterial 
membrane models. It will also be useful to determine whether daptomycin oligomerizes when 
inserting into lung surfactant, and if so, how many daptomycin molecules form this oligomer. 
Studies could also be performed in testing daptomycin’s bactericidal activity against S. pneumoniae 
in the presence of lung surfactant at different calcium concentrations, as stronger binding to 
bacterial membrane model liposomes was observed in this study at higher calcium 
concentrations. Another study related to daptomycin may involve laurdan fluorescence intensity 
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experiments to determine how daptomycin can change membrane phase properties for both 
bacterial membranes and lung surfactant due to its sensitivity to polarity within the bilayer. This 
would provide insight into whether daptomycin causes changes in membrane polarity and 
structure in the presence of calcium. CB-182,462 can be studied further using permeability 
testing to elucidate its mechanism of toxicity.  
105 
 
CHAPTER 6 
6 LANGMUIR-BLODGETT MONOLAYER STUDIES: 
DAPTOMYCIN STRONGLY INSERTS INTO AND 
DECREASES THE COMPRESSIBILITY OF LUNG 
SURFACTANT 
 
 
6.1 Introduction 
Daptomycin (Figure 1.3) is a lipopeptide antibiotic that has a 13 amino acid residues, 10 of 
which are arranged cyclically and 3 on an exocyclic tail [67, 355]. Its action mechanism is distinct 
from that of most other clinically used antibiotics, which means that it is unaffected by resistance 
mechanisms that are specific for the latter. Therefore, it can be used against resistant strains of 
Gram-positive pathogens, such as MRSA and VRE [4, 8, 9]. Consistent reports have shown that 
daptomycin’s mechanism of action involves depolarization of the bacterial membrane [61, 62, 
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96, 356], while other molecular targets and modes of actions have been suggested, such as the 
inhibition of peptidoglycan synthesis [65, 357]. Apart from its mechanism of action not being 
fully understood, even more peculiar is its inhibition by lung surfactant in the context of 
pneumococcal pneumonia caused by Streptococcus pneumoniae [10]. The study performed in 
Chapter 5 has shown evidence of daptomycin sequestration by lung surfactant at physiological 
calcium concentrations. However, daptomycin’s mechanism of inhibition by lung surfactant may 
very well be multifaceted and not as straightforward as having a binding affinity to surfactant.  
Although model membranes such as vesicles and supported bilayers may be used to study 
daptomycin’s effect, it is important to note that lipid monolayers are also excellent model systems 
that have provided a great deal of insight into surface interactions taking place on a single 
membrane leaflet [175, 176, 337]. This study aims to provide further insight into the effect of 
daptomycin on lung surfactant monolayer properties using Langmuir-Blodgett monolayer 
techniques. The data obtained from our daptomycin experiments will be compared with another 
set of experiments performed with CB-182,462 (see Figure 1.10), a semisynthetic derivative 
similar to daptomycin that is not inhibited by lung surfactant and still presents potent bactericidal 
activity, but causes kidney phospholipidosis (J. Silverman, personal communication). Although 
CB-182,462 was never brought to clinical trials due to its toxicity problems, comparing its effect 
on monolayer properties with that of daptomycin may prove useful in understanding their 
differences. The four lipid models that will be used in this study are related to systems that these 
two antibiotics would encounter in the case of a patient presenting with pneumonia caused by 
S. pneumoniae: a bacterial membrane model will be based off of the lipid composition of S. 
pneumoniae, a human membrane model will be based off of erythrocyte endothelial cell 
membranes, and both synthetic and natural lung surfactant models will be used. 
Compression isotherms were taken of each monolayer model by itself as a control and in the 
presence of calcium, daptomycin/CB-182,462 or both. These compression isotherms are 
obtained when the Langmuir-Blodgett trough barriers compress the monolayer until the 
minimum trough area is reached and provide data on monolayer compressibility at any chosen 
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pressure. Our results show that at a pressure of 40 mN/m, the elastic area compressibility 
modulus of our synthetic and natural lung surfactant monolayers increased significantly, which 
directly translated into reduced monolayer compressibility. 
Insertion assays were also performed for each monolayer model in the same scenarios as those 
presented in the compression isotherm studies. Here, the monolayers were compressed to a 
lower pressure of 20 mN/m and either daptomycin or CB-182,462 was injected underneath the 
monolayer to record any changes in pressure; any increase in pressure would represent a greater 
amount of insertion into the monolayer being studied. Our results strongly correlate with the 
fluorescence spectroscopy data obtained in Chapter 5.  
The studies presented in this chapter provide further insight into the behaviour of daptomycin 
in the presence of lung surfactant. From our results, it can be seen that daptomycin does not 
just insert more into lung surfactant than bacterial membrane lipid monolayers, but it also 
decreases the compressibility of lung surfactant significantly, especially in the case of BLES® 
natural bovine surfactant extract. This leads us to suggest a new model of daptomycin 
sequestration by lung surfactant, where daptomycin is not just inserted into the lung surfactant, 
but may help confer certain surfactant-spreading properties that promote the function of lung 
surfactant. This means that the lung surfactant may be able to form multilayers at lower pressures 
than normal, effectively trapping daptomycin within these layers of lung surfactant and 
reinforcing its sequestration.  
 
 
6.2 Materials and Methods 
6.2.1 Lipid Models 
There were four lipid models used in this study. The bacterial membrane (BM) lipid model 
consisted of 20% PG, 20% CL, and 60% PE while the human membrane (HM) lipid model was 
composed of 20% PC, 20% PE, 10% PS, 15% sphingomyelin, and 35% cholesterol. Modified 
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natural BLES® lung surfactant was used as our natural lung surfactant model while a synthetic 
lung surfactant (LS) model was made from 80% PC and 20% PG with 5% cholesterol by mass. 
Additional details regarding each of these models area available in Chapter 3.  
 
6.2.2 Solution Preparation 
The majority of the lipids used in each of the models were purchased from Avanti Polar Lipids 
(Alabaster, Alabama, US) in powder form with >99% purity: 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DOPG), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1,2-dioleoyl-sn-glycero-3-
[phospho-ʟ-serine] (DOPS), 1,1’2,2’-tetraoleoyl cardiolipin (TOCL), and sphingomyelin (egg, 
chicken). Cholesterol (>99% purity) was purchased from Sigma-Aldrich (St. Louis, Missouri, 
US). 
Prior to starting experiments on the Langmuir-Blodgett trough, 1 mM mixed lipid stock 
solutions had to be made for each of the models being studied (see Appendix C1 for detailed 
protocols). Stock solutions of 1 mM daptomycin, 1 mM CB-182,462 and 100 mM CaCl2 were 
also prepared (see Appendix A for detailed procedures). 
 
6.2.3 Langmuir-Blodgett Trough Techniques 
6.2.3.1 Monolayer Compression Isotherms 
A Langmuir-Blodgett micro-trough from NIMA Technology Ltd. (Coventry, England) was used 
for the monolayer experiments in this study. Trough cleaning procedures are available in 
Appendix C2. 
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For compression isotherms, the surface pressure of Langmuir monolayers was continuously 
measured as the area of the trough decreased to create a pressure-area isotherm. The trough was 
filled with a set amount of Milli-Q® ultrapure water (resistivity greater than 18.2 MΩ·cm) and, 
depending on whether calcium was incorporated into the solution, the final calcium 
concentration in the ultrapure water subphase was 2 mM. During the acquisition of compression 
isotherms, the chosen model lipid mixture (stock solution in 4:1 ratio of chloroform/methanol) 
was added on top of the subphase in between the two trough barriers and left for at least 10 
minutes to let the solvent evaporate. A Hamilton® gastight syringe (Reno, Nevada, United States 
of America) with a precision-machined PTFE plunger tip and leak-free seal was used for 
depositing lipid solutions. The trough barriers were then set at a speed of 20 cm2/min to 
compress the Langmuir monolayer on the surface of the subphase. A set amount of daptomycin, 
CB-182,462 or ultrapure water (for control runs without either antibiotic) was injected 
underneath the monolayer prior to the start of compression. The final concentration of 
daptomycin or CB-182,462 in the subphase was 4 µM (slightly higher than their MIC). For a 
detailed explanation of experimental protocols for compression isotherms, please refer to 
Appendix C3.  
Once the compression isotherms were recorded, the resulting plot had pressure (mN/m) on the 
y-axis and absolute area (cm2) on the x-axis. In order to calculate the elastic area compressibility 
modulus, this x-axis had to be converted to molecular area, or area per molecule (Å2/molecule) 
using the following equation [358], where am is the molecular area, A is the absolute area, Mw is 
the average molecular weight of all lipids in the mixture (g/mol), c is the concentration of the 
lipid mixture (mg/mL), NA is Avogadro’s number (molecules/mol), and V is the volume of lipid 
mixture added atop the subphase (µL): 
𝑎𝑎𝑚𝑚 = (𝐴𝐴)(𝑀𝑀𝑊𝑊)(𝑐𝑐)(𝑁𝑁𝐴𝐴)(𝑉𝑉) (Eq. 4) 
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From here, we can obtain a pressure versus molecular area isotherm, which can be directly used 
to calculate the elastic area compressibility modulus. A particular pressure is chosen at which the 
most changes are observed between slopes across all isotherms. In our case, a pressure of 40 
mN/m was chosen as clear differences in slope were qualitatively observed between each model 
and scenario. To calculate the elastic area compressibility modulus or Cs-1, the following equation 
was used, where A is molecular area, and Π is the surface pressure [290, 359, 360]. Note that 
higher Cs-1 values correspond to lower monolayer compressibility [290, 360]. 
𝜕𝜕𝑠𝑠
−1 = −𝐴𝐴�𝑑𝑑Π
𝑑𝑑𝐴𝐴
� (Eq.  5) 
A minimum of three compression isotherms were taken for at least three trials and variance was 
analyzed using one-way ANOVA with Tukey’s post hoc test for statistical significant (α = 0.01) 
  
6.2.3.2 Monolayer Insertion Assays 
Using the same Langmuir-Blodgett micro-trough, constant-area insertion assays were 
performed. Each monolayer was prepared on an ultrapure water subphase (with or without 2 
mM Ca2+) and compressed to a target pressure of 20 mN/m at a compression speed of 20 
cm2/min. Once this pressure was reached, the trough barriers were locked in place. Using a 
Hamilton® syringe (Reno, Nevada, United States of America) and a 22-gauge, 2-inch needle that 
was custom-bent into an L-shape, a set amount of either daptomycin, CB-182,462 or ultrapure 
water (as a control) was injected  gently and carefully underneath one of the trough barriers 
under the preformed monolayer using uniform force and speed. After injection, the Hamilton® 
syringe was carefully removed and the pressure readings were taken for at least 5 minutes until 
a steady plateau was reached. Detailed instructions for Langmuir-Blodgett trough operation and 
experimental protocols are available in Appendix C4.  
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At least 3 insertion assays were performed for each of the three trials, with fresh stock and lipid 
solutions made for each trial. The final pressure was recorded for each of the runs and averaged 
to obtain a mean pressure for each scenario. One-way ANOVA was used to test for variance 
and statistical significance, while Tukey’s post hoc test was used to compare individual scenarios.  
 
 
6.3 Results 
6.3.1 Daptomycin Significantly Decreases the Compressibility of Lung Surfactant 
Our previous studies (see Chapter 5) have shown that daptomycin inserts strongly into our 
synthetic and natural lung surfactant models, while CB-182,462 does not. However, we are 
interested in elucidating the mechanism of inhibition that lung surfactant imposes on 
daptomycin. Since monolayers are good representatives of one leaflet of a membrane bilayer, 
monolayer studies were performed to monitor the effect of daptomycin and CB-182,462 on 
monolayer properties for each of our membrane lipid models. 
Compression isotherms were gathered for each model monolayer (BM, HM, LS, and BLES® 
lipid models). Since it was not possible to enter the molecular weight of more than two different 
lipids and their ratios into the Langmuir-Blodgett trough control software, pressure versus 
absolute area isotherms were initially obtained so that proper calculations and conversion of the 
x-axis to molecular area could be completed using Eq. 3. Each lipid model had its own unique 
conversion rate due to their differing lipid ratios and molecular weights; the molecular weight 
used for Eq. 3 consisted of a weighted average of the molecular weights of each of the lipids 
within a particular model.  After conversion of absolute area to molecular area, the compression 
isotherms were replotted onto a pressure versus molecular area graph (see Figure 6.1).  
From these compression isotherms, it can be seen that each monolayer follows a particular curve, 
and the slope of that curve at certain pressures is what sets each monolayer apart in terms of 
compressibility. In general, each monolayer starts off in a two-dimensional gas phase, where the 
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lipid molecules are disordered and do not really interact with each other as they are far apart. As 
the area decreases, the lipids are pushed closer together and enter into a liquid phase, which 
increases the pressure. As the pressure continues to rise, the lipids enter into a solid phase where 
the molecules are packed tightly together into one continuous and stable monolayer. 
Qualitatively, it can be seen that for both the LS and BLES® compression isotherms with 
daptomycin and calcium, the slope of the curve at the liquid-solid phase is much steeper 
compared to the slope of the curve for the BM and HM compression isotherms. Meanwhile, it 
seems that the slope for LS compression isotherm in the presence of calcium and CB-182,462 
seems to be a bit steeper than the other models. However, qualitative observations are not 
enough to perceive the differences between these compression isotherms.  
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Figure 6.1 Pressure vs. molecular area graphs of compression isotherms. Compression 
isotherms were performed on each of the four membrane models: (A) bacterial membrane, (B) 
human membrane, (C) lung surfactant, and (D) BLES®. This data was then plotted using 
pressure versus molecular area. Each data point was obtained from at least 9 measurements 
spanning across three trials; error bars are shown for each measurement (shaded areas). 
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Figure 6.2 Comparison of Cs-1 for different models and scenarios. The elastic area 
compressibility modulus (Cs-1) was calculated for each compression isotherm at a chosen pressure 
of 40 mN/m and plotted in a bar graph (see Table 6.1 for values). In (A), the Cs-1 values for 
each model monolayer (BM, HM, LS, BLES®) in each scenario are shown. In (B), select 
compressibility moduli are shown for the controls of each monolayer model as well as in the 
presence of both Ca2+ and an antibiotic (DAP or 462). Statistical significance (p < 0.01) between 
means are depicted by an asterisk. 
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To calculate the elastic area compressibility modulus (Cs-1) for each compression isotherm, a set 
pressure must be chosen for this comparison. Since each of the isotherms had their steepest 
slope near their solid phase, a pressure of 40 mN/m was chosen and the elastic area 
compressibility modulus of each isotherm was calculated using Eq. 4. Figure 6.2A shows each 
value obtained for Cs-1, while Figure 6.2B shows the final results of these calculations for each 
model monolayer’s control isotherm as well as the compression isotherms obtained in the 
presence of calcium and either daptomycin or CB-182,462. If we look at Figure 6.2B, we can 
see that the compressibility of the BM or HM monolayers do not change much upon addition 
of calcium and daptomycin or CB-182,462. However, a significant change in compressibility is 
noticed for the lung surfactant monolayers. The synthetic LS monolayer has a base 
compressibility modulus of about 50.1 mN/m ± 9.7 mN/m, which increases to 74.7 mN/m ± 
9.5 mN/m in the presence of calcium and daptomycin. That represents an approximately 50% 
increase in compressibility modulus of the synthetic lung surfactant monolayer, or in other 
words, an approximate 33% decrease in monolayer compressibility.  
Remarkably, these changes are much more pronounced in the BLES® natural lung surfactant 
monolayer compressibility values. The control BLES® monolayer has a very low initial 
compressibility modulus of 11.4 mN/m ± 5.6 mN/m. However, in the presence of calcium and 
daptomycin, it experiences a six-fold increase and has a compressibility modulus of 69.1 mN/m 
± 8.8 mN/m, meaning its monolayer compressibility has decreased significantly. The stark 
difference between these two models may very well be due to the fact that the synthetic lung 
surfactant model does not have any surfactant-associated proteins present, while the natural 
BLES® model may still have some surfactant-associated proteins incorporated within the 
monolayer that were not extracted during sample preparation. 
From these results, it can be seen that daptomycin severely affects the compressibility of lung 
surfactant monolayers. However, additional monolayer properties could be tested using insertion 
assays, which would not only provide information on the insertion of either daptomycin or CB-
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182,462 into these monolayers, but provide data on the stability of these monolayers as well after 
insertion events. 
 
Table 6.1 Compressibility moduli of select models and scenarios. The elastic area 
compressibility modulus (mN/m) is presented for each model monolayer system (BM, HM, LS, 
and BLES®) at a pressure of 40 mN/m and select scenarios: monolayer control, monolayer with 
both calcium and daptomycin, and monolayer with both calcium and CB-182,462. Each value 
was obtained from at least 9 measurements. 
Model & Scenario Elastic Area Compressibility Modulus (mN/m) 
BM Control 37.93 ± 6.06 
BM + Ca2+ + Daptomycin 34.46 ± 7.26 
BM + Ca2+ + CB-182,462 33.60 ± 5.22 
HM Control 52.53 ± 4.42 
HM + Ca2+ + Daptomycin 65.97 ±15.61 
HM + Ca2+ + CB-182,462 58.25 ± 16.56 
LS Control 50.11 ± 9.71 
LS + Ca2+ + Daptomycin 74.67 ± 9.52 
LS + Ca2+ + CB-182,462 55.08 ± 9.33 
BLES® Control 11.38 ± 5.58 
BLES® + Ca2+ + Daptomycin 69.11 ± 8.69 
BLES® + Ca2+ + CB-182,462 22.12 ± 4.71 
 
 
6.3.2 Daptomycin Inserts More into Lung Surfactant than Bacterial Membrane 
Insertion assays with and without calcium were performed on each monolayer model in 
combination with a control injection (ultrapure water) or injections of either daptomycin or CB-
182,462. Once a monolayer was compressed to a target pressure of 20 mN/m (assumed to be 
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in a liquid-condensed phase for the lipid models used), it was left to equilibrate for about 2 
minutes prior to injection at t = 180 seconds. The resulting changes in pressure were then 
monitored for at least 5 minutes until t = 500 seconds. Figure 6.3 compares the insertion assays 
performed for each monolayer model with either DAP or 462 in the presence of calcium.  
In Figure 6.3A, it can be seen that daptomycin, in the presence of calcium, does not insert into 
the human membrane model monolayer; the observed trace resembles the wide range of controls 
obtained for these sets of experiments (cases where no calcium is added or just ultrapure water 
instead of daptomycin). Meanwhile, daptomycin inserts strongly into the bacterial membrane 
model monolayer, reaching a pressure of about 23.5 mN/m ± 0.4 mN/m. Similar to previous 
findings reported in Chapter 5, daptomycin experiences greater insertion into the lung 
surfactant models, reaching a final pressure of 26.10 mN/m ± 0.6 mN/m for the synthetic LS 
monolayer and 25.7 mN/m ± 0.3 mN/m for the natural BLES® monolayer. In the context of 
insertion, these results show us that our synthetic and natural lung surfactant models experience 
similar trends. 
In Figure 6.3B, the results for the CB-182,462 insertion assays can be observed. Once again, 
the lung surfactant monolayers have comparable results, and do not experience a significant 
degree of insertion from CB-182,462 in the presence of calcium (final pressure of 20.8 mN/m 
± 0.2 mN/m for the LS monolayer and 20.5 mN/m ± 0.2 mN/m for the BLES® monolayer). 
This is expected because CB-182,462 functions in the presence of lung surfactant, and therefore 
should not bind to it. However, this is not the case with the bacterial membrane or human 
membrane models. Since CB-182,462 should exhibit strong bactericidal activity, strong insertion 
should be seen, and this is shown in our results with a pressure increase to 24.1 mN/m ± 0.4 
mN/m at t = 500 seconds. Similar to the fluorescence experiments in Chapter 5, CB-182,462 
displays a strong interaction with the human membrane model, showing a great amount of 
insertion into the HM monolayer until a pressure of 25.1 mN/m ± 0.5 mN/m is reached. Figure 
6.3C shows a bar graph of select scenarios and their corresponding final pressures, while Table 
6.2 shows the values corresponding to all scenarios.  
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Figure 6.3 Insertion assay results for all model monolayers. Insertion assays were 
performed on each monolayer model (BM, HM, LS, BLES®) in different scenarios. Each 
monolayer was compressed to a target pressure of 20 mN/m, the trough barriers were locked in 
place, and an injection of either nanopure water (control), daptomycin, or CB-182,462 was made 
and the pressure changes recorded for a total of 5 minutes. At least 9 assays were performed per 
scenario. Plot (A) represents the insertion assays for the daptomycin experiments, plot (B) 
represents those for the CB-182,462 experiments, and plot (C) represents the pressure reached 
at t = 500 seconds. Statistical significance (p < 0.01) between groups is indicated by asterisks. 
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Table 6.2 Final surface pressure readings for insertion assay experiments. For each 
insertion assay experiment, the final surface pressure reading was taken at a time of 500 seconds. 
These readings are presented in this table, with each reading being an average of 9 measurements. 
Model & Scenario Surface Pressure @ t = 500 s (mN/m) 
BM Control 19.25 ± 0.31 
BM + Ca2+ 20.30 ± 0.15 
BM + Daptomycin 20.09 ± 0.43 
BM + CB-182,462 20.06 ± 0.30 
BM + Ca2+ + Daptomycin 23.46 ± 0.37 
BM + Ca2+ + CB-182,462 24.14 ± 0.40 
HM Control 19.28 ± 0.37 
HM + Ca2+ 19.42 ± 0.39 
HM + Daptomycin 19.08 ± 0.15 
HM + CB-182,462 19.32 ± 0.39 
HM + Ca2+ + Daptomycin 19.79 ± 0.30 
HM + Ca2+ + CB-182,462 25.14 ± 0.49 
LS Control 19.95 ± 0.18 
LS + Ca2+ 19.71 ± 0.25 
LS + Daptomycin 19.99 ± 0.16 
LS + CB-182,462 19.70 ± 0.27 
LS + Ca2+ + Daptomycin 26.10 ± 0.55 
LS + Ca2+ + CB-182,462 20.79 ± 0.20 
BLES® Control 20.31 ± 0.33 
BLES + Ca2+ 20.53 ± 0.18 
BLES + Daptomycin 20.56 ± 0.20 
BLES + CB-182,462 20.48 ± 0.14 
BLES® + Ca2+ + Daptomycin 25.71 ± 0.29 
BLES® + Ca2+ + CB-182,462 20.53 ± 0.25 
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6.4 Discussion 
The Langmuir-Blodgett (LB) monolayer technique has been widely used to study monolayer 
lipid films at the air-water interface [184, 258, 361-364]. These lipid monolayers have been shown 
to be excellent, simplified models that allow us to study complex lipid systems [365]. In this 
study, monolayers of each of our lipid model systems were successfully formed. Compression 
isotherms and insertion assays were obtained to help elucidate the inhibition of daptomycin by 
lung surfactant. 
The interaction of daptomycin with lung surfactant is important to understand, and is still 
relevant in cases of bacterial pneumonia, such as CAP. These causative bacteria have been shown 
to cause changes in lung surfactant: the bacteria may interact directly with secreted surfactant to 
change its physical properties (eg. density and surface tension), while others can indirectly affect 
surfactant by interacting with type II alveolar cells (eg. abnormal surfactant production and lipid 
composition) [366]. Although severe cases of pneumonia result in fluid-filled alveolar sacs with 
severely impaired surfactant, lung surfactant plays a significant role in the initial clearance of 
pneumococci during early stages of infection due to the lung’s innate immunity, made possible 
by surfactant proteins SP-A and SP-D [367, 368]. As the disease progresses, decreased SP-A, 
PG, and PC levels are observed [369, 370]. Therefore, lung surfactant is still present and 
functional during early stags of pneumococcal infection.  
The elastic area compressibility modulus (Cs-1) of a lipid monolayer is a measurement of its 
resistance to area expansion or compression [371]. Meanwhile, the term ‘compressibility’ is used 
to describe the ability of a specific lipid film in lowering surface tension during surface area 
reduction [372]. In other words, higher values of Cs-1 refer to lower degrees of monolayer 
compressibility. Good surfactants have low compressibility because of their ability to lower 
surface tension significantly during surface area reduction [372]. With regards to lung surfactant, 
the surfactant-associated proteins SP-B and SP-C have strong surface activity, because they allow 
the surfactant to reduce its surface tension upon film compression [372, 373]. Removing these 
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surfactant proteins has been shown to significantly increase monolayer compressibility, which 
reduces lung compliance as low compressibility is required for the easy reduction of surface 
tension [374]. A squeeze-out model has been proposed and modified throughout the years, 
suggesting that during the compression of a good surfactant, gel-phase phospholipids are 
retained in the primary surfactant layer, while fluid-phase lipids are expelled to form additional 
monolayers attached to the primary layer, effectively creating bilayers and multilayers at reduced 
surface areas [375, 376].  
The compression isotherm experiments performed in this study provide interesting results 
regarding the interaction of daptomycin with lung surfactant. In general, daptomycin decreased 
the compressibility of the lung surfactant monolayers, as it increased their Cs-1 values by a 
significant amount compared to the controls. These properties correlate with those of a good 
surfactant, where low compressibility allows for greater reduction in surface tension at lower 
surface areas. It is then plausible that daptomycin helps to confer surface activity, similar to the 
function of both SP-B and SP-C, allowing the surfactant to have greater flexibility in rearranging 
its lipids to achieve lower surface tensions upon compression.  
It is most interesting that the addition of daptomycin decreased the compressibility of the natural 
BLES® surfactant monolayer (from Cs-1 = 11.4 mN/m ± 5.6 mN/m in BLES® control to Cs-1 = 
69.1 mN/m ± 8.7 mN/m with calcium and daptomycin) much more than it did the synthetic 
LS monolayer (from Cs-1 = 50.1 mN/m ± 9.7 mN/m in BLES® control to Cs-1 = 74.7 mN/m ± 
9.5 mN/m with calcium and daptomycin). Part of the reason why there was such a drastic 
difference in compressibility between the control monolayers and their respective monolayers 
with calcium and daptomycin is that the BLES® control monolayer had a very low elastic area 
compressibility modulus compared to the other controls amongst all models. Since our modified 
BLES® is natural surfactant with most of it surfactant-associated proteins removed, and has a 
slightly more complex lipid composition that the simplified LS model, it can be conceived that 
the absence of most of these proteins has significantly impaired its ability to reduce surface 
tension, thus increasing its compressibility. However, upon the addition of daptomycin, its 
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compressibility decreased significantly by about six-fold, most likely because daptomycin may 
help to confer surface activity similar to what the hydrophobic surfactant proteins do. As a result, 
it is our belief that daptomycin not only associates itself with lung surfactant, but also plays a 
role in lowering its compressibility, making it an even better surfactant that can reduce surface 
tension at even lower surface areas than before. This suggests that at higher surface pressures 
and reduced surface areas, daptomycin would be more effectively sequestered within the lung 
surfactant, especially after multilayers have formed with daptomycin trapped within them. 
BLES® and other clinical surfactant films have been shown to undergo a monolayer-to-
multilayer transition plateau at around 40-50 mN/m, where the pressure slowly increases during 
monolayer compression [251]. However, our studies use a modified version of BLES® with most 
of its surfactant-spreading proteins removed; it would be considered more of a simplified lipid 
model derived from natural surfactant. When we performed compression isotherms, the slope 
of the curve was steeper in the synthetic LS model versus the BLES® model, suggesting that the 
surfactant-spreading properties of our BLES® monolayer may have been somewhat impaired 
from successive lipid extractions performed in its preparation. Nevertheless, their curves seem 
to correlate with typical isotherm collected for surfactant models, both synthetic and natural 
[251, 261].  However, upon the addition of calcium and daptomycin, we see a significant change 
in both surfactant models (especially in the BLES® model), where a very steep slope is observed, 
beginning at lower pressures. This suggests that daptomycin and calcium may alter the surface 
activity of lung surfactant, but the questions remain as to how much it changes surfactant 
function, and whether this monolayer-to-multilayer transition occurs at lower pressures. 
Insertion assays were used to study the insertion of peptides and molecules into lipid monolayers, 
but primarily using the constant-pressure technique where the changes in molecular area are 
measured and the target pressure is kept constant [293, 377-379]. A previous study used a 
constant-area technique for insertion assays, testing the effect of daptomycin on equal fractions 
of PC and PG monolayers with varying concentrations of cardiolipin [106]. Due to the various 
different lipid model systems being used, it was more suitable to use the constant-area technique 
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in our case so that the area could be held constant at a specific initial pressure, and the change 
in pressure compared afterwards for each scenario. 
The insertion assays obtained provide data that correlate nicely with the previous results obtained 
in Chapter 5, where fluorescence spectroscopy was used to study the insertion of daptomycin 
or CB-182,462 into model liposomes. In this study, monolayers were used instead of bilayers, 
and the similarities in results illustrate that monolayers are great models for membrane systems. 
Here, it was shown that daptomycin does not insert into the HM model monolayer, suggesting 
it does not interact with this model and supporting the fact that it is not as toxic as CB-182,462, 
which inserts significantly into the HM model monolayer. Both daptomycin and CB-182,462 are 
known to exhibit strong bactericidal activity against S. pneumoniae, and these results show that 
they insert strongly into the BM model monolayers, with CB-182,462 inserting a little bit more 
strongly on average. The main difference comes with the lung surfactant models. For both the 
LS and BLES® model monolayers, daptomycin inserts strongly into each model, about 3 to 4 
mN/m more than it does with the BM model monolayer. This supports our theory that 
daptomycin is strongly sequestered by lung surfactant. Meanwhile, since CB-182,462 is supposed 
to work in the lungs, minimal insertion is observed with both the lung surfactant models.  
 
6.5 Conclusion 
This study provides the first reported evidence of daptomycin affecting the physical properties 
of lung surfactant upon binding to it in the presence of calcium. Through our studies with 
monolayer insertion assays and compression isotherms, we provide novel evidence that 
daptomycin not only inserts and integrates strongly into the lung surfactant monolayer (due to 
a greater increase in pressure readings as compared to other lipid monolayer models), but also 
severely decreases the compressibility of the lung surfactant monolayer.  
124 
 
From these findings, we now present a new model of daptomycin inhibition by lung surfactant. 
We hypothesize that (1) daptomycin recognizes the lung surfactant and is most likely attracted 
to it, (2) daptomycin binds to and strongly inserts into the lung surfactant, whether it is in 
monolayer or multilayer form, effectively sequestering it, and (3) daptomycin reduces the 
compressibility of lung surfactant, allowing it to possibly form multilayers more easily at lower 
pressures and thus reinforce its sequestration.  
Interestingly, the development of the semisynthetic antibiotic CB-182,462 was halted due to 
manifested toxicity, specifically related to phospholipidosis within the kidneys. Our results 
provide supporting evidence to the fluorescence studies presented in Chapter 5, where CB-
182,462 strongly inserts into the human membrane lipid model. This suggests that a strong 
electrostatic attraction and subsequent insertion into erythrocytes or other tissue cells may be 
one of the first steps in the mechanism of action of CB-182,462 in relation to its toxicity.  
Much focus has been directed towards the effect of lung surfactant on daptomycin and how it 
can inhibit its bactericidal activity. Our study has effectively shown that the inhibition of 
daptomycin involves an alteration of lung surfactant on top of daptomycin’s ability to bind to 
the surfactant. Additional studies will need to be performed to focus on the effect of daptomycin 
on lung surfactant. Our study has also shown that constant-area insertion assays are highly 
reproducible and can be used as a good basis to compare the insertion of a peptide or molecule 
between different monolayer models.  
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CHAPTER 7 
7 AFM & KPFM IMAGING STUDIES: DAPTOMYCIN 
AND CALCIUM INDUCE LUNG SURFACTANT 
MULTILAYER FORMATION 
 
 
7.1 Introduction 
Daptomycin, commonly known as Cubicin® (Cubist Pharmaceuticals, a subsidiary of Merck & 
Co.), is a novel lipopeptide antibiotic that is rapidly bactericidal against major Gram-positive 
pathogens [7, 35, 49, 55, 58, 61, 69, 72, 96]. This antimicrobial peptide has a distinct proposed 
mechanism of action: it disrupts the membrane potential of a bacterial plasma membrane, 
ultimately leading to cell death [61, 81, 83, 84]. This mechanism of action has not been fully 
elucidated, and even more intriguing is its complete inhibition by lung surfactant in the case of 
pneumococcal-based pneumonia, such as community-acquired pneumonia [10]. One would 
think that, since Streptococcus pneumoniae is a Gram-positive bacterium (and one that is becoming 
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more resistant to conventional antibiotics), daptomycin would be a good antibiotic to combat 
this pathogen. However, this is not the case, since even though daptomycin is highly bactericidal 
against S. pneumoniae by itself, it is inhibited by lung surfactant [10, 82].  
Due to this inhibition of daptomycin by lung surfactant, additional derivatives and alternatives 
to daptomycin have been created to try and overcome this complication [171, 173]. Cubist 
Pharmaceuticals themselves created a semisynthetic derivative called CB-182,462, which was 
found to be very potent against Gram-positive pathogens, even in the presence of lung 
surfactant, but unfortunately was found to be toxic due to the potential development of 
phospholipidosis within the kidneys (J. Silverman, personal communication). Accordingly, it is 
important that daptomycin’s inhibition by lung surfactant be studied in an attempt to clarify its 
mode of action in the presence of lung surfactant. 
Our previous studies in Chapters 5 and 6 have shown that daptomycin inserts strongly into 
lung surfactant at physiological calcium concentrations and decreases its compressibility, 
suggesting an increase in the surfactant’s ability to reduce surface tension or form multilayers at 
lower surface pressures than the norm. The Langmuir-Blodgett compression isotherm and 
insertion assay studies performed in Chapter 6 allowed us to discover that daptomycin affected 
the properties of lung surfactant. The LB trough can also be used to prepare supported lipid 
monolayers on solid substrates for subsequent imaging. In this study, atomic force microscopy 
was used to try and visualize the effect of daptomycin on model monolayers. It is our hypothesis 
that at a physiologically relevant surface pressure, lung surfactant should exhibit greater 
multilayer formation in the presence of daptomycin and calcium than a control. 
Atomic force microscopy has been frequently used to study lipid monolayers of both simple and 
complex lipid mixtures [376, 380-388]. During AFM imaging of mixed lipid monolayers and 
bilayers, one can observe topographical features called domains [389, 390]. Domains are 
topographical features of a monolayer that arise because of the different composition of lipids 
within a mixture [391-394]. Each lipid mixture has its own ratio of different lipids, and their 
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properties (such as size, phase, polarity, etc.) will affect how they are organized when forming a 
solid monolayer [389]. Meanwhile, pores can help determine the depth of each monolayer or 
bilayer if they are present. Phase imaging is usually performed simultaneously with atomic force 
microscopy imaging and provides a powerful tool for mapping material differences within a 
sample’s surface and associating those with surface structures [395-399].  
Kelvin probe force microscopy (KPFM), a subset of atomic force microscopy, has also been 
used to study the electrostatic and physicochemical properties of lipid monolayers [250, 380, 
400]. Similar to phase imaging, KPFM can be performed simultaneously with AFM, which allows 
for the correlation of electrical surface potential with topographical surface structures [380, 401-
404]. We hypothesize that, should there be any changes to the monolayer due to daptomycin or 
CB-182,462, a noticeable change in local electrostatic potential should be observed, especially in 
the case with lung surfactant and possible multilayer formation. Although AFM, phase, and 
KPFM imaging can all be done simultaneously to help correlate structural features with material 
differences and electrostatic potential, one core disadvantage to KPFM is that it does not work 
in aqueous solutions. As a result, all of the simultaneous AFM, phase and KPFM images were 
obtained in air using conductive monolayer samples. 
Since KPFM imaging cannot be performed in biologically relevant conditions (in aqueous 
solutions), AFM liquid imaging was also performed with lipid bilayers to further mimic a 
physiologically suitable environment. These supported bilayer samples were created using vesicle 
fusion on top of a mica substrate and hydrated with an aqueous buffer solution during imaging.  
The images obtained in this study present compelling support for our new theory of daptomycin 
inhibition by lung surfactant. Not only do the synthetic and natural lung surfactant monolayer 
show increased multilayer formation upon the addition of calcium and daptomycin, but their 
corresponding membranes also show increased multi-bilayer formation. This strongly suggests 
that daptomycin helps confer surfactant-spreading properties to lung surfactant in the presence 
of calcium, causing it to be fully sequestered and rendered inactive by the surfactant. 
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7.2 Materials and Methods 
7.2.1 Lipid Models 
Mixed lipid monolayers and bilayers were prepared for this study using four different lipid 
membrane model systems: bacterial membrane (BM) lipid model, human endothelial membrane 
(HM) lipid model, synthetic lung surfactant (LS) lipid model, and extracted lipid BLES® model. 
The BM lipid model consisted of 20% phosphatidylglycerol, 20% cardiolipin, and 60% 
phosphatidylethanolamine; the HM model with 20% phosphatidylcholine, 20% 
phosphatidylethanolamine, 10% phosphatidylserine, 15% sphingomyelin, and 35% cholesterol; 
the LS model had 80% phosphatidylcholine and 20% phosphatidylglycerol with 5% cholesterol 
by mass; and the BLES® model consisted of modified natural bovine lipid extract surfactant that 
had gone through further lipid extraction protocols. More details regarding each of these lipid 
model systems can be found in Chapter 3.  
 
7.2.2 Solution Preparation 
Cholesterol was purchased from Sigma-Aldrich (St. Louis, Missouri, US), and the following 
lipids were purchased from Avanti Polar Lipids (Alabaster, Alabama, US) in powder form: 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-
glycerol)] (DOPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1,2-
dioleoyl-sn-glycero-3-[phospho-ʟ-serine] (DOPS), 1,1’2,2’-tetraoleoyl cardiolipin (TOCL), and 
sphingomyelin (egg, chicken). 
The procedures for preparing supported lipid monolayer and bilayer substrates are quite 
different. However, stock solutions of 1 mM daptomycin, 1 mM CB-182,462, and 100 mM CaCl2 
as well as a HEPES buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) were prepared for use in 
both experiments. Appendix A has detailed procedures on stock solution preparation. 
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For monolayer experiments (imaging in air), 1 mM mixed lipid stock solutions were made for 
each of the models being studied, as explained in Appendix C1. For membrane experiments 
(imaging in liquid), 5 mM liposome solutions were prepared with an extruder (see Appendix 
E1) and further diluted to a concentration of 1 mM using HEPES buffer. Prior to imaging in 
liquid, the liposome solutions were sonicated to reagitate the solution. 
 
7.2.3 Monolayer Sample Preparation for Air Imaging 
The Langmuir-Blodgett trough is widely used to prepare solid supported lipid monolayers on 
solid substrates. Here, mixed lipid monolayers for each model system (with or without calcium 
and with or without daptomycin or CB-182,462) were deposited onto freshly cleaved mica 
substrates to be imaged in air. A Langmuir-Blodgett micro-trough was used from NIMA 
Technology (Coventry, England).  
To deposit a lipid monolayer onto a mica substrate, the freshly cleaved piece of mica was 
submerged into the LB trough well prior to monolayer formation. Once the monolayer was 
compressed to a targeted pressure of 20 mN/m at a speed of 20 cm2/min, the pressure was held 
constant while the mica was very slowly withdrawn from the well. A pressure of 20 mN/m was 
chosen because surface pressures between ~15 to ~30 mN/m create conditions in monolayers 
that are similar to those within a lipid membrane [394, 405]. As the mica is withdrawn, the lipid 
monolayer deposits itself onto both sides of the mica, with the hydrophilic heads facing the 
hydrophilic surface of the mica substrate and the hydrophobic tails exposed to the air. See 
Appendix C5 for full details and procedures regarding the LB monolayer deposition technique. 
Once the lipid monolayer was deposited onto the mica substrate, it was left to air-dry for about 
30 minutes prior to being placed in a desiccator for at least 48 hours. Afterwards, the sample had 
to be processed for KPFM imaging as mica by itself is an insulator and non-conductive. As a 
result, modifications had to be made to the mica substrate to give it conductive properties. This 
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involved attaching a conductive substrate (aluminum foil) to the bottom of the mica using 
double-sided conductive tape. The excess aluminum foil around the edge of the mica was then 
folded over and secured in each corner with an additional sliver of conductive tape (holding it 
in place to the mica surface). A detailed explanation of this procedure is available in Appendix 
D1.  
 
7.2.4 Supported Bilayer Sample Preparation for Liquid Imaging 
As indicated in Chapter 7.2.2, 1 mM liposomes were prepared for use in preparing supported 
bilayer samples. Mica was chosen to be the solid substrate, as it is chemically inert and 
hydrophilic. Since the JPK NanoWizard® II AFM from JPK Instruments AG (Berlin, Germany) 
has a liquid cell, this apparatus was used to prepare the supported bilayers using vesicle fusion. 
In our vesicle fusion procedures, a vesicle or liposome solution is added to a freshly cleaved 
piece of mica substrate (placed inside the liquid cell) and incubated for 15 minutes to allow the 
vesicles to adhere to the mica. During this time, the vesicles will eventually reach a threshold 
concentration that ruptures the vesicles, allowing them to fuse and form a supported bilayer on 
top of the mica substrate. After 15 minutes, calcium and either daptomycin or CB-182,462 can 
be added, to be incubated for another 3 minutes. After this allotted amount of time, the sample 
is gently rinsed 10 to 15 times with small aliquots of HEPES buffer; each time, approximately 
100 µL of the original solution is removed by a pipette and 100 µL of HEPES buffer is added 
to the substrate with another pipette. This effectively removes excess free and unbound vesicles 
from the solution to prevent vesicle deposits on top of the supported bilayer. The sample is then 
ready to be imaged and is stable for approximately 48 hours under constant hydration with 
HEPES buffer. Detailed protocols for vesicle fusion are available in Appendix E2. 
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7.2.5 AFM, Phase and KPFM Imaging in Air 
Atomic force microscopy, phase, and Kelvin probe force microscopy imaging were done in air 
using the SmartSPM™ 1000 fully-automated scanning probe microscope from Advanced 
Integrated Scanning Tools for Nano-Technology or AIST-NT™ (Novato, California, US). A 
MikroMasch® HQ:NSC14 Au coated conductive cantilever tip was used to obtain each of the 
images. These gold-coated cantilevers have a tip radius of ~35 nm, resonance frequency of 160 
kHz, length of 125 µm ± 5 µm, and force constant of 5 N/m.  
Each set of images for AFM, phase and KPFM were obtained simultaneously. Typically, a 
preliminary scan had to be performed first using the SmartSPM™ 1000’s QScan Mode to ensure 
a high-quality AFM and phase image could be obtained. Next, the SmartSPM™ 1000 was set to 
Kelvin mode to perform two-pass amplitude-modulation (AM) KPFM imaging, where a tip is 
scanned across a surface in the first pass to get a topographical and phase image and in the 
second pass to obtain an image of the surface’s contact potential difference. A detailed overview 
of using the AIST-NT™ SmartSPM™ 1000 is available in Appendix D2. 
For each model system and their respective scenarios, at least three samples were made from 
fresh stock solution. For each scenario (a particular monolayer with or without daptomycin or 
CB-182,462 in the absence or presence of calcium), at least 10 images (mixture of 2 µm by 2 µm 
and 5 µm by 5 µm images) were obtained in total amongst the multiple samples made. Image 
analysis and processing was performed on each of the images using either Gwyddion image 
processing (non-proprietary and free online software, Version 2.47) or AIST-NT™ IAPro image 
analysis and processing (proprietary software, Version 3.3.4). These images were first processed 
using a plane correction to eliminate any unwanted tilt in the image. When necessary, the z-range 
(scale) was adjusted on an image and filtered accordingly to improve the quality of the image. 
Surface roughness analysis was done using the IAPro statistical analysis features while cross-
sectional statistical analyses were performed manually by taking at least 100 measurements of 
cross-sections for different observed structural features within a sample to find the average 
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height of these features as well as their distribution. Statistical significance of reported values 
were tested with one-way ANOVA with Tukey’s post hoc test to compare means. 
 
7.2.6 AFM Imaging in Liquid 
AFM imaging of supported lipid bilayers was done in liquid using the JPK NanoWizard® II from 
JPK Instruments AG (Berlin, Germany). For liquid imaging, non-conductive silicon nitride 
probes from Bruker AFM Probes Americas (Camarillo, California, US) were used: DNP-S10 
sharpened, high-resolution triangular probes with a tip radius of >10 nm, resonance frequency 
of 56 kHz, spring constant of 0.24 N/m, and length of 205 µm. 
Proper care must be employed when setting up the liquid cell for imaging. After the liquid cell 
was placed in position and the NanoWizard® II apparatus and associated software for AFM 
imaging were set up, the liquid cell was left to equilibrate for approximately 15 to 20 minutes. 
Images were then taken using intermittent contact mode in liquid. A detailed overview of using 
the JPK NanoWizard® II is available in Appendix E3. 
Each model membrane system was tested by itself or with a combination of calcium and either 
daptomycin or CB-182,462. For each scenario, at least three supported bilayer samples were 
prepared, and at least 5 images in total were obtained for each of those samples. Image analysis, 
processing and statistical analysis were performed using the JPK image processing software 
(proprietary software from JPK Instruments AG) and SPIP™ Version 6.6.4 from Image 
Metrology (Hørsholm, Denmark). Each image was plane-corrected and leveled using a 
polynomial fit, with adjustment of z-range and filters to improve image quality whenever 
necessary. Large artefacts were removed and surface roughness analysis was performed using 
the SPIP™ software on every image. Cross-sectional analyses of different surface features were 
taken on representative images to obtain approximate height differences of these features.  
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7.3 Results & Discussion 
In order to study the effect of daptomycin and CB-182,462 on different membrane systems, 
numerous samples had to be prepared and imaged. For each of the four model membrane 
systems, 6 monolayer samples (each sample representing one scenario) for air imaging were made 
in triplicate: the model monolayer by itself, the monolayer with only calcium or daptomycin or 
CB-182,462, and the monolayer with both calcium and either daptomycin or CB-182,462. Since 
each of these model membrane systems consisted of at least three different lipids (with the LS 
and BM models made up of 3 different lipids, the HM model made up of 5 different lipids, and 
the BLES® model being the most complex), the structure and arrangement of these lipids within 
a monolayer can be quite complex, and may very well involve the formation of more than one 
 
Figure 7.1 Simplified overview of monolayer domains in a model lipid system. This figure 
represents a theoretical model of domain separation in a three-component model lipid system 
that is not to scale. These lipids have been attached to a hydrophilic, solid substrate (such as 
mica), and due to their different levels of saturation, the acyl tail length of each type of lipid 
differs slightly. Depending on how the lipids interact with each other and how they are arranged 
in the monolayer, there will be different regions (domains) of these lipids which can be detected 
using various types of imaging methods. Atomic force microscopy allows for topographical 
imaging of the monolayer, and height differences (Δh) can be detected between these different 
domains (notice the first domain below lower in height than the second domain, and the third 
domain being lower in height than both the first and second types of domains). Phase imaging 
can also provide information on the phase shift between two different domains (Δφ), which 
allows us to map material differences in the monolayer. Kelvin probe force microscopy allows 
for the mapping of electrical surface potential, where different domains may have different 
changes in electrical surface potential (ΔV). 
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type of domain within the monolayer. Figure 7.1 shows a general overview of how these 
different domains can be distinguished from each other using cross-sectional analysis of AFM, 
phase, and KPFM images, which can provide us with quantitative values of domain height 
differences (Δh), phase lag differences (Δφ), and electrical surface potential differences (ΔV) 
respectively.  
 
 
Figure 7.2 Effect of cholesterol and temperature on lipid membrane phase. Normally, a 
bilayer can exist in two main phases: a gel phase at lower temperatures and a fluid phase at higher 
temperatures. The transition from a gel phase to a fluid phase increases the fluidity of the 
membrane significantly. However, when cholesterol is introduced to the lipid bilayer system, an 
intermediate state is created between the gel phase and fluid phase, called the liquid-ordered 
phase. This phase occurs because cholesterol is able to alter the conformation of lipid acyl chains 
while increasing the fluidity of the bilayer. 
 
The formation of domains is strongly tied to the properties of the individual lipid molecules 
within a lipid mixture, specifically their phase [406]. A lipid’s phase is highly dependent on the 
length of the lipid’s acyl chain (increased chain lengths correspond to increased transition 
temperatures), its degree of saturation (increased presence of double- and triple-bonds in the 
acyl chain corresponds to a decreased degree of saturation and therefore a decreased transition 
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temperature), its headgroup size, and the presence of other lipids [184, 185, 407, 408]. In general 
(Figure 7.2), a bilayer can exist in two phases: a gel-phase (Lβ) at lower temperatures and a fluid-
phase (Lα) at higher, physiologically relevant temperatures [394, 407, 409, 410]. However, in the 
presence of a sterol (mainly cholesterol), an intermediate state between the gel- and fluid-phases 
can form, called the liquid-ordered phase (Lo) [394, 411-413]. This occurs because cholesterol is 
able to induce conformational changes in the acyl chains of neighbouring lipids without reducing 
the fluidity of the bilayer [388, 407, 414-419]. Understanding the properties of each lipid will 
help provide insight into the results obtained in this study. 
 
7.3.1 Daptomycin Enhances Lung Surfactant Multilayer Formation on Monolayer 
Samples 
AFM, phase, and KPFM images were taken of each lipid model in six different scenarios: by 
itself, with only calcium, with only DAP, with only 462, with both Ca2+ and DAP, and with both 
Ca2+ and 462. A collection of all topographical images can be found in Appendix F, while only 
relevant AFM, phase, and KPFM images and their respective cross-sections are presented here. 
The bacterial membrane model system was studied first, which consisted of 20% DOPG, 20% 
TOCL, and 60% POPE. Each of the monolayer samples was imaged using AFM, phase, and 
KPFM imaging techniques. Figure 7.3 shows representative images for the BM monolayer 
control as well as in combination with both calcium and daptomycin or CB-182,462. A 
qualitative analysis of each of these images shows that there are multiple types of domains visible, 
some that are more prominent or taller than others, and some that seem to be larger than what 
one would assume would be a domain. In the BM monolayer control (Figure 7.3A-7.3C), there 
are two types of visible, elliptically-shaped domains with an average surface roughness Ra = 0.32 
± 0.03 nm and approximate dimensions of 70 × 60 nm. The lower domains have Δh = 1.17 ± 
0.20 nm, Δφ = 10.23 ± 2.06° and ΔV = 21.36 ± 2.43 mV, while the higher domains have Δh = 
1.76 ± 0.30 nm, Δφ = 9.24 ± 0.29° and ΔV = 30.23 ± 2.11 mV. These different domains 
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correspond to lipid molecules in different phases, and it is suspected that the lower domains 
correspond to DOPG molecules, while the higher domains correspond to TOCL molecules. 
The POPE molecule has a polar head group with a cationic amine residue and an anionic 
phosphate residue, making POPE zwitterionic (see Figure 3.3). These POPE molecules can 
therefore form hydrogen bonds with each other, forming a compact and rigid head-group 
network at the air-water interface [420, 421]. Meanwhile, DOPG molecules interact with each 
other using an extensive network of hydrogen bonds, ionic bonds and co-ordination bonds, 
suggesting a more ordered phase that is thicker than the POPE molecules [422, 423]. Cardiolipin 
is a fairly compact molecule that has a double-glycerophospholipid structure that is connected 
to a glycerol residue [424]. Its small polar head group allows for a tight packing of acyl chains 
between the TOCL molecules, but most likely cannot interact with the tight network or DOPG 
molecules, which would effectively cause patches of TOCL molecules to form [393]. As a result, 
it seems that the BM model monolayer has DOPG domains that contain localized domains of 
TOCL.  
When daptomycin or CB-182,462 are added with calcium, a third type of “domain” is observed, 
which is higher than the two domains seen in the control. In the BM + Ca2+ + Daptomycin 
monolayers (see Figure 7.3D-7.3F), the surface roughness is now higher at 0.44 ± 0.05 nm, 
which can be explained by the presence of additional types of domains. The lower domains have  
Figure 7.3 AFM, phase and KPFM images of BM monolayer samples. Every row of images  
and their associated cross-sections are representative images of one particular BM monolayer 
sample. Images A-C represent the topography, phase, and electrical surface potential of a 20% 
DOPG, 20% TOCL, and 60% POPE monolayer sample, respectively. Images D-F represent 
the BM monolayer in the presence of 2 mM Ca2+ and 4 µM daptomycin, while images G-I 
represent the BM monolayer in the presence of 2 mM Ca2+ and 4 µM CB-182,462. By comparing 
the AFM images for each sample, it can be seen that additional, higher domains are visible in the 
monolayer samples with either DAP or 462, and these domains can be differentiated from each 
other by looking at the phase images as well. The KPFM images show that higher domains are 
associated with larger differences in electrical surface potential. All corresponding sets of AFM, 
phase and KPFM images (in other words, images in each row) were taken simultaneously and 
scanned in air under ambient conditions. The images presented here are all 1 µm by 1 µm.  
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averages of Δh = 1.10 ± 0.31 nm, Δφ = 2.93 ± 0.50° and ΔV = 44.07 ± 0.44 mV, the mid-sized 
domains have averages of Δh = 2.31 ± 0.20 nm, Δφ = 8.55 ± 1.93° and ΔV = 58.65 ± 0.49 
mV, and the higher “domains” have averages of Δh = 4.87 ± 0.58 nm, Δφ = 8.91 ± 0.47° and 
ΔV = 62.36 ± 0.47 mV. It is hypothesized that the lower domains of these monolayers are 
POPE molecules that have bound to either calcium or daptomycin, thus changing its fluidity 
and forming patches within the monolayer. The mid-sized domains, which we suspect to be 
DOPG or TOCL, are now much larger (occurring in patches with dimensions of about 500 × 
600 nm) and remain at approximately the same height difference (slightly higher than the control 
monolayer’s lower domains), but the electrostatic surface potential difference has changed 
drastically, increasing by approximately 28 mV. These increased values are likely caused by the 
binding of calcium and daptomycin to the DOPG lipid molecules, which has been known to 
occur [68]. They can also be correlated with patches of TOCL that are assumed to be expelled 
from DOPG patches since they cannot interact with their tight network [393]. The higher 
“domains” in this daptomycin monolayer are 4.87 ± 0.20 nm, which is highly unusual for a 
typical domain. As a result, we suspect that these higher “domains” are actually regions of lipids 
that have been bound to daptomycin and are raised up due to daptomycin’s cyclic head (see 
Figure 7.4). We believe that this orientation of daptomycin in the lipid monolayer occurs 
because during sample preparation, the monolayer is created at an air-water interface, where the 
polar heads are facing the water subphase. When daptomycin is injected into this water subphase, 
insertion of the tail into the monolayer (representative of one side of the bilayer leaflet) would 
occur in such an orientation. The deposition of these daptomycin-bound monolayers onto mica 
means that the hydrophilic heads of the lipid monolayer will face the hydrophilic surface of the 
mica substrate. These results imply that daptomycin, in the presence of calcium, induces 
significant changes in the bacterial membrane monolayer, which are characterized by increased 
height profiles of lipid domains as well as enhanced electrical surface potential. 
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Figure 7.4 Schematic of proposed arrangement of lipids and surface features on bacterial 
lipid monolayer with calcium and daptomycin. The AFM, phase and KPFM images of the 
BM monolayer + 2 mM calcium + 4 µM daptomycin samples showed three different surface 
features assumed to be different regions of lipid domains. It is possible that the lower and mid-
sized domains are regions of lipids which are more saturated, while the higher domains are 
regions of lipids that are raised up due to daptomycin bound to its head groups.  
 
When calcium and CB-182,462 are added to the BM monolayer, similar effects comparable to 
its daptomycin counterpart are observed. The surface roughness is greater for the CB-182,462 
BM monolayers with calcium, with a value of 0.53 ± 0.02 nm, and this is primarily due to the 
presence of larger mid-sized domains (most likely DOPG) that are highly irregular in shape and 
reach sizes of up to 700 × 1300 nm. Higher domains, similar in height to those observed with 
calcium and daptomycin, are also seen sporadically throughout the monolayer, suggesting that 
these regions have CB-182,462 bound to them (similar to how daptomycin binds to the 
monolayer in Figure 7.4). The average values for Ra, Δh, Δφ, and ΔV are summarized for each 
sample in Table 7.1.  
Next, the human membrane model system was studied (which was composed of 20% DPPC, 
20% POPE, 10% DOPS, 15% sphingomyelin, and 35% cholesterol). In the HM monolayer 
control sample, the surface roughness is 0.35 ± 0.03 and only one type of domain can be 
observed with an average height profile of 1.48 ± 0.21 nm, phase difference of 8.13 ± 1.89°, and 
ΔV of 50.55 ± 2.09 mV. It is highly likely that these domains consist of cholesterol, 
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sphingomyelin, and DPPC, effectively forming lipid rafts (see Figure 3.1) that are elevated 
compared to the rest of the monolayer composed of unsaturated and kinked phospholipids. In 
these domains, cholesterol can insert itself in between phospholipids within the raft, filling up 
any void molecular space between the associated lipids and therefore forces them into a tighter 
alignment [425]. As can be seen in Figure 7.5A-7.5C, the HM monolayer control sample has 
domains that are more irregularly-shaped and larger than the lower domains seen in the BM 
monolayer samples.  
When calcium and daptomycin are added into the HM monolayer (see Figure 7.5D-7.5F), the 
sample is slightly smoother with Ra = 0.24 ± 0.04 nm, and the domains are larger, while the 
average height and phase differences are comparable to the control. Although the average 
difference in electrical surface potential increases by about 17 mV, this value is seen across other 
controls (with just calcium, daptomycin or CB-182,462; see Appendix F), which means that the 
addition of daptomycin and calcium have caused the surface charge to fluctuate and increase.  
However, when we look at the HM monolayer with calcium and CB-182,462, radical changes 
are observed, starting with the height profile and shape of the domains (see Figure 7.5G-7.5I). 
No longer do we see large, smooth domains, but rather multiple circular patches of smaller 
domains with different height profiles. As a result, the surface roughness has increased to 0.46 
± 0.05 nm. The lower domains (about 40 nm in diameter) have an average Δh = 1.14 ± 0.37 
nm, average Δφ = 3.13 ± 0.52° and average ΔV = 16.31 ± 0.35 mV, the mid-sized domains 
(about 60 nm in diameter) have an average Δh = 1.37 ± 0.64 nm, average Δφ = 8.49 ± 0.64° 
and average ΔV = 36.47 ± 2.98 mV, while the largest domains (about 120 nm in diameter) have 
an average Δh = 4.11 ± 2.03 nm, average Δφ = 16.55 ± 2.0° and average ΔV = 107.49 ± 4.06 
mV. The reduction of overall domain size and the significant increase in ΔV of these larger, 
circular domains (at least 50 mV above the control samples’ domains) tells us that CB-182,462 
not only disrupts the formation of lipid domains, but also interacts with them to form thicker 
structures. These thicker structures may very well be caused by the binding of CB-182,462 to 
the lipids and subsequent insertion into them, thus raising the height of these regions to see the 
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higher domains through AFM imaging. Since CB-182,462 is presumed to be toxic to human 
membranes and may cause phospholipidosis within the kidneys, it is evident here that CB-
182,462 does affect the structural organization, aggregation and/or clustering of these lipids 
within a human membrane model system, which may play a role in its toxic mode of action. 
More studies will need to be performed to elucidate this mechanism of action. 
With regards to lung surfactant, both the synthetic lung surfactant lipid model system and the 
natural BLES® surfactant model system were examined. The LS model system was made up of 
80% DPPC and 20% DOPG with 5% cholesterol by mass. In the LS monolayer control sample, 
the surface roughness was 0.97 ± 0.04 nm with large, irregularly-shaped domains spanning the 
surface with average differences of Δh = 1.87 ± 0.21 nm, Δφ = 57.03 ± 1.91 ° and ΔV = 30.30 
± 2.06 mV. These domains also seem slightly porous in nature, as this characteristic is visible in 
all three images (Figure 7.6A-7.6C). Previous studies using a similar LS model system have 
shown similar features and heights in their domains, but compressed at much higher pressures 
of 45-50 mN/m, where multilayer formation is seen as well [250, 258]. Since the samples used 
in this study were compressed to a final pressure of 20 mN/m, multilayers for control samples 
should not form. Similar to the HM model, it is suspected that these domains primarily consist 
 
Figure 7.5 AFM, phase and KPFM images of HM monolayer samples. Representative  
topographical, phase, and electrical surface potential images for each human membrane model 
monolayer sample are presented in each row, along with their associated cross-sections. Images 
A-C represent the AFM, phase, and AM-KPFM images of a 20% DPPC, 20% POPE, 10% 
DOPS, 15% sphingomyelin and 35% cholesterol monolayer sample, respectively. Images D-F 
are representative images of the HM monolayer in the presence of 2 mM calcium and 4 µM 
daptomycin, and G-I are images of the HM monolayer with 2 mM calcium and 4 µM CB-
182,462. When looking at the AFM images for each sample, we can see that the surface 
topography drastically changes in the case of CB-182,462, where not only the domain size and 
shape of the monolayer are disrupted, but also the height profile and the emergence of different 
types of spherical domains which look like clusters of lipids. The phase and KPFM images show 
greater phase shifts and larger surface potential readings for higher domains. All corresponding 
sets of 1 µm by 1 µm AFM, phase and KPFM images were simultaneously scanned in air under 
ambient conditions.  
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of unsaturated DPPC and cholesterol. 
Upon the addition of calcium and daptomycin (see Figure 7.6D-7.6F), not only does the shape 
of the domains change significantly, but also their height profiles. Although the domains are still 
spread across the surface of the sample, they are much more porous and randomly arranged. 
Most intriguing is the average height difference of Δh = 7.30 ± 1.94 nm and average electrical 
surface potential difference of ΔV = 96.53 ± 2.09 mV, suggesting daptomycin (in the presence 
of calcium) strongly binds to and inserts into the LS monolayer and promotes multilayer 
formation, a phenomenon that is only seen at higher surface pressures for lung surfactant alone 
[263]. Since the height difference of these so-called domains is 7.30 ± 1.94 nm, it is most 
probable that they contain an additional bilayer of 5 to 6 nm in height that rests on top of the 
lipid monolayer. Figure 7.7 provides a schematic of the possible organization of lung surfactant 
multilayers in the presence of daptomycin and calcium, where bound daptomycin acts as an 
anchor between each monolayer. These data correlate with the findings from Chapters 5 and 6 
of this thesis and the new model presented of daptomycin’s inhibition by lung surfactant (Figure 
8.1) . This new model suggests that strong binding of daptomycin to lung surfactant, in the 
 
Figure 7.6 AFM, phase and KPFM images of synthetic LS monolayer samples. Every row  
of images and their associated cross-sections are representative 1 µm by 1 µm images of a specific 
lung surfactant monolayer sample taken in air under ambient conditions. Images A-C represent 
the atomic force microscope, phase, and Kelvin probe force microscopy images of a 80% DPPC, 
20% DOPG with 5% cholesterol lung surfactant monolayer sample, respectively. Images D-F 
represent the LS monolayer with 2 mM calcium and 4 µM daptomycin, while Images G-I 
represent the LS monolayer with CB-182,462 instead of daptomycin. In the control sample, the 
monolayer domains are about 1.87 ± 0.21 nm, but upon addition of calcium and daptomycin, 
the height of the visible domains increase to about 7.30 ± 1.94 nm. Minor topographical changes 
are observed in the LS monolayer sample with 462 and calcium, but rather a greater presence of 
very larger surface artifacts and debris. Higher topographical domains correspond to larger phase 
shifts and larger differences in contact potential in the phase and KPFM images, respectively.  
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Figure 7.7 Schematic of proposed multilayer formation of lipids in lung surfactant 
monolayer models due to daptomycin and calcium. Very tall and flat surface features above 
7 nm in height were observed for the lung surfactant monolayer models. This schematic shows 
a potential multilayer stack comprised of three layers of lipids, each bound to the next because 
of the presence of calcium-bound daptomycin, which is proposed to insert into lung surfactant 
and help connect these layers together. Such an arrangement will help explain the height 
differences observed in the AFM topographical images, suggesting an additional bilayer of lipids 
rests on top of the original lung surfactant monolayer.  
 
presence of calcium, not only allows it to be sequestered, but also exhibit surfactant-spreading 
properties that allow the lung surfactant to achieve multilayer formation at lower pressures than 
normal.  
When CB-182,462 is added to the LS monolayer with calcium, the results are fairly consistent 
with the control samples with just the monolayer or with only calcium, daptomycin or CB-
182,462. As can be seen in Figure 7.6G-7.6I and Table 7.1, the LS + Ca2+ + CB-182,462 
samples are smoother with Ra = 0.20 ± 0.03 (comparable to the controls with just daptomycin 
and CB-182,462), and the average ΔV is a bit higher at 52.31 ± 4.13 mV while the height profile 
does not change much. This suggests that CB-182,462 does not bind to or change the properties 
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of the LS monolayer, implying that the minor fluctuations seen are a result of the addition of 
charged calcium ions and CB-182,462 molecules into the monolayer.  
Contrary to the LS model, the BLES® model system’s exact composition is not known, but can 
be considered more complex than the LS model system due to the possible presence of multiple 
other neutral and charged lipids in lower concentrations. As a result, it is expected that 
differences are seen between the LS and BLES® monolayers. For the BLES® monolayer control 
samples (Figure 7.8A-7.8C), the average values for the domains are Δh = 1.26 ± 0.21 nm, Δφ 
= 6.91 ± 2.05 ° and ΔV = 36.63 ± 2.04 mV, with the surface quite smooth at Ra = 0.20 ± 0.02 
nm and the general size of the domains larger than those in the LS monolayer. Similar to the LS 
control, these domains are most likely regions of unsaturated phospholipids (such as DPPC) 
with cholesterol. The presence of larger, spherical structures with height profiles greater than 5-
10 nm were observed in most of the images with the BLES® monolayer. We suspect that these 
non-lipid components from the natural BLES® surfactant that were unsuccessfully filtered out 
during our sample preparation, such as proteins.  
When daptomycin and calcium are added to the BLES® monolayers, the results are quite 
comparable to those of the LS monolayers in this scenario. In general, the observed domains, 
which are actually multilayers, are much larger in lateral size than those observed in the LS 
monolayers, but the height profiles are very similar with the average Δh = 7.51 ± 2.02 nm, 
indicating the presence of an additional bilayer on top of the original monolayer (see Figure 
 
Figure 7.8 AFM, phase and KPFM images of BLES® monolayer samples. Each row 
contains representative images of a specific sample’s surface topography, phase shift, and 
electrical surface potential and their associated cross-sections. Images A-C represent the AFM, 
phase and KPFM images of a BLES® bovine natural lung surfactant monolayer, respectively. 
Images D-F represent the BLES® monolayer in the presence of 2 mM Ca2+ and 4 µM 
daptomycin, while images G-I represent the monolayer with 4 µM CB-182,462 instead. Similar 
to the LS images, the domains seen in the BLES® control are quite flat, but in the presence of 
calcium and daptomycin, larger and higher domains emerge. The images presented are all 1 µm 
by 1 µm in size, with images taken under ambient conditions and scanned in air. 
147 
 
 
 
148 
 
7.8D-7.8F). The average difference in electrical surface potential is ΔV = 84.42 ± 2.07 mV, 
which means that daptomycin and calcium together have a measurable effect on lung surfactant’s 
electrostatic non-homogeneity. These results are in alignment with the new model presented for 
daptomycin inhibition as well, presented in Chapters 5 and 6.  
In the presence of calcium and CB-182,462, the BLES® monolayers have a surface roughness of 
0.30 ± 0.04 nm and the domains experience more phase separation amidst being smaller in lateral 
size (see Figure 7.8G-7.8I). In this scenario, although the KPFM image shows us that the 
electrical surface potential has an average value of ΔV = 51.02 ± 5.10 mV (which is similar to 
the controls), the AFM and phase images show us that the size and shape of the domains has 
changed significantly from the controls. What this means is that even though CB-182,462 does 
not impart any electrostatic effects onto natural lung surfactant, it may very well still effect the 
distribution and ordering of the lipids within the surfactant.  
From these AFM, phase, and KPFM images, it is possible to visualize the effects of daptomycin 
and CB-182,462 on different model systems in the presence of calcium. Our results show that 
daptomycin’s effect is dependent on the presence of calcium, and that together, they promote 
the formation of multilayers within lung surfactant. From the images, it seems plausible that 
three-layer multilayer stacks are formed when daptomycin and calcium incorporate themselves 
 
Table 7.1 Table of values for roughness, differences in height, phase shift, and electrical 
surface potential for AFM, phase, and KPFM images for each monolayer sample. Each 
model is separated by a different colour scheme (blue for bacterial membrane, green for human 
membrane, red for synthetic lung surfactant, and black for BLES®). For each model, 6 different 
scenarios were tested: the monolayer by itself, the monolayer with just 2 mM calcium, the 
monolayer with 4 µM daptomycin, the monolayer with 4 µM CB-182,462, the monolayer with 
both calcium and daptomycin, and the monolayer with both calcium and CB-182,462. For each 
scenario, at least 3 monolayer samples were prepared, and from those samples, at least 10 images 
were obtained in total. From these AFM, phase, and KPFM images, at least 100 height, phase 
shift, and electrical surface potential measurements were taken for each type of domain 
observed, respectively. These measurements were then averaged and presented here in this table. 
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Model & Scenario Ra (nm) Δh (nm) Δφ (deg) ΔV (mV) 
Bacterial Membrane (BM) Model 
    BM Control 0.32 ± 0.03    
        Lower Domains 1.17 ± 0.20 10.23 ± 2.06 21.36 ± 2.43 
        Higher Domains 1.76 ± 0.30 9.24 ± 0.29 30.23 ± 2.11 
    BM + Ca2+ 0.25 ± 0.03    
        Lower Domains 1.08 ± 0.21 5.04 ± 0.58 22.15 ± 1.36 
        Higher Domains 5.17 ± 1.52 8.74 ± 1.94 36.04 ± 2.02 
    BM + Daptomycin 0.33 ± 0.04    
        Lower Domains 1.35 ± 0.20 8.21 ± 0.58 22.12 ± 1.53 
        Higher Domains 2.82 ± 0.53 9.31 ± 2.01 37.35 ± 1.96 
    BM + CB-182,462 0.31 ± 0.05    
        Lower Domains 1.25 ± 0.22 5.53 ± 0.72 35.84 ± 2.05 
        Higher Domains 2.57 ± 0.35 9.21 ± 2.19 39.76 ± 0.68 
    BM + Ca2+ + Daptomycin 0.44 ± 0.05    
        Lower Domains 1.10 ± 0.31 2.93 ± 0.50 44.07 ± 0.44 
        Mid-sized Domains 2.31 ± 0.20 8.55 ± 1.93 58.65 ± 0.49 
        Higher Domains 4.87 ± 0.58 8.91 ± 0.47 62.36 ± 0.47 
    BM + Ca2+ + CB-182,462 0.53 ± 0.02    
        Lower Domains 1.80 ± 0.47 3.17 ± 0.54 48.77 ± 0.65 
        Mid-sized Domains 2.79 ± 0.23 9.13 ± 1.97 59.78 ± 0.66 
        Higher Domains 4.63 ± 0.43 12.76 ± 0.64 59.57 ± 0.73 
Human Membrane (HM) Model 
    HM Control 0.35 ± 0.03 1.48 ± 0.21 8.13 ± 1.89 50.55 ± 2.09 
    HM + Ca2+ 0.30 ± 0.04 1.41 ± 0.21 11.16 ± 1.97 47.41 ± 1.90 
    HM + Daptomycin 0.32 ± 0.04 1.48 ± 0.20 6.08 ± 1.98 47.15 ± 3.96 
    HM + CB-182,462 0.27 ± 0.03 1.46 ± 0.20 9.82 ± 2.04 67.26 ± 2.07 
    HM + Ca2+ + Daptomycin 0.24 ± 0.04 1.51 ± 0.21 7.12 ± 1.95 67.06 ± 4.99 
    HM + Ca2+ + CB-182,462 0.46 ± 0.05    
        Lower Domains 1.14 ± 0.37 3.13 ± 0.52 16.31 ± 0.35 
        Mid-sized Domains 1.37 ± 0.64 8.49 ± 0.64 36.47 ± 2.98 
        Higher Domains 4.11 ± 2.03 16.55 ± 2.02 107.49 ± 4.06 
Lung Surfactant (LS) Model 
    LS Control 0.97 ± 0.04 1.87 ± 0.21 57.03 ± 1.91 30.30 ± 2.06 
    LS + Ca2+ 0.95 ± 0.04 1.77 ± 0.20 44.16 ± 2.09 31.96 ± 4.08 
    LS + Daptomycin 0.35 ± 0.04 1.66 ± 0.19 25.41 ± 2.02 40.83 ± 1.99 
    LS + CB-182,462 0.27 ± 0.05 1.78 ± 0.19 30.40 ± 2.02 49.43 ± 2.98 
    LS + Ca2+ + Daptomycin 1.50 ± 0.04 7.30 ± 1.94 51.50 ± 2.98 96.53 ± 2.09 
    LS + Ca2+ + CB-182,462 0.20 ± 0.03 1.67 ± 0.20 8.21 ± 1.99 52.31 ± 4.13 
Bovine Lipid Extract Surfactant (BLES®) Model 
    BLES Control 0.20 ± 0.02 1.26 ± 0.21 6.91 ± 2.05 36.63 ± 2.04 
    BLES + Ca2+ 0.25 ± 0.02 1.34 ± 0.20 11.84 ± 2.99 40.55 ± 3.06 
    BLES + Daptomycin 0.37 ± 0.04 1.81 ± 0.20 21.01 ± 1.88 46.05 ± 1.92 
    BLES + CB-182,462 0.48 ± 0.03 2.22 ± 0.19 28.84 ± 2.08 49.25 ± 3.94 
    BLES + Ca2+ + Daptomycin 1.52 ± 0.02 7.51 ± 2.02 64. 93 ± 2.05 84.42 ± 2.07 
    BLES + Ca2+ + CB-182,462 0.30 ± 0.04 1.45 ± 0.20 8.74 ± 2.04 51.02 ± 5.10 
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into the lung surfactant monolayer at a pressure of 20 mN/m. The data shows that the total 
height difference of these stacks atop the monolayer was at least 7 nm in height, which is greater 
than the typical thickness of a bilayer, about 5 to 6 nm [426-428]. However, when preparing 
multilayers at an air-water interface (like we did using the LB trough), multilayers must have an 
odd number of layers as the polar heads must face the water and the tails must face the air. 
Therefore, it is more plausible that a daptomycin-bound area with a height of 7 nm is one bilayer 
with daptomycin in between each monolayer. This corresponds to our theory that daptomycin 
is sequestered by lung surfactant due to an intense attraction to the lipids within the model and 
subsequent folding of monolayers on top of each other, reinforcing this sequestration. 
These images also provide us with additional evidence to support the toxic mechanism of action 
of CB-182,462 with human tissue cells and erythrocytes. Our previous studies have shown that 
CB-182,462 strongly binds and inserts into the human membrane model system. This study 
shows that CB-182,462 not only interacts with the lipids, but completely changes the 
organization of lipid domains, and may very well cause clumping of lipids in regions where there 
is a high concentration of CB-182,462.  
 
 
7.3.2 Daptomycin Causes Multi-Bilayer Formation on LS/BLES Model Bilayers 
Since the monolayer experiments showed that daptomycin had a profound effect on the lipid 
organization and orientation in lung surfactant, the next step was to see whether these effects 
could be seen using membranes instead of monolayers. Due to daptomycin’s proven interaction 
with lung surfactant, it is believed that it will also interact with the lipids in a lung surfactant 
bilayer to form additional bilayers. Since daptomycin is also known to insert into and depolarize 
bacterial membranes, we assume that topographical differences can be observed as well. 
In order to image membrane samples, vesicles were first made for each of the four lipid model 
systems we are studying: bacterial membrane, human membrane, lung surfactant and BLES®. 
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Once these vesicles were formed, supported bilayer samples were prepared on mica using vesicle 
fusion and subsequently imaged in liquid using atomic force microscopy. By imaging within a 
liquid environment, it is possible to measure the surface roughness of the membrane, the height 
profile of various features, as well as visualize any topographical differences that either 
daptomycin or CB-182,462 may impart on the membrane. Figures 7.9 – 7.12 present 
representative AFM images of each of the model membranes by itself or with calcium and 
daptomycin/CB-182,462. Corresponding surface roughness measurements are summarized in 
Table 7.2.  
In the bacterial membrane control (Figure 7.9A), the surface roughness of the membrane is 
0.36 ± 0.03 nm, which is fairly smooth considering there are not a lot of surface features. The 
image represents full surface coverage of the membrane on mica, and there are some circular 
deposits that can be associated with unruptured vesicles, which has been shown to occur with 
AFM imaging in liquid [429, 430]. Sometimes these vesicles do not rupture and are adsorbed or 
trapped atop the membrane [426]. In the BM control, each of these small vesicles are 
approximately 10-20 nm in height, with a lateral diameter of 150-200 nm. Since the vesicle 
solutions were stored in the fridge and sonicated prior to vesicle fusion, it is highly likely that 
these vesicles (of various shapes and sizes ranging from approximately 50-150 nm) 
spontaneously fuse to form larger vesicles due to the high degree of curvature within the 
membranes [431]. When calcium and daptomycin are added to the sample, the surface roughness 
increases drastically to 3.36 ± 0.83 nm, suggesting the presence of more surface structures and 
aggregates. If we look at Figure 7.9B, we can see that apart from the large spherical deposits 
ranging from diameters of 100-300 nm, there is an elevated domain with an average height 
profile of 8.08 ± 0.83 nm. Within these elevated domains are additional elevated areas that are 
slightly larger than the size and height profiles of the large spherical deposits. This suggests that 
the elevated domains are an additional bilayer patch that has formed on top of the original 
supported bilayer. Since daptomycin has been previously shown to bind and insert into our  
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Figure 7.9 Liquid AFM images of BM model membrane. Bacterial membrane model 
vesicles, made of 20% DOPG, 20% TOCL, and 60% POPE, were deposited onto mica 
substrates and imaged using an atomic force microscope in an aqueous environment. Image A 
represents the bacterial membrane control, which is fairly smooth and void of any large defects. 
Image B and C represent the BM membrane with 2 mM of Ca2+ and 4 µM of daptomycin or 
CB-182,462, respectively. Both of these membranes have large domains and spherical artefacts 
(most likely unruptured vesicles) that span the surface of the membrane. All images are 5 µm by 
5 µm.  
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bacterial membrane model, it can be construed that these bilayer patches are highly concentrated 
in membrane-bound daptomycin, extending the bilayer height above normal values. This 
daptomycin-rich area further attracts additional vesicles, where they rupture and fuse to form an 
additional bilayer on top. A similar effect can be seen with the BM + Ca2+ + CB-182,462 AFM 
image (Figure 7.9C), where an additional patch of bilayer with an average height profile of 6.20 
± 0.72 nm can be seen amongst the flatter part of the membrane. The surface roughness here is 
2.42 ± 0.15 nm, which is somewhat smoother than the daptomycin sample, but still prevalent 
with a wide range of topographical features.  
In the human membrane control, the surface roughness is 0.44 ± 0.02 nm. Similar to the bacterial 
membrane model, the control membrane (see Figure 7.10A) is fairly smooth with the exception 
of spherical deposits that range in height from 10 to 100 nm with diameters of approximately 
120 nm. These are indicative of unruptured vesicles that are trapped or adsorbed to the surface, 
respectively. When daptomycin and calcium are added to the HM sample, the surface roughness 
has now increased to 3.53 ± 0.17 nm due to the presence of additional unruptured vesicles 
(Figure 7.10B). The reason for this increase in unruptured vesicles is unknown, but we postulate 
that it may be due to slight variations in vesicle incubation times and speed of washing the 
solutions during sample preparation. However, when the HM sample is combined with calcium 
and CB-182,462, bilayer patches appear with an average height profile of 9.81 ± 0.78 nm (see 
Figure 7.10C). The surface roughness is now 6.60 ± 0.14 nm, which is significantly higher than 
both the control and that of the daptomycin sample. This increase in surface roughness is 
partially due to the presence of unruptured vesicles and bilayer patches, but also additional 
rounded areas of elevation within each bilayer patch that reach heights of up to 40 nm. It may 
be that these bilayer patches form on top of large, unruptured vesicles to achieve this curved 
effect. Since CB-182,462 is known to insert into and bind strongly to our human membrane 
model, it makes sense that membrane-bound CB-182,462 may attract additional vesicles to a 
certain area, which cause them to rupture and form an additional bilayer above the original HM 
model membrane.  
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Figure 7.10 Liquid AFM images of HM model membranes. Human endothelial membrane 
model vesicles, made of 20% DPPC, 20% POPE, 10% DOPS, 15% sphingomyelin and 35% 
cholesterol, were deposited onto mica substrates using vesicle fusion. Atomic force microscopy 
was used to obtain 5 µm by 5 µm images under a liquid environment. Image A represents the 
HM control, which is smooth and void of larger surface artefacts. Both Image A and B represent 
the HM membrane in the presence of 2 mM Ca2+ and either DAP or 462. However, while both 
contain spherical surface artefacts (presumed to be unruptured vesicles), the 462 sample contains 
additional large, surface-spanning domains on top of the primary membrane 
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The lung surfactant membrane by itself was shown to have a surface roughness of 1.25 ± 0.02 
nm, which is higher than the other control samples for BM and HM. This is due to the fact that 
there are additional bilayer patches approximately 5-6 nm high located sporadically across the 
membrane, and within those patches are additional bilayer patches approximately 5-6 nm in 
height (see Figure 7.11A). We believe that because lung surfactant forms multilayers when highly 
compressed, the process of vesicle fusion ensures that a high pressure is reached in order for the 
vesicles to rupture, essentially forming multi-bilayers due to lung surfactant’s low compressibility 
properties. However, when calcium and daptomycin are added to lung surfactant, these effects 
are significantly enhanced (Figure 7.11B). The surface roughness is now 6.07 ± 0.03 nm because 
of the formation of extensive, irregular multi-bilayers that cover most of the membrane surface. 
If we look closely at this sample, there are indistinct layers visible behind the more prominent 
ones. These lower domains are multilayer patches that are already about 9 nm in height. On top 
of these patches are additional bilayer patches of approximately 5-6 nm in height. In other areas 
where there are unruptured 50-150 nm diameter vesicles, the total height can reach up to 70 nm. 
These results are in agreement with our findings from our monolayer experiments. It is believed 
that calcium and daptomycin bind to lung surfactant, and due to its strong attraction (and 
therefore sequestration by lung surfactant), additional LS vesicles are attracted to areas heavily 
bound to daptomycin, allowing these vesicles to rupture and form additional bilayers on top of 
preformed ones. In addition, since lung surfactant is thought to reduce the compressibility of 
lung surfactant, it facilitates the formation of multilayers at lower pressures. In summary, 
daptomycin and calcium together allow for lung surfactant vesicles to form additional bilayers 
on top of the original lung surfactant bilayer, and because of the reduced compressibility, a more 
extensive network of these additional bilayers can be seen across the sample surface. If we look 
at Figure 7.11C, the addition of calcium and CB-182,462 does not affect the structure of the 
bilayer much and is quite similar to the corresponding control. The surface roughness is 2.69 ± 
0.09 nm, and there are slightly larger, more uniform bilayer patches of about 5 nm in height 
along with a large number of unruptured vesicles. 
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Figure 7.11 Liquid AFM images of synthetic LS membranes. 5 µm  by 5 µm AFM images 
were taken of lung surfactant model vesicles in liquid. Image A represents the LS membrane, 
made of 80% DPPC and 20% DOPG with 5% cholesterol. For the most part, the membrane 
surface is very smooth, with some additional smaller patches of membranes (possibly from the 
rupture of vesicles that were not fused with the primary membrane). However, when 2 mM 
calcium and 4 µM daptomycin are added to the vesicle solution, the resulting membrane has 
multiple layers of membranes on top of the primary membrane. This is not the case with the 
462 sample (Image C), which only has large, spherical surface artefacts representative of 
unruptured vesicles.  
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Figure 7.12 Liquid AFM images of BLES® membranes. BLES® vesicles were prepared and 
deposited onto mica substrates using vesicle fusion. These samples were then imaged in liquid 
using atomic force microscopy to obtain multiple 5 µm by 5 µm images. Image A represents the 
BLES® membrane control, which contains larger domains on top of the primary membrane 
compared to its synthetic LS counterpart. Image B represents the membrane with calcium and 
DAP, and similar to its LS counterpart, has many more, smaller domains stacked on top of each 
other, suggesting multi-bilayer formation. Image C represents the membrane with calcium and 
462, and although it has some patches of monolayers and bilayers on the surface, it is primarily 
riddled with presumably unruptured vesicles.  
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Table 7.2 Average surface roughness of different membrane models and scenarios. The 
average surface roughness, Ra is presented for every model and its associated three scenarios: the 
membrane by itself, the membrane with 2 mM calcium and 4 µM daptomycin, and the membrane 
with both calcium and CB-182,462. Each average value was obtained from no less than 5 liquid 
AFM images.  
Model & Scenario Ra (nm) 
Bacterial Membrane (BM) Model 
    BM Control 0.32 ± 0.03 
    BM + Ca2+ + Daptomycin 0.44 ± 0.05 
    BM + Ca2+ + CB-182,462 0.53 ± 0.02 
Human Membrane (HM) Model 
    HM Control 0.35 ± 0.03 
    HM + Ca2+ + Daptomycin 0.24 ± 0.04 
    HM + Ca2+ + CB-182,462 0.46 ± 0.05 
Lung Surfactant (LS) Model 
    LS Control 0.97 ± 0.04 
    LS + Ca2+ + Daptomycin 1.50 ± 0.04 
    LS + Ca2+ + CB-182,462 0.20 ± 0.03 
Bovine Lipid Extract Surfactant (BLES®) Model 
    BLES Control 0.20 ± 0.02 
    BLES + Ca2+ + Daptomycin 1.52 ± 0.02 
    BLES + Ca2+ + CB-182,462 0.30 ± 0.04 
 
Since the LS model is a synthetic one, comparing it with a natural surfactant model will give us 
further insight and physiological relevance to our findings. A quick glance at the BLES® 
membrane samples shows us that the results are very similar to those observed in the LS 
membrane samples. In the BLES® control membrane, the surface roughness is 3.56 ± 0.30 nm, 
which is rougher than the LS control, but explainable due to the large bilayer patches visible in 
the sample. These bilayer patches are approximately 8 nm in height (see Figure 7.12A). Since 
BLES® is supposed to have some remaining hydrophobic surfactant proteins, it is highly possible 
that it spreads more easily than its synthetic counterpart. In the presence of calcium and 
daptomycin, multi-bilayers are once again observed with a surface roughness of 6.00 ± 0.26 nm 
(see Figure 7.12B), this time with bilayer patches reaching 40-60 nm in height in different areas 
of the sample. This supports our hypothesis that daptomycin helps confer additional surfactant 
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spreading properties, and that the inclusion of daptomycin allows lung surfactant (BLES®) to 
continuously form multilayers and spread more easily across the surface of the membrane, 
effectively sequestering daptomycin in layers of lung surfactant. Meanwhile, no significant 
differences are observed when calcium and CB-182,462 are added as the surface roughness is 
4.27 ± 0.33 nm, which is very similar to the control sample, only that there are more unruptured 
vesicles present (Figure 7.12C).  
Overall, these AFM images of our membrane models have allowed us to substantiate our 
findings from the monolayer experiments. In the presence of calcium and daptomycin, lung 
surfactant is hypothesized to achieve lower compressibility upon binding of these molecules, 
thus allowing it to more easily form multilayers and effectively sequester daptomycin and render 
it inactive. 
 
7.4 Summary & Conclusion 
Our study has shown that daptomycin physically affects the lung surfactant monolayer or 
membrane by allowing for multilayer formation of either monolayers or bilayers, respectively. 
KPFM studies also showed enhanced electrostatic domains associated with additional multilayer 
formation on lung surfactant monolayers. This correlates with our previous findings in Chapters 
5 and 6 and our new proposed model of daptomycin inhibition by lung surfactant, where 
daptomycin is not only attracted to and inserts strongly into lung surfactant, but also reduces its 
compressibility and makes it easier for it to form multilayers, effectively reinforcing its 
sequestration. This study also marks the first atomic force microscopy and Kelvin probe force 
microscopy study of daptomycin and its effect on model monolayers and membranes.   
Although it was not possible to resolve the oligomerization or insertion of daptomycin on 
monolayer or membrane surfaces, it was possible to visualize the effect of daptomycin on these 
surfaces using atomic force microscopy. The fact that daptomycin has such a significant effect 
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on lung surfactant suggests that further studies should be done on their interaction with each 
other. It would be good to compare the effect of daptomycin on lung surfactant held at different 
pressures and then relate those results to a lung surfactant control at various pressures. This 
would allow us to determine the degree of surface activity enhancement that daptomycin confers 
to lung surfactant.  
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CHAPTER 8 
8 CONCLUSIONS & FUTURE RESEARCH 
 
 
8.1 Summary & Conclusion 
The general objective of this thesis was to provide additional insight into daptomycin’s inhibition 
by pulmonary surfactant as well as its molecular mechanism of action. Although daptomycin is 
a potent antibiotic against serious Gram-positive infections, even those that are highly resistant 
against most antibiotics, it is inhibited when combatting Gram-positive pathogens within the 
lungs. Specifically, it cannot be used to treat infections caused by Streptococcus pneumoniae, the 
primary cause of community-acquired pneumonia.  
At the beginning of this thesis in Chapter 2, we outlined the specific objectives of our work in 
elucidating daptomycin’s inhibition by pulmonary surfactant. The studies that have been done 
before have used generic or simplified model membrane systems to examine daptomycin’s 
mechanism of action. In order to gain insight into daptomycin’s inhibition by pulmonary 
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surfactant in the case of community-acquired pneumonia, we wanted to closely mimic the 
different types of membranes that daptomycin would encounter. These lipid model systems 
include those of S. pneumoniae, erythrocytes or tissue cells, as well as synthetic and natural lung 
surfactant. We successfully developed these lipid models in Chapter 3, and have used these 
models throughout each of the experiments in this thesis. 
Once these models had been developed, we wanted to see whether daptomycin would strongly 
bind to lung surfactant. There is evidence that shows daptomycin is capable of inserting into 
lung surfactant, which has brought forth a widely accepted theory that the vast abundance of 
surfactant within the lungs can sequester the antibiotic. However, there have been no binding 
studies done which compare the degree of binding or insertion of daptomycin to different model 
systems. In Chapter 5, we performed fluorescence spectroscopy experiments to test the binding 
and insertion of daptomycin into all four model membrane systems. It was discovered that 
daptomycin inserted more strongly into lung surfactant liposomes than the bacterial membrane 
liposomes at lower, physiologically-relevant concentrations of calcium (2 mM). Even more 
intriguing was the opposite effect that was observed when the calcium concentration was 
increased to 10 mM. At higher concentrations of calcium, it was shown that daptomycin 
interacted more with the bacterial membrane than it did with lung surfactant. During this study, 
we developed novel protocols to create modified BLES® (bovine lipid extract surfactant) 
liposomes, or large unilamellar vesicles of approximately 100 nm in diameter, which has not 
been successfully accomplished before. The results we obtained for the synthetic lung surfactant 
liposomes and the BLES® liposomes correlated very nicely together, validating our BLES® 
protocols as well as showing that the synthetic model is a good and simplified representation of 
the real thing. 
With the insertion of daptomycin into lung surfactant proven to be very strong, the next step 
was to quantify the changes that daptomycin’s insertion incurs on lung surfactant as well as other 
model systems. In Chapter 6, we performed Langmuir-Blodgett monolayer experiments to help 
collect data on whether daptomycin can change the properties of each monolayer model in the 
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presence of calcium.  The compression isotherms obtained showed that daptomycin significantly 
increased the elastic area compressibility modulus of lung surfactant, which translates into 
reduced compressibility. This means that with daptomycin and calcium, lung surfactant is less 
compressible and more prone to the formation of multilayers at lower surface pressures and 
smaller changes in surface area. Subsequently, Langmuir monolayer insertion assays were 
performed to directly compare the insertion of daptomycin into each of the different lipid model 
monolayers in the presence of calcium. The results showed that daptomycin inserts into lung 
surfactant more than it does any other lipid model, verifying our results from Chapter 5. In this 
study, we presented a new model of daptomycin inhibition by lung surfactant, where daptomycin 
binds more strongly to lung surfactant than bacterial membrane (encouraging its sequestration), 
and lowers the compressibility of lung surfactant, possibly allowing it to confer surfactant-
spreading properties similar to those of other hydrophobic surfactant proteins. 
The next set of questions we posed involved being able to visualize the changes that daptomycin 
may cause on both model monolayer systems as well as model membrane systems. In Chapter 
7, we performed scanning probe microscopy studies to obtain atomic force microscopy, phase, 
and Kelvin probe force microscopy images in air for each monolayer model in different 
scenarios. From these images, it was clear that daptomycin (in the presence of calcium) promotes 
the formation of multilayers in lung surfactant. The images showed that daptomycin and calcium 
changed the shape and arrangement of the lipid domains significantly, with increased height 
profiles reminiscent of bilayers on top of monolayers (and therefore termed ‘multilayers’) 
associated with larger differences in electrical surface potential. Afterwards, supported bilayers 
on mica substrates were prepared for AFM imaging in liquid. The AFM images showed multi-
bilayer formation in the lung surfactant bilayer samples in the presence of calcium and 
daptomycin, substantiating the results obtained from the monolayer samples.  
Throughout all of these experiments, a semisynthetic antibiotic derivative called CB-182,462 was 
tested along with daptomycin. CB-182,462 was under development to help overcome 
daptomycin’s inhibition by lung surfactant, and it was shown to be unhindered by lung surfactant 
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Figure 8.1 New proposed model of daptomycin interaction with lung surfactant. It was previously thought that daptomycin was 
sequestered by lung surfactant through binding interactions. From the experiments in this thesis, we have shown this binding to be 
true, and additional experiments have allowed us to propose a more detailed model of daptomycin inhibition by lung surfactant. Step 
1: In the presence of calcium, daptomycin (of unknown specific quantity) is attracted to the lung surfactant monolayer and therefore 
binds to it quite strongly. Step 2: Once inserted into the monolayer, daptomycin confers surfactant-spreading properties, similar to the 
function of surfactant-spreading proteins SP-B and SP-C, and reduces the compressibility of the lung surfactant. Step 3: Due to this 
reduction in compressibility, the lung surfactant can more easily form multilayers at lower pressures than before, folding in on itself 
multiple times. Step 4: With each fold of the monolayer, daptomycin becomes more “trapped” within the depths of the lung surfactant 
multilayer, effectively sequestering it and reinforcing its inhibition and inability to free itself. 
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during cell viability studies. However, due to possible toxicity, its development was permanently 
ceased. The experiments performed through Chapter 5 to Chapter 7 have provided additional 
insight into CB-182,462’s mechanism of action as well, suggesting its toxicity is due to its strong 
binding and insertion to the human membrane model as well as its ability to severely alter the 
physical structure and organization of lipid domains.  
From the results obtained throughout this thesis, we were able to present a new model of 
daptomycin inhibition by lung surfactant (Figure 8.1) that is more robust than its predecessor. 
This new model suggests that (1) daptomycin requires the presence of calcium to strongly insert 
into lung surfactant, (2) daptomycin confers surfactant-spreading properties by decreasing the 
compressibility of lung surfactant, (3) this reduction in compressibility allows lung surfactant to 
fold in on itself at lower pressures to form multilayers, and (4) daptomycin is further sequestered 
within these multilayers and effectively inhibited.  
This thesis successfully provides additional insight into daptomycin’s inhibition by lung 
surfactant. The lipid model systems, experimental protocols, and hypotheses presented in this 
thesis can also be beneficial to future studies not limited to daptomycin, but other molecules and 
systems as well.  
 
8.2 Future Research 
Microorganisms are constantly evolving and growing more resistant to typical antibiotic 
regimens. As a result, it is in our interest to continue studying effective antibiotics that can help 
us gain some ground in the arms race against these resistant strains of bacteria. One such 
antibiotic is daptomycin, which is highly effective against severely resistant Gram-positive 
pathogens such as MRSA and VRE. Since Streptococcus pneumoniae is a bacteria that is quickly 
growing in resistance, it is even more imperative that we elucidate daptomycin’s inhibition by 
lung surfactant. 
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The findings presented in this thesis provide intriguing results that can be expanded upon with 
further studies. Competitive binding assays can be used to test daptomycin’s preference in 
binding between lung surfactant lipid models and bacterial membrane models. Since daptomycin 
binds less to lung surfactant at higher calcium concentrations, it may be a good option to test 
daptomycin’s bactericidal activity against S. pneumoniae at these higher levels of calcium ions. 
With the emergence of advanced nanotechnology tools, studies regarding daptomycin delivery 
to the diseased lung and targeted binding to S. pneumoniae or generic lipoteichoic acids may prove 
to be very useful as well. 
Apart from elucidating daptomycin’s inhibition by lung surfactant, the results obtained in this 
thesis present a different question, one that is somewhat reversed: how does daptomycin affect lung 
surfactant? The focus of this thesis has been placed on why daptomycin is inhibited by lung 
surfactant, but the results have shown that daptomycin may confer surfactant-spreading 
properties for lung surfactant. There may be possible merits to studying whether daptomycin 
could have beneficial properties and be able to play a different role in respiratory physiology.  
The models and methods developed in this thesis can also be applied to many other studies. 
Lung surfactant, erythrocytes or tissue cells, and bacterial membranes are common systems that 
need to be studied, and the models presented here can be used in many other ways outside the 
scope of this thesis, for other diseases, antibiotics, bacteria, or peptide interaction studies. The 
protocols and experimental procedures developed through our work will also be very useful for 
future studies and applications in the field of membrane biophysics.  
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APPENDICES 
 
APPENDIX A: PREPARATION OF SOLUTIONS 
 
 
A.1 Buffer Solutions 
A buffer solution is an aqueous solution that helps to maintain a consistent pH upon minute 
additions of acid or base. To make a buffer solution, one must combine a weak acid or weak 
base with a salt containing its conjugate base or acid, respectively. 
In the work presented in this thesis, the buffer solutions that were used were made from HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), a buffering agent that is commonly used 
to maintain physiological pH levels. Specifically, the HEPES buffer solution contained 20 mM 
HEPES and 150 mM NaCl at a pH of 7.4.  
206 
 
Procedures are given below to make 500 mL of a HEPES buffer, with HEPES and NaCl having 
molar masses of 238.3 g/mol and 58.44 g/mol respectively. Sample calculations are provided 
here to determine the amount of HEPES and NaCl to add to the solution. 
Calculations: 
Given:  Mhepes = 238.3 g/mol     MNaCl = 58.44 g/mol      V = 500 mL = 0.50 L 
   Chepes = 20 mM       CNaCl = 150 mM 
Equations: n = m/M     and     C = n/V      so      m = CMV 
Find mhepes: mhepes = (0.02 mol/L)(238.3 g/mol)(0.50 L) = 2.383 g = 2383 mg 
Find mNaCl: mNaCl = (0.15 mol/L)(58.44 g/mol)(0.50 L) = 4.384 g = 4384 mg 
Procedure: 
1. Make sure you clean a large beaker (greater than 500 mL), graduated cylinder (at least 
500 mL), and bottle (at least 500 mL).  
2. Add the following into the large beaker: 
a. 500 mL nanopure water with a graduated cylinder 
b. 2383 mg HEPES, weighed with weighing dish on analytical scale 
c. 4384 mg NaCl, weighed with weighing dish on scale 
3. Mix the contents of the beaker using a magnetic stirrer on a stir plate. 
4. Calibrate the pH meter and record the pH level.  
a. If the pH is lower than 7.4, prepare a basic NaOH solution. Add this solution 
drop by drop into the buffer until a pH of 7.4 is reached. 
b. If the pH is higher than 7.4, prepare an acidic HCl solution. Add this solution 
drop by drop into the buffer until a pH of 7.4 is reached. 
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5. Once a pH level of 7.4 has been reached, get a large, plastic and sterile syringe as well as 
a 25 mm diameter syringe filter (made with polypropylene with a pore size of 0.2 μm) 
for the syringe tip.  
6. Transfer the buffer solution from the beaker to a clean bottle using the syringe and 
syringe filter. Here are some helpful tips: 
a. Every time you load up the syringe, the filter must be removed. Once the 
solution has been drawn up into the syringe, place the filter back on and push 
the solution past the filter and into the bottle. 
b. Do not push too hard when filtering the solution to prevent tearing of the filter 
membrane. 
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7. When done, label and store the buffer solution in the refrigerator at about 4°C. 
 
A.2 Calcium Stock Solutions 
The experiments in this thesis involved the use of calcium, which is required as part of 
daptomycin’s and CB-182-462’s mechanisms of action. 
A 100 mM calcium stock solution was prepared using calcium chloride dihydrate (CaCl2 • 2H2O, 
Mcalcium = 147.01 g/mol) for use in each experiment. Procedures and sample calculations are 
provided below for the preparation of 100 mL of 100 mM calcium stock solution. 
Calculations: 
Given:  Mcalcium = 147.01 g/mol        Ccalcium = 100 mM V = 100 mL = 0.10 L 
Equations: n = m/M     and     C = n/V      so      m = CMV 
Find mcalcium: mcalcium = (0.10 mol/L)(147.01 g/mol)(0.10 L) = 1.4701 g = 1470.10 mg 
Procedure: 
1. Add the following items into a beaker: 
a. 100 mL of HEPES buffer 
b. 1470.10 mg of calcium chloride dihydrate 
2. Mix well using a magnetic stirrer on a stir plate. 
3. Label and store the calcium stock solution in the refrigerator at 4°C until use. 
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A.3 Daptomycin and CB-182,462 Stock Solutions 
Stocks solutions of daptomycin and CB-182,462 were required for the experiments in this thesis. 
Both stock solutions contained 1 mM of the respective antimicrobial peptide. 
Calculations and procedures are provided below to make the 1 mM daptomycin stock solution, 
with daptomycin having a molar mass of 1620.67 g/mol. 
Daptomycin Stock Calculations: 
Given:  Mdap = 1620.67 g/mol        Cdap = 1 mM V = 10 mL = 0.01 L 
Equations: n = m/M     and     C = n/V      so      m = CMV 
Find mdap: mdap = (0.001 mol/L)(1620.67 g/mol)(0.01 L) = 16.21 mg 
Daptomycin Stock Procedure: 
1. Add the following items into a beaker: 
a. 10 mL of HEPES buffer 
b. 16.21 mg of daptomycin 
2. Mix well using a magnetic stirrer on a stir plate 
3. Divide into 5 aliquots of 2 mL each to prevent repeated freeze-thaw cycles. 
4. Label and store the daptomycin stock solution in the freezer at -20°C until use. 
Calculations and procedures are provided below to make the 1 mM CB-182,462 stock solution, 
with CB-182,462 having a molar mass of 1687.82 g/mol. 
CB-182,462 Stock Calculations: 
Given:  M462 = 1687.82 g/mol        C462 = 1 mM V = 10 mL = 0.01 L 
Equations: n = m/M     and     C = n/V      so      m = CMV 
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Find m462: m462 = (0.001 mol/L)(1687.82 g/mol)(0.01 L) = 16.88 mg 
CB-182,462 Stock Procedure: 
1. Add the following items into a beaker: 
a. 10 mL of HEPES buffer 
b. 16.88 mg of CB-182,462 
2. Mix well using a magnetic stirrer on a stir plate 
3. Divide into 5 aliquots of 2 mL each to prevent repeated freeze-thaw cycles. 
4. Label and store the CB-182,462 stock solution in the freezer at -20°C until use. 
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APPENDIX B: FLUORESCENCE SPECTROSCOPY 
 
 
B.1 Preparing Vesicle Solutions with an Extruder 
For fluorescence spectroscopy experiments, unilamellar vesicles or liposomes were prepared 
using an extruder. The preparation of these vesicles involved multiple steps, including (1) 
measuring out the lipids for a specific membrane model and dissolving them in volatile solutions, 
(2) drying the solutions until a thin film forms, (3) rehydrating and resuspending the vesicles in 
a buffer solution, and (4) passing this solution through an extruder. Sample calculations and 
detailed procedures are provided below to make 3 mL of a 5 mM liposome solution with an 
extruder. 
 
B.1.1 Measuring Out the Lipids for a Specific Membrane Model 
There were four lipid systems used in this thesis: bacterial membrane model, human membrane 
model, lung surfactant model, and BLES®. The steps to preparing lipid models are identical, 
while BLES® required a different set of procedures to make the initial solution prior to drying. 
 
B.1.1.1 Preparing the Lipid Mixture with Lipid Models: BM, HM, LS 
Each lipid model contains a different ratio of lipids. The bacterial membrane model will be used 
for subsequent examples and sample calculations. The composition of the bacterial membrane 
model is a 20:20:60 molar ratio of DOPG:TOCL:POPE. Sample calculations and procedures 
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are provided below to create 3 mL of 5 mM BM liposomes starting with lipid stock in powder 
form. 
Calculations: 
Given: MCL = 1501.98 g/mol        MPE = 718.01 g/mol        MPG = 797.04 g/mol        
 PCL = 0.2     PPE = 0.6    PPG = 0.2    CBM = 5 mM    V = 3 mL = 0.003 L 
Find ntotal: ntotal = (CBM)(V) = (0.005 mol/L)(0.003 L) = 1.5 x 10-5 mol 
Find mCL: mCL = (PCL)(MCL)(ntotal) = (0.2)(1501.98 g/mol)(1.5 x 10-5 mol) = 4.51 mg 
Find mPE: mPE = (PPE)(MPE)(ntotal) = (0.6)(718.01 g/mol)(1.5 x 10-5 mol) = 6.46 mg 
Find mPG: mPG = (PPG)(MPG)(ntotal) = (0.2)(797.04 g/mol)(1.5 x 10-5 mol) = 2.39 mg 
Procedure: 
1. Thoroughly clean a round bottom flask by using an organic solvent to clean it (eg. 
methanol) and end with chloroform to help dissolve any remaining lipids from previous 
experiments. 
2. Add the calculated amount of lipid powder for TOCL, POPE, and DOPG into the clean 
round bottom flask with the help of an analytical scale and some weighing paper. 
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3. Add chloroform to the round bottom flask using a glass pipette. This helps to dissolve 
the lipids due to its weak polarity.  
a. Try to deposit the solvent at the mouth of the flask to catch any remaining lipid 
powder (from when you weighed it and added it into the flask). 
b. Add a sufficient amount of chloroform until you can see the lipids dissolving 
and the solution turning clear. 
c. If the lipid solution does not appear clear or has some undissolved specks of 
lipid powder still visible, don’t worry – move onto the next step. 
4. Add a small amount of methanol to the round bottom flask using a separate glass pipette.  
a. Adding a small amount of methanol should help dissolve additional lipids due to 
its increased polarity.  
5. Swirl the round bottom flask until the lipids are fully dissolved. Make sure you keep the 
solution at the bottom half of the flask to make it easier for subsequent steps. 
 
 
B.1.1.2 Preparing the Lipid Mixture with BLES® 
BLES® is bovine lipid extract surfactant and comes in suspensions of 27 mg phospholipids per 
mL. The packaging for BLES® states that their manufacturing process selectively removes 
hydrophilic proteins while keeping hydrophobic phospholipids and surfactant-associated 
proteins SP-B and SP-C. Considering our lung surfactant model contains an 80:20 molar ratio 
of DPPC:DOPG, we will assume the same of these BLES® solutions to simplify our calculations 
and sample preparation. 
The goal is to make an approximate 5 mM BLES® liposome solution to be used in conjunction 
with the other model liposome solutions for experimental purposes.  
Lipid Extraction Procedure: 
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1. Add 2 mL of BLES® to a centrifuge tube. 
2. Add a small amount of 4:1 chloroform:methanol solvent to the centrifuge tube. 
3. Spin for 5 minutes at 2000 RPM.  
4. There should be a separation of phases. Save the bottom phase by transferring it to 
another centrifuge tube. In the original tube, add more chloroform and methanol to the 
supernatant and centrifuge again.  
5. Repeat Steps 3-4 a total of 18 times. With each transfer, transfer into the second tube 
where all the lipids are being stored. 
6. You should now have a centrifuge tube (the second one) with a collection of “bottom 
phases” that you’ve transferred from the original tube. These are the lipids. 
Making the BLES® Solution for Drying: 
Let’s assume that you end up with 3 mL of your extracted BLES® solution and you started out 
with 2 mL of original BLES® stock. Since the original stock had a concentration of 27 mg of 
phospholipids per mL, that means that a total of 54 mg of phospholipids were present in the 
solution. And since our lipid extraction procedure would have kept these lipids, this means that 
we can make an assumption and say that all the lipids, the 54 mg, were transferred to your new 
3 mL of extracted BLES® solution.  
We now have to make another assumption and say that these phospholipids are primarily 
composed of 80% DPPC and 20% DOPG. This means that from the original 54 mg of 
phospholipids, 43.2 mg of DPPC and 10.8 mg of DOPG are present in the extracted BLES® 
solution. Since we know that the molar masses of DPPC and DOPG are 734.05 g/mol and 
797.04 g/mol respectively, we can calculate how many moles of phospholipids are present in 
total and use C = n/V to determine the volume of HEPES buffer required to make an 
approximate 5 mM BLES® solution. This calculated volume will be required in the rehydration 
step in Appendix B.1.3. 
The steps below are to make the BLES® solution prior to drying. 
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1. Thoroughly clean a round bottom flask by using an organic solvent to clean it (eg. 
methanol) and end with chloroform to help dissolve any remaining lipids from previous 
experiments. 
2. Add all of the BLES® solution (no buffer) to the round bottom flask.  
3. Swirl the round bottom flask and make sure the lipids are fully dissolved. Make sure you 
keep the solution at the bottom half of the flask to make it easier for subsequent steps. 
 
B.1.2 Creating a Thin Film and Drying It 
1. Using a narrow tube of nitrogen gas (from a compressed gas cylinder), insert the tube 
into the round bottom flask (without touching the inner walls of the flask or the solution) 
and gently dry/evaporate the mixture while simultaneously spinning the round bottom 
flask. 
a. These combined actions help the dissolved lipid mixture form a thin film around 
the bottom half of the round bottom flask once the entire solution is dry. 
b. Once you see a thin film form and everything is dry, you can stop. 
2. Vacuum-dry the round bottom flask for at least 12 hours to ensure that the round 
bottom flask contents are completely dry. 
3. Seal and store the round bottom flask in freezer (-20°C) until ready for liposome 
resuspension or rehydration. 
 
B.1.3 Rehydration and Liposome Formation 
When a thin lipid film, or cake, was created in the previous step, hydrating this dried layer of 
lipids promotes the formation of lipid vesicles, or liposomes. When water or a buffer is added, 
the dried lipid films will start to detach from one another as they get more and more hydrated, 
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and when agitated, these sheets will fully detach and self-close to form large multilamellar vesicles 
(LMV). 
1. Whether you take the round bottom flask with the lipid thin film from the freezer or 
from the vacuum pump, the round bottom flask needs to be warmed up to at least room 
temperature so that it is above the majority of the lipids’ transition temperatures. 
2. Add 3 mL of HEPES buffer if you are using the BM, LS, or HM lipid models. 
a. If you are rehydrating a BLES® thin film, add the calculated amount of HEPES 
buffer from Appendix B.1.1.1 
3. Swirl the flask around to agitate the mixture and promote vesicle formation. 
4. As liposomes are resuspended, the solution will become cloudy. 
a. Make sure all (or most) of the liposomes are resuspended in the buffer by making 
sure the buffer is cloudy and that the thin film is no longer visible with the naked 
eye. 
b. If it is too difficult to resuspend, use a vortex to agitate the round bottom flask 
(around the remaining thin films) so as to promote its resuspension into the 
buffer. 
 
5. Parafilm the mouth of the round bottom flask and set aside until ready for extrusion. 
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B.1.4 Extruding Liposomes to Reduce their Size 
In the previous step, large multilamellar vesicles (LMV) were formed when the lipid films were 
hydrated. However, for experimental purposes, we want the size of these vesicles to be much 
smaller. To achieve smaller-sized vesicles, we can either sonicate or extrude the vesicles. For 
fluorescence spectroscopy, we wish to have smaller vesicles that are approximately the same size 
to maintain consistency across numerous trials and repeats. As a result, the extrusion technique 
will be used to enhance the consistency of our results.  
There are many models of extruders that can be used. The one used in the experiments presented 
in this thesis is the 10 mL LIPEX™ Thermobarrel Extruder from Northern Lipids (now 
Transferra Nanosciences Inc.). 
 
The procedures presented below relate to this particular model of extruder: 
1. Clean and assemble the extruder according to the manufacturer’s guidelines. 
a. Make sure 100 nm polycarbonate filters are used. 
2. Since the temperature needs to be regulated to at least body temperature, circulate 
water through the thermobarrel jacket. 
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a. To heat the thermobarrel jacket, connect the outlet of a re-circulating water 
bath to the lower hose barb connection on the thermobarrel jacket and the 
inlet of the re-circulating bath to the upper hose barb.  
b. You can use a heated water bath to set the appropriate extrusion temperature 
c. Allow the unit some time (approximately 10-20 minutes) to equilibrate 
3. There will be Tygon tubing coming out of the extruder, for the extruded vesicle 
solution to go. 
a. Make sure this tubing is secured to the mouth of a vial with parafilm. 
b. Also make sure that the parafilm doesn’t cover the entire mouth of the vial as 
you need to extrude the same solution multiple times. 
c. You are now ready to start extruding. 
4. Use a glass pipette to add all of the liposome solution (from the round bottom flask) to 
the extruder top’s hole. 
5. Close the extruder top with the Quick-Connect (QC) sleeve until you hear a “click” 
and close the pressure relief valve (black). 
6. Turn on the pressure control valve (green) carefully and slowly until the solution flows 
out of the extruder into the vial through the Tygon tubing. Turn off the valve when 
done. 
a. Turn off or close the green valve as soon as the solution starts flowing out of 
the extruder to minimize bubbling of the solution in the vial, and possible 
overflow. 
7. Open the black pressure relief valve to release the pressure in the extruder. Close this 
black pressure relief valve when finished (when the “hissing” has stopped). 
8. Remove the QC sleeve. 
9. Transfer the extruded solution from the vial to the extruder top’s hole using a glass 
pipette. 
10. Repeat the extrusion (Steps 5 to 9) at least 15 times until the solution is clear. 
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a. If the solution is not clear, you can centrifuge it to remove residual large 
particles that remain in suspension. 
 
11. Store the vesicle preparation in the refrigerator (4°C) for a maximum of 3-4 days. 
 
B.2 Using the PTI Spectrofluorimeter to take Fluorescence Readings 
The fluorescence spectroscopy experiments required the use of a Photon Technology 
International (PTI) QuantaMaster Spectrofluorometer to take measurements of the samples in 
this work. The following steps detail the configurations and setup for the experiments. 
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1. Start the FeliX32 application on the computer. 
2. Click on “Emission Scan” 
3. Click on “Digital Configuration” and enter the following settings (for daptomycin 
readings specifically): 
a. Excitation 1: 365 nm for Kyn 
b. Emission 1 Emission Range: 400-600 nm 
c. Length: 200 nm 
d. Step Size: 3 nm 
4. Click on “Acquire (Prep)” to prepare for the readings 
a. Make sure the instrument has micrometer settings at 2 mm for each slit, which 
allows for greater intensity 
b. Make sure the instrument is hooked up to a heated water bath at 37°C 
5. Prepare your sample in a 1 mL cuvette and incubate at warm temperature for at least 3 
minutes. 
a. Ensure that the amount of daptomycin, 462, vesicle solution and HEPES buffer 
you add into the 1 mL cuvette adheres to the correct concentrations.  
6. Place your sample (in a 1 mL cuvette) in the holder, and click “Start” 
a. Fluorescence readings will be recorded and can be saved using the software. 
7. Repeat steps 4-5 for each sample you want to take readings of. 
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APPENDIX C: LANGMUIR-BLODGETT TROUGH 
 
 
C.1 Preparing Lipid Solutions 
For the experiments involving the use of the Langmuir-Blodgett trough, lipid stock solutions 
were made for each of the models (BM, LS, HM) as well as for BLES®. The procedure for lipid 
models varies from the procedures for BLES® and both types are presented below. 
 
C.1.1 Preparing Lipid Model Solutions 
Each lipid model contains a different ratio of lipids. Similar to Appendix B.1.1.1, the amount 
of each lipid must be calculated and then weighed out in order to prepare the lipid mixture for 
a particular model. The composition of the bacterial membrane model is a 20:20:60 molar ratio 
of DOPG:TOCL:POPE and the following sample calculations and procedures will be relevant 
to making 10 mL of a 1 mM BM lipid stock. 
Calculations: 
Given: MCL = 1501.98 g/mol        MPE = 718.01 g/mol        MPG = 797.04 g/mol        
 PCL = 0.2    PPE = 0.6   PPG = 0.2  CBM = 1 mM   V = 10 mL = 0.01 L 
Find ntotal: ntotal = (CBM)(V) = (0.001 mol/L)(0.01 L) = 1.0 x 10-5 mol 
Find mCL: mCL = (PCL)(MCL)(ntotal) = (0.2)(1501.98 g/mol)(1.0 x 10-5 mol) = 3.00 mg 
Find mPE: mPE = (PPE)(MPE)(ntotal) = (0.6)(718.01 g/mol)(1.0 x 10-5 mol) = 4.31 mg 
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Find mPG: mPG = (PPG)(MPG)(ntotal) = (0.2)(797.04 g/mol)(1.0 x 10-5 mol) = 1.59 mg 
Procedure: 
1. Take a sterile 20 mL scintillation vial and label it accordingly. 
2. Add the calculated amount of lipid powder for TOCL, POPE, and DOPG into the vial 
with the help of an analytical scale and some weighing paper.  
3. Add 10 mL of a 4:1 chloroform:methanol mixture to the vial 
a. You can add 8 mL of chloroform and 2 mL of methanol if you don’t have a pre-
mixed solution already. 
4. Swirl the vial or use a magnetic stirrer on a stir plate to help agitate and dissolve the lipids 
throughout the solution. 
5. Store the solution in the freezer (-20°C) when not in use. 
 
C.1.2 Preparing BLES® Solutions 
As mentioned in Appendix B.1.1.2, BLES® is bovine lipid extract surfactant and comes in 
suspensions of 27 mg of phospholipids per mL. The first step is to extract the lipids from the 
BLES® stock using the “Lipid Extraction Procedure” presented in Appendix B.1.1.2.  
Our goal is to prepare a 1 mM stock solution of BLES® lipids. After the lipids have been 
extracted from 2 mL of BLES® (equivalent to 54 mg of phospholipids), it is assumed that all the 
phospholipids have been transferred over to the new vial and 54 mg of phospholipids still exists 
within the solution to allow for further calculations. 
Since BLES® is highly comparable to model lung surfactant systems with 80% DPPC and 20% 
DOPG, we must also assume that our BLES® solution contains the same ratio of lipids. From 
the 54 mg, this would mean that 43.2 mg of DPPC and 10.8 mg of DOPG are present in the 
extracted BLES® solution. Since we know that the molar masses of DPPC and DOPG are 734.05 
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g/mol and 797.04 g/mol respectively, we can calculate how many moles of phospholipids are 
present in total and use C = n/V to determine the volume of 4:1 chloroform:methanol mixture 
required to make an approximate 1 mM BLES® solution.  
Once this value has been calculated, add the determined amount of chloroforom:methanol 
solution to the BLES® vial and mix well. Store in the freezer at -20°C until use. 
 
C.2 Cleaning the Langmuir-Blodgett Trough 
Prior to starting any experiments on the Langmuir-Blodgett trough, certain steps need to be 
taken to clean the surface of the trough as well as the barriers to prevent crossover contamination 
between samples. The following steps will allow you to clean the LB trough thoroughly. 
 
1. Wet a Kimwipe (delicate task wipers made of virgin wood fibers) with HPLC methanol. 
a. Ensure that proper ventilation is in place, either by using a fume hood or opening 
windows. 
2. Using the wet Kimwipe, wipe the PTFE (polytetrafluoroethylene) teflon surface of the 
trough. 
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3. Lift each PTFE Teflon barriers. Using the same Kimwipe, either fold or use a different 
area of the wiper and wipe the surface of these barriers as well. 
4. Toss the Kimwipe after you are done. 
5. Repeat the cleaning procedure from Steps 1-4 at least 5 times. 
6. When finished with cleaning, let the LB trough dry for about 5-10 minutes prior to 
continuing on with subsequent steps and experiments.  
 
C.3 Using the LB Trough to take Compression Isotherms 
The Langmuir-Blodgett trough is capable of taking multiple types of measurements. One of 
these measurements is a compression isotherm, where the surface pressure of Langmuir 
monolayers can be measured as the area of the trough decreases. Depending on the composition 
of the monolayers being formed, the pressure-area isotherms allow us to characterize monolayer 
structure, phase transitions, monolayer compressibility, and more.  
The compression isotherm experiments performed in this thesis involved the compression of a 
chosen monolayer toward the point of monolayer collapse on a small Langmuir-Blodgett trough 
from Nima. 
The following procedures outline the setup, operation, and collection of such compression 
isotherms. 
1. Make sure the LB trough is clean using the procedures outlined in Appendix C.2. 
2. Attach a new or recycled Wilhelmy plate to the extension hook of the trough. 
a. The pre-cut paper Wilhelmy plate uses Whatman CHR1 chromatography paper 
that has a width of 10 mm. 
b. These Wilhelmy plates are capable of measuring the surface pressure of LB thin 
films at the air-liquid interface. 
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c. If you choose to recycle the paper Wilhelmy plates, you can submerge them 
overnight in a HPLC chloroform solution, then dry them on a Kimwipe or by 
nitrogen gas prior to use. 
3. Fill the trough with 55 mL of nanopure water using a clean graduated cylinder. 
a. When the trough is filled with water, the Wilhelmy plate will begin to absorb the 
water and equilibrate with the water subphase.  
b. Should an experiment require the addition of calcium into the subphase, add 1.1 mL of 100 
mM calcium stock solution to the 55 mL of nanopure water in the graduated cylinder prior to 
adding it into the trough. This will give the trough a final calcium concentration of 2 mM. 
4. Allow approximately 10 minutes for the Wilhelmy plate to be fully equilibrated with the 
subphase. 
a. If you are uncertain as to whether the Wilhelmy plate is fully equilibrated, one 
way to check for this is to monitor the pressure reading. If the pressure reading 
stabilizes and does not fluctuate rapidly, then you are ready to proceed to the 
next step. 
5. Zero the pressure sensor, open the barriers (by clicking on the ‘O’ button), and lift the 
pressure sensor (with the Wilhelmy plate) out of the water. Check to see whether a 
reading of about 70 mN/ is obtained for ideal room temperature conditions. If so, move 
on to the next step. 
a. If not, you will need to recalibrate the pressure sensor using the software’s 
Calibrations Menu, which allows you to calibrate the pressure sensor by 
providing on-screen instructions. To calibrate, you will need a 100 mg calibration 
weight that is provided in the monolayer plate. 
6. Once pressure equilibration has been achieved, you must check the trough’s cleanliness 
before proceeding. Open the barriers to their farthest positions by clicking on the ‘O’ 
button and make sure that the lower edge of the Wilhelmy plate is just in contact with 
the surface of the subphase (in this case, water).  
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7. Close the barriers by clicking on the ‘C’ button and closely monitor the change in surface 
pressure as the barriers move closer and closer together. 
a. If the change in surface pressure is less than 0.1 mN/m, your subphase and 
trough are clean enough to proceed with the experiment and adding your lipid 
sample in. 
b. If the change in surface pressure exceeds 0.1 mN/m significantly, you will need 
to keep cleaning the trough by aspirating the surface of the subphase with the 
use of an aspirator pump. 
i. By aspirating the surface of the subphase with a small pipette tip, you are 
attempting to remove any surface contaminants and floating material that 
may be affecting surface pressure measurements, such as dust or 
amphiphilic contaminants.  
ii. The pipette tip should be held at an angle of approximately 30° to 45°. 
If positioned correctly slightly above the subphase, a loud suctioning 
noise will be heard as the tip is passed above the water.  
iii. The pipette tip should be moved around, across the surface of the water, 
to try and rid the entire surface of any contaminants. 
iv. Should too much water be sucked up, the trough can be refilled as 
necessary and the cleaning process continued. Just make sure that if 
additional water is required, add the water from behind the barriers (from 
the sides) so as not to disrupt or contaminate any of the cleaning that 
was performed in the center of the trough.  
8. When you are ready to begin your experiment with a particular lipid model, open the 
Monolayer Menu within the software. A popup will appear where you can enter the ratio 
of lipids in your lipid sample, the molecular weight of each lipid, the concentration of 
your solution, the volume of your solution in μL, and other pertinent information 
regarding your sample. Make sure you save these monolayer settings so you can load 
them again for the same model during your next run. 
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9. Once the conditions have been set and the pressure has been zeroed, close the barriers 
so that they are approximately 75% open.  
10. Draw up 30 μL of your lipid stock solution and deposit it drop by drop onto the surface 
of the water, without touching the surface but as close as possible to prevent unnecessary 
ripples. 
a. You will notice a significant increase in surface pressure readings, and they will 
be fluctuating regularly. This is normal as the solvents will be evaporating. 
11. Let the solvent evaporate for at least 10 minutes until the surface pressure is around 10-
20 mN/m.  
12. Open the barriers fully, and you will see the surface pressure drop even further. 
a. This action further facilitates the evaporation of the solvent, and the pressure 
reading should now be close to 0 mN/m.  
b. When the reading is close to zero, continue to the next step. 
13. Set the barrier speed of the trough to 20 cm2/min by entering “20” in the Barrier Speed 
field. 
14. Click on “Clear” or “Delete” to clear the memory of the software. 
a. The software can only hold data for up to three runs before it prevents you from 
taking further readings. As a result, when you start the software, you may not 
need to clear or delete the memory. But once you have taken a few isotherms, 
you will need to perform this step. 
15. If you are performing an experiment where daptomycin or CB-182,462 needs to be added into the trough, 
very slowly inject 220 μL of the desired 1 mM antimicrobial peptide stock solution. 
a. Make sure you use a bent or L-shaped syringe to inject the drug underneath one of the trough 
barriers, and therefore underneath the lipids on top of the subphase.  
b. By adding 220 μL of the drug solution, the final concentration of that particular antimicrobial 
peptide within the trough’s boundaries would be 4 μM, above daptomycin’s typical MIC50. 
c. Once you have injected the solution, let it equilibrate for approximately 1-2 minutes before 
moving onto the next step. It is okay if the isotherm does not start at a pressure of 0 mN/m. 
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16. Press the “Play” button as soon as you are ready to start the compression and the 
software has space to take another reading. 
a. As the compression is taking place, you can adjust the axes of the graph. For 
compression isotherms, typical axes were surface pressure vs. area. 
17. Continue to monitor the compression isotherm and when the isotherm begins to 
collapse (steep, rapid drop in pressure readings), press the “Stop” button to stop the 
compression. 
18. Remember to save the isotherm. 
a. You will be prompted to save both the data as a *.txt file and the operating 
conditions as a *.con file.  
19. Suck up all the water and lipid from the trough after you have saved the isotherm, and 
properly clean the trough. 
20. Take at least three compression isotherms for each scenario/sample you desire. 
 
C.4 Using the LB Trough to Record Insertion Assays 
Apart from compression isotherms, the Langmuir-Blodgett trough can also be used to record 
insertion assays. The goal of the insertion assay is to test the incorporation of a particular 
substance, like an antimicrobial peptide, into a preformed monolayer at a certain surface 
pressure. 
The insertion assays involve compressing the lipids to a target pressure above which a monolayer 
is formed and is biologically relevant to the study. Once this target pressure is reached, an 
injection of antimicrobial peptides (or a blank) will take place and the resulting pressure changes 
recorded for a total of 5 minutes. It is expected that the greater the insertion of the molecules 
into the lipid monolayer, the larger the change in pressure readings from start to finish.  
The following procedures outline the setup, operation, and collection of such insertion assays. 
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1. Make sure the LB trough is clean using the procedures outlined in Appendix C.2. 
2. Set up the LB trough to prepare for a compression of lipids (to a set target pressure) by 
following Steps 1-12 of Appendix C.3. 
a. Make sure the surface pressure is close to or at zero prior to continuing on to 
further steps. 
b. At this stage, you will be ready to start your experiment. 
3. Set the Barrier menu to “Pressure Control” and enter the following settings: 
a. Set the barrier speed of the trough to 20 cm2/min 
b. Set the target pressure of the trough to 20 mN/m, which corresponds to the 
relevant biological membranes being studied 
4. Click on “Clear” or “Delete” to clear the memory of the software. 
a. The software can only hold data for up to three runs before it prevents you from 
taking further readings. As a result, when you start the software, you may not 
need to clear or delete the memory. But once you have taken a few isotherms, 
you will need to perform this step. 
5. Press the “Play” button as soon as you are ready to start the compression and the 
software has space to take another reading. 
a. As the compression is taking place, you can adjust the axes of the graph. For 
insertion assays, typical axes were surface pressure vs. time. 
6. After 2 minutes, or 120 seconds (t = 120 s), change the settings to the following: 
a. Set the barrier speed of the trough to 0 cm2/min, which will stop the movement 
of the barriers 
b. This action should result in a flat pressure reading as time passes by 
7. Once you have frozen the barriers, let the readings continue on for 1 minute or 60 
seconds (t = 180 s) to ensure that there is no leakage in the trough 
a. If there is leakage, you will need to start over and clean the trough, especially the 
two barriers.  
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b. If there is no leakage, that means that your lipid monolayer is still holding strong 
at 20 mN/m without the help of the barriers to constantly adapt by adjusting the 
area of the trough. 
8. Once that minute has passed, at t = 180 s, inject 220 μL of the desired 1 mM 
antimicrobial peptide stock solution (or a blank for control and calcium-only scenarios). 
a. Make sure you use a bent or L-shaped Hamilton syringe to inject the drug 
underneath one of the trough barriers, and therefore underneath the lipid 
monolayer in the center. 
b. Make sure you try and use the same force and speed of injection for each run. It 
does not make a huge difference to inject slowly or quickly, but maintaining 
consistency is important. 
c. By adding 220 μL of the drug solution, the final concentration of that particular 
antimicrobial peptide within the trough’s boundaries would be 4 μM 
d. For control runs, adding 220 μL of nanopure water acts as a blank and allows 
you to create a baseline for comparison amongst the other runs with daptomycin 
or CB-182,462. 
9. Once you have completed the injection, let the insertion assay continue for another 5 
minutes until t ≥ 500 s.  
10. When the insertion assay is done, press the “Stop” button to stop the current run. 
11. Remember to save the insertion assay run. 
a. You will be prompted to save both the data as a *.txt file and the operating 
conditions as a *.con file. 
12. Suck up all the water and lipid from the trough after you have saved the insertion assay, 
and properly clean the trough. 
13. Record at least 3 insertion assays for each scenario/sample you have. 
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C.5 Using the LB Trough to Deposit Lipid Monolayers on Mica 
The Langmuir-Blodgett trough is commonly used to prepare solid supported lipid monolayers 
on substrates. In this thesis, monolayers were deposited onto mica substrates to be imaged using 
various atomic force microscopy techniques.  
To deposit a lipid monolayer onto a mica substrate, one must first submerge a freshly cleaved 
piece of mica into the well of the trough prior to forming a monolayer. Once the monolayer is 
formed via a targeted pressure compression, the mica can be very slowly withdrawn from the 
well while the monolayer deposits itself onto both sides of the mica as it is vertically removed 
from the subphase. 
The following steps and procedures pertain to the creation of a solid supported lipid monolayer 
on a mica substrate using the LB trough. 
1. Make sure the LB trough is clean using the procedures outlined in Appendix C.2. 
2. Attach a new or recycled Wilhelmy plate to the extension hook of the trough. 
a. The pre-cut paper Wilhelmy plate uses Whatman CHR1 chromatography paper 
that has a width of 10 mm. 
b. These Wilhelmy plates are capable of measuring the surface pressure of LB thin 
films at the air-liquid interface. 
c. If you choose to recycle the paper Wilhelmy plates, you can submerge them 
overnight in a HPLC chloroform solution, then dry them on a Kimwipe or by 
nitrogen gas prior to use. 
3. Fill the trough with 55 mL of nanopure water using a clean graduated cylinder. 
a. When the trough is filled with water, the Wilhelmy plate will begin to absorb the 
water and equilibrate with the water subphase.  
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b. Should an experiment require the addition of calcium into the subphase, add 1.1 mL of 100 
mM calcium stock solution to the 55 mL of nanopure water in the graduated cylinder prior to 
adding it into the trough. This will give the trough a final calcium concentration of 2 mM. 
4. Allow approximately 10 minutes for the Wilhelmy plate to be fully equilibrated with the 
subphase. 
a. If you are uncertain as to whether the Wilhelmy plate is fully equilibrated, one 
way to check for this is to monitor the pressure reading. If the pressure reading 
stabilizes and does not fluctuate rapidly, then you are ready to proceed to the 
next step. 
5. While waiting for the Wilhelmy plate to equilibrate, cleave a square or rectangular piece 
of mica using Scotch® Magic™ tape. 
a. When cleaving mica, be sure to use gloves to prevent contamination of the mica 
surface. 
b. Press the tape firmly onto one side of the mica, and slowly peel off a layer of 
mica. 
i. If the cleave is successful, there will be no cracked appearance on the 
mica surface or discolouration of the peeled layer 
ii. If you see these abnormalities, re-cleave until you get a successful and 
clean cleave. 
c. Be sure to note which side is the cleaved surface – you only need to cleave one 
side. 
6. Using tweezers, secure the mica onto the dipper arm by placing it in the substrate clamp 
at the bottom of the dipper rod. 
a. Make sure you know which side is the cleaved surface so you know how to store 
the sample once the monolayer has been deposited. 
7. In the Dipper Menu, click on “Down” to ensure that the dipper arm is at its lowest 
position. 
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a. Adjust the dipper rod (held in place by a magnetic holder) and base so that the 
mica fits perfectly into the trough well. 
b. The mica should be placed in such a position that it is parallel with the length of 
the trough barriers and the edge of the mica just above the subphase so that a 
curved meniscus is seen at the subphase/substrate boundary. 
8. Set up the LB trough to prepare for a compression of lipids (to a set target pressure) by 
following Steps 5-12 of Appendix C.3. 
a. Make sure the surface pressure is close to or at zero prior to continuing on to 
further steps. 
b. At this stage, you will be ready to start your experiment. 
9. Compress the monolayer to a target pressure of 20 mN/m by following Steps 3-5 of 
Appendix C.4.  
10. Once the target pressure has been reached, wait 5 minutes (or 300 seconds) and make 
sure the pressure of the monolayer remains unchanged (to show its stability as a 
monolayer). 
11. At t = 300 s, click on “Creep Up” on the Dipper Menu and you will see the dipper arm 
slowly raising itself and the mica substrate along with it. 
a. Since Pressure Control is still turned on, Creeping Up the dipper arm allows a 
consistent monolayer to be deposited onto the mica surface as it is removed from 
the subphase. 
12. When the mica substrate is completely removed from the subphase, let it air-dry for 
approximately 5-10 minutes.  
13. When done drying, place the mica substrate (cleaved side up) in a small petri dish and 
put it in a desiccator to store until ready for imaging.  
a. These samples can be kept at room temperature. 
14. Thoroughly clean the trough and repeat all steps for each sample you prepare. 
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APPENDIX D: AFM, PHASE AND KPFM IMAGING IN AIR 
 
Atomic force microscopy, phase imaging and Kelvin probe force microscopy experiments were 
performed in this thesis using the Advanced Integrated Scanning Tools for Nano-Technology 
(AIST-NT™) SmartSPM™ 1000 fully-automated scanning probe microscope.  
The samples prepared for these experiments were monolayers deposited on solid mica 
substrates, and special care was taken into modifying the sample to allow for simultaneous AFM, 
phase and KPFM imaging using the AIST-NT™ instrumentation.  
 
D.1    Preparing Samples for AFM, Phase and KPFM Imaging 
The AIST-NT™ SmartSPM™ 1000 has the ability to record simultaneous AFM, phase and KPFM 
images. As a result, all the samples prepared were modified to be conductive (since mica is 
nonconductive) to allow for KPFM imaging. The following steps and procedures will explain 
this modification technique. 
1. Deposit your monolayer onto a freshly cleaved mica substrate (about ½” square 
dimensions) as explained in Appendix C.5. Make sure the sample is completely dry 
(overnight in dessicator) prior to continuing onto Step 2. 
2. Cut a piece of aluminum foil that is much larger than the dimensions of the mica 
substrate. Lay it down flat and make sure there are no creases in the foil. 
3. Cut two equally-sized pieces of electrically-conductive, double-sided tape and place them 
side by side on the aluminum foil to form an approximate square. 
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a. The preferred tape is 3M™ XYZ Axis Tape Type 9712, which is available in 6.35 
mm width. You can also use the 12.7 mm width (½” model) for this step, but 
you’ll need the smaller-width tape for subsequent steps. 
b. Assuming you are using the 6.35 mm width electrically conductive tape, you 
would cut out two pieces that are approximately ¼” inch (6.35 mm) in length so 
that when placed side by side, this would form a square that the mica substrate 
can fit on perfectly. 
c. Make sure you don’t cut out pieces that are greater than the dimensions of your 
mica substrate. In this case, ½”. 
4. When the two pieces of tape are stuck onto the aluminum foil side by side, remove the 
other sticky side of the conductive tape. You will expose the sticky, black, conductive 
fibres. 
5. Using a tweezer, carefully position your mica sample onto this conductive tape and 
secure the substrate by pressing down on the edges.  
a. Do not touch or scrape the middle of the sample in any way to prevent 
contamination and sample damage. 
6. Use scissors or a utility knife to cut away the excess aluminum foil so that approximately 
3-5 mm of aluminum foil is sticking out of each end of the mica substrate. 
7. When you have a 3-5 mm thick aluminum border around your sample, use a flat razor 
blade (or something with a thin, solid edge) to wrap the aluminum foil against the edge 
of the mica substrate and fold it over so that it covers the edge of the substrate.  
a. Once you have folded over the aluminum foil, use the flat edge to press down 
on the aluminum foil so that it is flush with the surface of the sample – you want 
to maximize contact throughout. 
8. After all four aluminum foil edges have been properly folded, cut out four small pieces 
of double-sided electrically conductive tape. 
a. These small pieces of conductive tape need to be cut from the 6.35 mm width 
or smaller roll of double-sided conductive adhesives from 3M™.  
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b. The length of each piece should be about 2-3 mm (very thin and narrow).  
9. Place one small piece of double-sided electrically conductive tape onto each corner of 
the mica sample’s surface. 
a. This helps “tie” each edge of aluminum foil to the sample, acting as a bridge 
between the sample and the different sides of aluminum foil 
10. When done placing all four small pieces of conductive tape onto each corner, pick one 
piece and remove the adhesive sticker on it (just one!).  
11. Place the sample in the petri dish until ready for imaging.  
 
D.2    Operating the AIST-NT™ SmartSPM™ for Air Imaging 
The AIST-NT™ SmartSPM™ can be used to obtain simultaneous AFM, phase, and KPFM 
images in air through the conventional high-resolution Kelvin mode that is available on the 
instrumentation. But in order to get these high-resolution KPFM images, the SmartSPM™ must 
be properly set up before any imaging can be performed.  
The KPFM mode used in the SmartSPM™ Kelvin Mode is AM-KPFM (amplitude modulation 
Kelvin probe force microscopy). Although FM-KPFM (frequency modulation KPFM) generally 
provides higher resolution due to the use of force gradients, AM-KPFM still provides high-
resolution images when set up properly, and when the conductive tips being used are easily 
blunted or worn through multiple image scans. 
The following procedures will go through the proper setup in SmartSPM’s™ accompanying 
software, called AIST-NT SPM Control Software. 
1. Make sure the power box to the SmartSPM™ is turned on and connected properly. Then 
turn on the computer and open the AIST-NT SPM Control Software program. 
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2. A pop-up window will appear asking whether you want to “Initialize SPM” or enter 
“View Only Mode”. Click on “Initialize SPM”. 
3. When the program has loaded, you will see that the program tells you to choose an 
operating mode from the Tools menu. Click “Close”. 
4. Under the Tools menu at the top menu bar, click on “AC Mode”. 
5. The tip must be installed at this point. Inside the SmartSPM™, there is a tip holder with 
a clip. Remove the tip holder and place your desired cantilever inside the clip. Make sure 
that this cantilever is conductive to allow for KPFM imaging capabilities. 
a. Place the entire tip holder back into the SmartSPM™ as shown. Lock it in place 
with the silver lever. 
b. Push the end of the tip holder into the hole and make sure it is securely attached. 
6. Once the tip has been installed, the sample must be installed as well. 
a. Before starting anything, make sure there is enough space between the tip and 
the sample stand so that you have some room to manipulate the sample with. 
You don’t want to break the tip! 
i. Since the tip is fixed, it is the sample stage that can be moved up or down. 
If the sample stage is too far up, click on the “Z-motor” button in the 
AC Mode options. A ZMotor Ctrl pop-up control panel will appear. 
“Move” the sample stage a distance of -3.00 mm. Make sure the value is 
negative, which means the stage will move down.  
b. Select a KPFM sample holder (with the red pin) and place the KPFM sample 
holder onto a stand. Lock it in place by using the fixing clench rod (push the 
button at the bottom of the stand to raise the rod, place the sample inside, then 
release the clench to snap it in place). 
c. Once the sample holder is secure, make sure there is some conductive tape on 
the surface of the holder. If not, cut a small piece of double-sided conductive 
tape and place it in the centre of the holder. 
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d. Place your modified mica sample (wrapped in aluminum foil) on the KPFM 
sample holder and secure it in place with the holder’s conductive tape. 
e. The KPFM holder has a contact pin. Gently lift it up and place it onto the corner 
of the mica sample, where one of the conductive tape pieces are exposed. This 
acts to ground the sample or to apply a voltage to the sample for working in 
electrical modes of SPM. 
f. When you have secured the sample onto the sample holder, remove it from the 
stand and place it into the AIST using a similar fixing clench procedure. 
i. There is a fixing clench handle at the bottom of the SmartSPM™. Turn 
this down 90° clockwise to lift the rod. 
ii. While the rod is lifted, slide the sample holder under the clench head and 
release the handle. 
iii. Wiggle the sample holder a bit to ensure the holder is fixed and centred 
for imaging. 
g. Now that the sample is in place, the red pin from the sample holder needs to be 
placed in the tiny, golden hole located beside the stage. Make sure this red pin is 
inserted and secure in the hole. 
7. With the sample in place, it is now necessary to find the tip. 
a. Go to the Laser Adjustment Window and click on the “Init position” button to 
set the cantilever holder to its initial position.  
b. Click on “Find Tip” to tell the software to begin its search for the tip. The 
cantilever holder will start moving from its current position, following an 
expanding trajectory until the laser beam hits the cantilever. Once the laser beam 
has found the cantilever, it will move up and down across the cantilever to 
determine its length and width. After that, the laser beam will settle on a specific 
location above the tip of the cantilever, marked by a red cross. 
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c. Once the tip has been found, click on “Adjust Diode” to adjust the position of 
the photodiode so that the laser beam reflected from the cantilever is located at 
its center. 
8. At this point, it is possible for the SmartSPM™ to automatically set up the rest of the 
settings to allow for imaging by clicking the “Auto” button (with the magic wand) under 
the AC Mode control panel. However, we will go through each step manually, starting 
with finding the resonant frequency of the cantilever. 
a. Click on the “Init tuning” button on the AC Mode control panel. The software 
will search for the cantilever’s resonant frequency. The highest peak within the 
selected range (which can be adjusted by setting low and high values) will 
automatically become the resonance peak, which defines the operating 
frequency.  
b. With the operating frequency set, the initial amplitude of the cantilever must be 
set as well.  
i. Enter the length of the cantilever in the “len” field in the AC Mode 
control panel. 
ii. Then enter the amplitude, in nm, in the “amp” field. This value is 
determined by the type of cantilever used. For non-contact modes, use 
values between 5 and 20 nm. The cantilevers used in the experimental 
work done in this thesis were set with an amplitude of 20 nm. 
iii. Click on “set amplitude” to set the amplitude. 
9. Once the resonant frequency and amplitude of the cantilever have been set, it is 
necessary to approach the sample to the tip. 
a. If the sample stage is very far away from the tip, use the ZMotor Ctrl control 
panel to raise the sample stage (enter positive value) 1 mm at a time until it is 
very close to the tip. 
b. Click on “m_approach” in the AC Mode control panel to start the approach. In 
the Curves View window, a graph will show the dependence of the cantilever’s 
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amplitude (Mag signal) on the scanner’s vertical position. Near the sample’s 
surface, the amplitude will drop. 
c. Click on “fine tuning” to readjust the operating frequency since the approach 
procedure may have dampened the probe’s oscillations. 
d. Due to the same reason above, click on “set amplitude” to set the Mag signal to 
25000 and automatically optimize the Phase signal. 
e. Click on “landing” on the AC Mode control panel to start the landing procedure, 
where the scanner approaches the sample to the tip of the cantilever.  
i. A landing curve will appear in the Curves View window. You want to 
have a curve that has a steep drop. If this is not the case, then the sample 
may have too much static, therefore letting the sample sit in the 
SmartSPM™ chamber for a few hours may help, or try moving the tip to 
another area on the sample. 
10. When the tip is now approached and landed on the sample surface, it is necessary to run 
spectroscopy on the curve and find a decent setpoint (either automated or manual). 
a. Once the tip has landed, click on the green arrow in the Curves View window to 
do a sweep of the landing curve and find a decent setpoint.  
b. The software will automatically choose a setpoint for you on the more vertical 
part of the curve. Look at the setpoint number at the top of the program window 
and make sure it doesn’t correlate with any part of the curve that has more than 
one x-value for each colour (blue and red).  
c. If you want to change the setpoint, you can enter a number in the “Sp” field. 
d. Once you have the setpoint, go to the Scan Window. 
11. Prior to working with Kelvin Mode, we need to be able to get a decent AFM image first.  
a. In the Scan Window, select “QScan Mode”.  
b. Open the golden settings button and make sure “Adaptive” scanning is enabled. 
c. Click on “Signals” in the AC Mode control panel and make sure Height(Dac), 
Height(Sen), Mag and Phase are checked/selected. 
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d. Select a minimum number of points as 400 x 400, set the scanning speed to 1 
Hz, and set the scan area to whichever size is required (for example, 1 μm square, 
5 μm square or 10 μm square).  
e. Click on the green arrow to start scanning. 
f. You can continue to scan in QScan Mode to obtain high-speed AFM and phase 
images, or you can now move on to Kelvin mode to perform simultaneous AFM, 
phase and KPFM imaging. 
12. If a clear Height(Dac) and Phase image can be obtained using QScan Mode, switch to 
Kelvin mode, which offers conventional amplitude modulation KPFM (AM-KPFM) 
imaging capabilities. This means that a tip is scanned across a surface and a feedback 
loop is used to keep the voltage equal between the tip and the surface. This two-pass 
technique measures topography on the first pass and surface contact potential difference 
on the second pass.  
a. Switch to Kelvin mode, and a Kelvin control panel will pop up. 
b. Click on “Auto Setup” to automatically adjust the instrument to switch on and 
work in KPFM mode.  
c. Click on ‘Lift”, and then “Show bird” to show a dependence curve between tip 
oscillation amplitude and the applied AC voltage. The goal is to see a nice “V” 
shape. 
i. If you cannot see a nice “V” shape, it is still possible to attempt KPFM 
imaging, but the image resolution will be low. Similar to other modes, 
you can try imaging different areas or let the sample sit for some time 
before attempting KPFM again to see if a better “V” shape can be 
obtained. 
d. Return to the Scan window and make sure the CPD[2] signal is checked. You 
can set the Signals so that in the first [1] pass, the Height(Dac), Height(Sen), Mag 
and Phase signals are recorded while on the second [2] pass, the CPD signal is 
recorded. 
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13. In the Scan window, after you have selected an area to scan, click on the green arrow to 
start scanning.  
14. Continue scanning different areas of the sample until it is ready to switch to another 
location or another sample.  
a. When switching to another sample, make sure you lower the stage using the 
ZMotor control panel so that the sample is clear from the fragile tip. 
b. The tip may need to get switched out every few samples as it suffers increasingly 
from wear and tear (you will notice the resolution for both AFM and KPFM 
deteriorating with each additional scan). 
15. When finished scanning, make sure the tip is away from the sample surface. Turn off the 
SPM control software, as well as the power box for the SmartSPM™. 
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APPENDIX E: AFM IMAGING IN LIQUID 
 
Atomic force microscopy imaging in liquid was performed in this thesis using the JPK 
NanoWizard® II atomic force microscope.  
The samples prepared for these experiments consisted of supported lipid bilayers on solid mica 
substrates, which were constantly hydrated in HEPES buffer solution. To prepare these samples, 
one must first create a unilamellar vesicle solution and then promote membrane formation via 
vesicle fusion onto the mica substrate. Once this sample has been made, it needs to be constantly 
hydrated before and during imaging, and is fairly time-sensitive. 
 
E.1    Preparing Vesicle Solutions 
Vesicle solutions can be prepared using an extruder to create large unilamellar vesicles (LUVs) 
or sonication to create small unilamellar vesicles (SUVs). For the purpose of these experiments, 
LUVs were used as they were prepared through an extruder with a 100 nm filter to promote 
consistency in vesicle size. If sonication is to be used, SUVs of sizes ranging from 5 nm to 50 
nm could be created, and repeated periods of sonication and stirring would be required to 
promote the formation of uniform vesicles. 
The instructions to prepare large unilamellar vesicles using an extruder are presented in 
Appendix B1. 
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E.2    Preparing Samples for AFM Liquid Imaging 
To prepare a supported bilayer on a solid substrate, the choice of substrate is quite important. 
First of all, the substrate needs to be chemically inert and be hydrophilic, such as mica. Secondly, 
how you image your sample needs to be decided right from the beginning as imaging will occur 
in liquid. For atomic force microscopy, instruments such as the JPK NanoWizard® II have their 
own liquid cells that can be used to prevent leakage. If a liquid cell is to be used, the mica 
substrate must be placed and secured within the liquid cell holder prior to sample preparation. 
If a liquid cell is not to be used, an O-ring can be placed on top of the mica substrate and secured 
with glue or tape on the outside to hold it in place and prevent leakage. The experiments 
performed in this thesis used the liquid cell holder provided by the JPK NanoWizard® II. 
Once the substrate and its holder are chosen, samples can be prepared. The goal is to add vesicles 
solutions to the substrate and incubate the sample for some time to allow the vesicles to adhere 
to the substrate and eventually reach a threshold concentration that ruptures the vesicles to form 
a bilayer.  
The following steps and procedures will explain how to form a membrane using vesicle fusion.  
1. Freshly cleave a piece of large, circular mica (make sure it fits perfectly inside the JPK 
liquid cell). 
2. Assemble the JPK liquid cell by placing the mica substrate in the holder first, followed 
by the rubber piece and cover/clamp. Make sure the clamp is secure and tightened to 
prevent any leakage.  
3. During this time, pick your vesicle solution depending on what you are studying. 
4. Add approximately 200 μL of the vesicle solution to the surface of the mica substrate 
and let it incubate for 15 minutes to promote vesicle adhesion and fusion to the surface.  
5. Once the sample has been incubated for some time, add in calcium and/or your 
antibiotic to the membrane and let this incubate for about 3 minutes. 
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a. Make sure that relevant amounts of daptomycin/CB-182,462 at 2 µM and 
calcium at 2 mM are added into the solution.  
6. After incubation, use a pipette to gently rinse away the excess vesicle solution. 
a. To do this, remove 100 μL of the solution using one pipette, and add 100 μL of 
HEPES buffer using another pipette. 
b. Repeat approximately 10 to 15 times. 
c. Note that great care must be taken while rinsing the solution as any disturbances 
may create physical defects in the membrane. 
7. After rinsing, the sample is ready to be imaged. 
a. The sample should be stable for at least 48 hours and must remain in constant 
hydration.  
 
E.3    Operating the JPK NanoWizard® II for AFM in Liquid 
The JPK NanoWizard® II can be used for both liquid and air atomic force microscopy imaging. 
But in order to get high-resolution AFM liquid images, the NanoWizard® II must be properly 
set up before any imaging can be performed. For liquid imaging, non-conductive cantilevers with 
low spring constants are recommended. 
The following procedures will go through the proper setup and use of the JPK NanoWizard® II 
and its accompanying software. 
1. Clean the JPK glass holder with ethanol, and then use KimWipes to dry it. Be very careful 
as it is fragile. 
2. Get two tweezers. With the first one, pick up the cantilever chip and place it on the glass 
holder. The tip should be pointing towards the polished side and slightly sticking out. 
With the second tweezer, pick up the cantilever spring. Squeeze the bottom loops of the 
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spring firmly with this tweezer to open up the front part of the spring. Slide the spring 
into the groove so that it clamps the cantilever chip onto the glass block firmly. 
3. The cantilever should now be secured on the glass block. Insert and lock this glass block 
onto the AFM head. 
a. This glass block is held in the AFM heading with a locking mechanism. 
b. The notches in the glass must be lined up with the metal tabs on the AFM head 
to insert the glass block inside the AFM head.  
c. Once inserted, turn the glass block clockwise or counterclockwise so that the tip 
is pointing towards the right (the spring is on the left side). 
d. Then lock it in position by turning the knob to the left. 
4. If necessary, wash this area with ethanol. Use bibulous paper and compressed air spray 
to clean it and make sure it is dry before proceeding.  
5. Place the AFM head back onto the AFM machine, making sure the farthest leg goes 
down first. 
a. Also make sure that there is nothing on the stand so that the glass block or tip 
will not hit something. 
6. Use the eye viewer to look at the image. This should be the black nob located at the 
bottom of the AFM stand. 
7. Focus the tip using the coarse and fine adjustment knobs on the side of the microscope. 
You may need to use the positioning screws to bring the tip into the field of view. 
8. Start the JPK NanoWizard® II Control software. Once the tip is focused, use the camera 
view to see the image on the computer screen. 
9. Open the Laser Alignment window.  
a. Use the laser adjustment screws to align the laser onto the cantilever tip. 
b. Use the detector adjustment screws to make sure that the vertical and lateral 
deflections are approximately 0 V and that the sum value is maximized. 
10. Adjust the tip position (retract the piezo) by clicking the motor icon.  
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a. Bring the tip up a reasonable amount so that you can see a gap between the tip 
and the surface of the AFM stand. We do this so that when we install the sample, 
the tip and block are not in danger of crashing into the sample or the holder. 
11. Remove the AFM head and place the JPK liquid cell onto the AFM stand.  
12. Slowly put the AFM head back in position and ensure that the cantilever and glass block 
fit nicely inside the liquid cell. 
a. If you feel like the cantilever is too close to the mica surface, you can always raise 
the AFM head a bit more to create a larger gap between the tip and the surface. 
13. Set up the JPK NanoWizard® Control.  
a. On startup, the screen should be fairly empty with many options running along 
the top and left of the viewport. 
b. Make sure the following settings and displays are on the screen throughout 
scanning: Image Viewer (Height Trace), Image Viewer (Lock-in Phase), 
Oscilloscope, Scan List, Laser Alignment. 
14. Make sure the Intermittent Contact (Liquid) scanning mode is selected 
15. Set up the system to save the scans automatically using the save and save settings icons. 
16. Use the Stepper Motor to retract/extend the tip or piezo at an interval of your choice. 
Use the retract (up arrow) button to retract once and the approach (down arrow) button 
to approach the surface of the sample. 
17. Set the scan size to your preferred dimensions and start with a resolution of 512 x 512 
pixels with a line rate of 1 Hz. 
18. Use the Outline Scanning Mode button to find an initial scan region. You can look 
through the microscope with your eyes to find this region, but keep in mind that 
movement within the liquid cell is limited. 
19. Tune the cantilever using the Cantilever Tuning window. Here, you can find the 
cantilever resonance for intermittent contact mode. Make sure they are lined up like the 
images below. If there are too many peaks, clean the tip again and make sure it is still 
there. 
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20. Retract the tip again. Make sure the cantilever is tuned, and approach the surface by 
pressing the blue down arrow. Once it has approached, retract the tip again a few times. 
a. If the approach does not work, try adjusting the IGain/PGain values, and 
double-check the Cantilever Tuning settings to make sure your setpoint is still in 
the right place. You can also try increasing or lowering the setpoint. 
21. Make sure the Z Range is adjusted to the maximum resolution at 1.5 μm.  
22. Press the lock button on the oscilloscope (the button looks like a lock). 
23. Recheck the settings, especially the tuning of the cantilever before you start scanning. 
Once ready, approach the surface by pressing the blue down arrow. 
24. Once approached, press RUN to start scanning. 
25. To take another image, you can always right-click the area and select “New Scan Region” 
to click and drag another area you want to scan. 
26. The resolution can be adjusted at any point, and the files renamed to any preferred label 
you desire. 
27. When finished with the scans, retract the tip. 
28. Take the liquid cell out, drain it of its vesicle solution, clean it with ethanol at least 5 
times and let it dry. 
29. Take the tip out if you are not reusing it, or give it a good rinse with ethanol if you are 
reusing it for another sample. 
30. When finished, make sure the AFM is clean, the light is off, and that the NanoWizard 
software is closed. 
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APPENDIX F: AFM IMAGES OF MONOLAYERS 
 
 
Figure F.1 AFM images of BM monolayer samples in different scenarios 
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Figure F.2 AFM images of HM monolayer samples in different scenarios 
 
 
 
 
251 
 
 
Figure F.3 AFM images of LS monolayer samples in different scenarios 
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Figure F.4 AFM images of BLES® monolayers in different scenarios 
 
